Analysis of Assembly Bill 1738: Health Care Coverage: Tobacco Cessation

A Report to the 2011-2012 California Legislature
April 20, 2012
The California Health Benefits Review Program (CHBRP) responds to requests from the State Legislature to provide independent analyses of the medical, financial, and public health impacts of proposed health insurance benefit mandates and proposed repeals of health insurance benefit mandates. CHBRP was established in 2002 by statute (California Health and Safety Code, Section 127660, et seq). The program was reauthorized in 2006 and again in 2009. CHBRP’s authorizing statute defines legislation proposing to mandate or proposing to repeal an existing health insurance benefit as a proposal that would mandate or repeal a requirement that a health care service plan or health insurer (1) permit covered individuals to obtain health care treatment or services from a particular type of health care provider; (2) offer or provide coverage for the screening, diagnosis, or treatment of a particular disease or condition; or (3) offer or provide coverage of a particular type of health care treatment or service, or of medical equipment, medical supplies, or drugs used in connection with a health care treatment or service.

A small analytic staff in the University of California’s Office of the President supports a task force of faculty and staff from several campuses of the University of California, as well as Loma Linda University, the University of Southern California, and Stanford University, to complete each analysis within a 60-day period, usually before the Legislature begins formal consideration of a mandate or repeal bill. A certified, independent actuary helps estimate the financial impacts, and a strict conflict-of-interest policy ensures that the analyses are undertaken without financial or other interests that could bias the results. A National Advisory Council, drawn from experts from outside the state of California and designed to provide balanced representation among groups with an interest in health insurance benefit mandates or repeals, reviews draft studies to ensure their quality before they are transmitted to the Legislature. Each report summarizes scientific evidence relevant to the proposed mandate, or proposed mandate repeal, but does not make recommendations, deferring policy decision making to the Legislature. The State funds this work through a small annual assessment on health plans and insurers in California. All CHBRP reports and information about current requests from the California Legislature are available at the CHBRP Web site, www.chbrp.org.
A Report to the 2011-2012 California State Legislature

Analysis of Assembly Bill 1738
Health Care Coverage:
Tobacco Cessation

April 20, 2012

California Health Benefits Review Program
1111 Franklin Street, 11th Floor
Oakland, CA 94607
Tel: 510-287-3876
Fax: 510-763-4253
www.chbrp.org

Additional free copies of this and other CHBRP bill analyses and publications may be obtained by visiting the CHBRP Web site at www.chbrp.org.

Suggested Citation:
PREFACE

This report provides an analysis of the medical, financial, and public health impacts of Assembly Bill 1738. In response to a request from the California Assembly Committee on Health on February 17, 2012, the California Health Benefits Review Program (CHBRP) undertook this analysis pursuant to the program’s authorizing statute.

Chris Tonner, MPH, Janet Coffman, MPP, PhD, Edward Yelin, PhD, and Gina Evans-Young, all of the University of California, San Francisco, prepared the medical effectiveness analysis. Bruce Abbott, MLS, of the University of California, Davis, conducted the literature search. Diana Cassady, ScD, Dominique Ritley, MPH, and Julia Huerta, MPH, all of the University of California, Davis, prepared the public health impact analysis. Todd Gilmer, PhD and Jennifer Kempster, MS, both of the University of California, San Diego, prepared the cost impact analysis. Robert Cosway, FSA, MAAA and Scott McEachern of Milliman provided actuarial analysis. Content expert Elisa Tong, MD, MA of the University of California, Davis provided technical assistance with the literature review and expert input on the analytic approach. Hanh Kim Quach and Tory Levine-Hall of CHBRP staff prepared the introduction and synthesized the individual sections into a single report. A subcommittee of CHBRP’s National Advisory Council (see final pages of this report) reviewed the analysis for its accuracy, completeness, clarity, and responsiveness to the Legislature’s request.

CHBRP gratefully acknowledges all of these contributions but assumes full responsibility for all of the report and its contents. Please direct any questions concerning this report to:

California Health Benefits Review Program
1111 Franklin Street, 11th Floor
Oakland, CA 94607
Tel: 510-287-3876
Fax: 510-763-4253
www.chbrp.org

All CHBRP bill analyses and other publications are available on the CHBRP Web site, www.chbrp.org.

Garen Corbett, MS
Director
# TABLE OF CONTENTS

LIST OF TABLES ................................................................................................................. 4

EXECUTIVE SUMMARY ..................................................................................................... 5

INTRODUCTION .................................................................................................................. 14

MEDICAL EFFECTIVENESS ............................................................................................... 29
  Types of Smoking Cessation Treatments ........................................................................ 29
  Research Approach and Methods .................................................................................... 29
  Methodological Considerations ........................................................................................ 30
  Outcomes Assessed ........................................................................................................... 30
  Study Findings .................................................................................................................. 30
  Effects of Health Insurance Coverage for Smoking Cessation Treatments .................... 42
  Summary of Findings ....................................................................................................... 47

BENEFIT COVERAGE, UTILIZATION, AND COST IMPACTS .............................................. 60
  Current (Baseline) Benefit Coverage, Utilization and Cost ............................................ 60
  Impacts of Mandated Benefit Coverage .......................................................................... 60

PUBLIC HEALTH IMPACTS .................................................................................................. 71
  Public Health Outcomes .................................................................................................. 73
  Impact on Gender and Racial Disparities ......................................................................... 73
  Impacts on Premature Death and Economic Loss ............................................................ 75
  Long-Term Public Health Impacts .................................................................................... 78
  Conclusion ......................................................................................................................... 80

APPENDICES ......................................................................................................................... 81
  Appendix A: Text of Bill Analyzed ................................................................................... 81
  Appendix B: Literature Review Methods ........................................................................... 84
  Appendix C: Summary Findings on Medical Effectiveness .............................................. 89
  Appendix D: Cost Impact Analysis: Data Sources, Caveats, and Assumptions ............... 95
  Appendix E: Information Submitted by Outside Parties .................................................. 105
  Appendix F: Public Health Calculations .......................................................................... 107

REFERENCES .......................................................................................................................... 108
LIST OF TABLES

Table 1. AB 1738 Impacts on Benefit Coverage, Utilization, and Cost, 2012 ......................... 12

Table 2. Tobacco Cessation Benefit Coverage Mandates in Other States ............................. 18

Table 3. Comparison of Benefit Coverage Mandated by AB 1738 and Recommended by the U.S. Preventive Services Task Force, as part of the Affordable Care Act of 2010 Preventive Services Mandate .......................................................... 21

Table 4. Potential Interaction of Essential Health Benefits in 2014-2015 with Benefit Mandates in AB 1738 .......................................................................................................................... 23

Table 5. Smoking Prevalence Rates Among Currently Insured California Adults (%), 2009 .... 24

Table 6. Leading Causes of Tobacco-Related Deaths in California, 2005 .............................. 26

Table 7. Smoking Cessation Attempts in California, 2008 ..................................................... 28

Table 8. Summary of Findings from Studies of the Effectiveness of Smoking Cessation Treatments ........................................................................................................................................ 50

Table 9. Summary of Findings from Studies of the Effects of Coverage for Smoking Cessation Treatments on Use of Treatments and Abstinence from Smoking ........................................ 56

Table 10. Baseline (Premandate) Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2012 .................................................................................................. 67

Table 11. Impacts of the Mandate on Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2012 .......................................................................................... 69

Table 12. Improved Perinatal and Adult Health Outcomes Due to Smoking Cessation ......... 72

Table C-1. Summary of Findings on Medical Effectiveness ...................................................... 89
EXECUTIVE SUMMARY

California Health Benefits Review Program Analysis of Assembly Bill 1738

The California Assembly Committee on Health requested on February 17, 2012 that the California Health Benefits Review Program (CHBRP) conduct an evidence-based assessment of the medical, financial, and public health impacts of Assembly Bill (AB) 1738, a bill that would impose a health benefit mandate. In response to this request, CHBRP undertook this analysis pursuant to the provisions of the program’s authorizing statute.1

Analysis of AB 1738

Approximately 21.9 million Californians (59%) have health insurance that may be subject to a health benefit mandate law passed at the state level.2 Of the rest of the state’s population, a portion is uninsured (and so has no health insurance subject to any benefit mandate) and another portion has health insurance subject to other state law or only to federal laws.

Uniquely, California has a bifurcated system of regulation for health insurance subject to state-level benefit mandates. The California Department of Managed Health Care (DMHC)3 regulates health care service plans, which offer benefit coverage to their enrollees through health plan contracts. The California Department of Insurance (CDI) regulates health insurers,4 which offer benefit coverage to their enrollees through health insurance policies.

All DMHC-regulated plans and/or CDI-regulated policies would be subject to AB 1738. Therefore, the mandate would affect the health insurance of approximately 21.9 million Californians (59%).

AB 1738 would require health care service plans and health insurance policies to provide coverage for at least two courses of treatment within a 12-month period for all tobacco cessation services rated “A” or “B” by the U.S Preventive Services Task Force (USPSTF). Specifically, AB 1738 mandates the following tobacco cessation services and treatments:

- Telephone, group, or individual counseling (requiring four or more sessions, each of at least 10 minutes duration);
- Food and Drug Administration (FDA)-approved prescription medications;5 and
- FDA-approved over-the-counter (OTC) medications.6

---

3 DMHC was established in 2000 to enforce the Knox-Keene Health Care Service Plan of 1975; see Health and Safety Code, Section 1340.
4 CDI licenses “disability insurers.” Disability insurers may offer forms of insurance that are not health insurance. This report considers only the impact of the benefit mandate on health insurance policies, as defined in Insurance Code, Section 106(b) or subdivision (a) of Section 10198.6.
5 FDA-approved prescription medications for smoking cessation include Chantix (varenicline tartrate), Zyban (buproprion), and the nicotine replacement therapy (NRT), Nicotrol, as a nasal spray and oral inhaler.
AB 1738 would prohibit CDI-regulated policies and DMHC-regulated plans from:

- Imposing copayments, coinsurance, or deductibles for those services; and
- Imposing prior authorization or stepped care requirements on tobacco cessation treatments.

The Affordable Care Act of 2010 (ACA) already requires that non-“grandfathered” plans provide coverage for specified preventive services with “A” and “B” recommendations from the USPSTF—including tobacco cessation treatments and services—without cost sharing. AB 1738 would mandate that grandfathered DMHC-regulated plans and CDI-regulated policies in California, currently exempt from the ACA mandate, also provide tobacco cessation treatments and services.

CHBRP is aware of similar mandates in seven other states (Colorado, Maryland, New Jersey, New Mexico, Oregon, Rhode Island, and Vermont). Illinois requires health insurers to offer the option of tobacco cessation benefit coverage. North Dakota requires a $150 lifetime smoking cessation benefit for specific group plans.

Medical Effectiveness

Efficacy of Smoking Cessation Treatments

The literature on the efficacy of behavioral interventions (e.g., counseling, brief advice) and pharmaceuticals for smoking cessation is large and includes numerous meta-analyses of randomized controlled trials (RCTs), the strongest form of evidence for CHBRP analyses. These meta-analyses provide clear and convincing evidence that behavioral and pharmacological treatments and combinations of the two improve quit rates and increase the likelihood of sustained abstinence from smoking. These conclusions about the efficacy of smoking cessation interventions are not likely to be diminished or altered with the publication of new studies, because of the large quantity of literature summarized in the meta-analyses.

Behavioral interventions

- There is clear and convincing evidence that use of multiple types of counseling increases smoking cessation.

- Individual, group, and telephone counseling by physicians and other health professionals increases smoking cessation.

---

6 FDA-approved, over-the-counter (OTC) nicotine replacement products include skin patches, chewing gum, and lozenges.

7 Stepped care requires an enrollee to try a first-line of treatment (often a generic alternative) prior to receiving coverage for a second-line of treatment (often a brand-name medication).

8 A grandfathered health plan is defined as “A group health plan that was created—or an individual health insurance policy that was purchased—on or before March 23, 2010. Grandfathered plans are exempted from many changes required under the ACA. Plans or policies may lose their ‘grandfathered’ status if they make certain significant changes that reduce benefits or increase costs to consumers” (http://www.healthcare.gov/glossary/g/grandfathered-health.html).
Brief counseling interventions (as little as a few minutes) are effective, and the
preponderance of evidence suggests that more intensive counseling is associated with larger
effects.

Psychologists, physicians, pharmacists, and nurses are all effective in providing smoking
cessation counseling.

RCTs that enrolled smokers at high risk for adverse health outcomes (e.g., persons with
coronary heart disease, pregnant women) report similar findings to RCTs that enrolled
smokers who were not at increased risk relative to other smokers.

**Pharmacotherapy**

Pharmacological agents for smoking cessation are commonly divided into those used in
initial attempts to quit smoking (“first-line agents”), followed by those used when initial
attempts to quit have not been successful (“second-line agents”). First-line agents for
smoking cessation include the following: nicotine replacement therapy (NRT) administered
by gum, patch, lozenge, nasal spray, and inhaler; varenicline, a nicotine receptor partial
agonist;9 and the non-nicotine agent bupropion SR, an antidepressant useful in treating
certain addiction syndromes. Second-line agents include clonidine and nortriptyline.

Among first-line agents:
- There is clear and convincing evidence that NRT administered by gum, lozenge, patch,
nasal spray, and inhaler increases smoking cessation.
- There is also clear and convincing evidence that varenicline and bupropion10 increase
smoking cessation.
- There is a preponderance of evidence that varenicline is more effective than bupropion.
- There is a preponderance of evidence that smokers who receive NRT combined with
varenicline or bupropion are more likely to abstain from smoking than persons who
receive a single pharmacological agent.

Among second-line agents:
- There is clear and convincing evidence that clonidine and nortriptyline also increase
smoking cessation relative to placebo.

There is a preponderance of evidence that smokers who receive both counseling and
pharmacological agents are more likely to abstain from smoking than smokers who only
receive counseling.

---

9 The nicotine receptor partial agonist simulates the effects of nicotine to reduce cravings and the pleasurable effect
of smoking cigarettes.
10 Although bupropion SR at strengths of 100 or 150 milligrams is the only formulation of bupropion approved by
the FDA for smoking cessation, meta-analyses regarding the efficacy of bupropion for smoking cessation do not
indicate whether all of the RCTs they included in their analyses assessed bupropion SR. Some of the RCTs included
may have evaluated other formulations of bupropion or other strengths of the medication.
Effects of Coverage for Smoking Cessation Treatments

The evidence base from which conclusions can be drawn about the effects of coverage on utilization of smoking cessation treatments and abstinence from smoking is much less robust than the evidence base regarding the efficacy of these treatments.

Use of smoking cessation treatments

- The preponderance of evidence suggests that persons who have full coverage for NRT and/or bupropion are more likely to use these smoking cessation medications than are persons who do not have coverage for them.

- The evidence of the effect of full coverage for smoking cessation counseling on receipt of counseling relative to no coverage is ambiguous.

- Findings from studies suggest that persons who have more generous coverage for NRT and/or counseling are more likely to use these smoking cessation treatments than are persons who have less generous coverage for them.

Abstinence from smoking

- The preponderance of evidence suggests that full coverage for smoking cessation counseling and pharmacotherapy is associated with improved abstinence from smoking relative to no coverage for smoking cessation treatments.

- The evidence of the effect of more generous coverage for smoking cessation counseling and pharmacotherapy relative to less generous coverage on abstinence from smoking is ambiguous.

Benefit Coverage, Utilization, and Cost Impacts

Nearly 21.9 million Californians are currently enrolled in DMHC-regulated health care service plans and CDI-regulated health insurance policies. AB 1738 mandates that all enrollees in DMHC-regulated plans or CDI-regulated policies would be offered no-cost smoking cessation services. Therefore, the coverage increase in 2012 would immediately affect the 4.5 million enrollees who currently do not have full coverage for counseling, the 17.2 million enrollees who do not currently have full coverage for OTC medications, and the 16.7 million enrollees who do not currently have full coverage for prescription smoking cessation treatments (Table 1). Under AB 1738, all enrollees would have full coverage for smoking cessation services, including counseling, NRT (either available OTC or through a prescription), or prescription medication for smoking cessation, at no cost to the individual. In this section, we focus on the impact of AB 1738 on increasing premium costs among all 21.9 million enrollees with plans or policies subject to the proposed mandate, and on the estimated increase of utilization of smoking cessation treatment among the 1.92 million adult smokers, since they will be the population who might

---

11 For purposes of this report, full coverage for smoking cessation treatments is defined as coverage of all three treatments of smoking cessation with no cost sharing.
attempt to quit using services covered by this newly mandated benefit coverage.

Coverage Impacts

- Eight in 10 (79.4%) enrollees have full coverage for smoking cessation-related counseling, 21.5% have full coverage for OTC smoking cessation treatment, and 23.5% have full coverage for prescription smoking cessation treatment (Table 1). If AB 1738 were enacted, 100% of insured adults would have full coverage for smoking cessation services. CHBRP defines full tobacco cessation benefit coverage as having benefit coverage for all three treatments with no cost sharing.

- Adults in Medi-Cal Managed Care (Medi-Cal HMOs), Major Risk Medical Insurance Program, Access for Infants and Mothers, and Healthy Families (11.2% of adults subject to the proposed mandate) already have comprehensive smoking cessation benefits, which includes smoking cessation-related counseling, OTC smoking cessation treatment, and prescription smoking cessation treatment benefits at no charge to enrollees.

Utilization Impacts

- CHBRP used the 2008 California Tobacco Survey data and the RAND Health Insurance Experiment’s (HIE) estimated impact of cost sharing for well care to estimate pre- and postmandate utilization. Premandate, of the 1.92 million adult smokers enrolled in DMHC-regulated plans or CDI-regulated policies, 304,400 used one or more smoking cessation treatments, with 252,000 using treatments covered through their existing insurance and 52,400 enrollees using treatments that were not covered.

- Postmandate, of the 1.92 million insured adult smokers, CHBRP estimated that the utilization of counseling services would increase by 13.2%, OTC treatments by 44.0%, and prescription treatments by 25.4%.

- Postmandate utilization of one or more smoking cessation treatments would increase by 27.5%, representing an additional 83,300 insured adult smokers using smoking cessation treatment.

Cost Impacts

- Increases in per member per month (PMPM) premiums for the newly mandated benefit coverage vary by market segment (see Table 11 in Benefit Utilization, Cost, and Benefit Coverage Impacts). Increases, as measured by percentage changes in PMPM premiums, are estimated to range from a low of 0.00% (for DMHC-regulated Medi-Cal HMO plans) to a high of 0.28% (for CDI-regulated individual policies) in the affected market segments. Increases, as measured by PMPM premiums, are estimated to range from $0.00 to $0.58.

- In the privately funded large-group market, the increase in premiums is estimated to range from $0.26 PMPM among DMHC-regulated plans to $0.39 PMPM among CDI-regulated policies (Table 11).
For enrollees in the privately funded small-group market, health insurance premiums are estimated to increase by approximately $0.29 PMPM for DMHC-regulated plan contracts and $0.46 PMPM for CDI-regulated policies.

In the privately funded individual market, health insurance premiums are estimated to increase by $0.29 PMPM and by $0.58 PMPM in the DMHC- and CDI-regulated markets, respectively.

For publicly funded DMHC-regulated health plans, CHBRP estimates that premiums would decrease slightly or remain flat for Medi-Cal HMOs and Managed Risk Medical Insurance Board (MRMIB) programs (including Healthy Families), with the impact ranging from 0.00% to 0.03% ($0.00 to $0.03). For California Public Employees’ Retirement System HMOs, CHBRP estimates that premiums would increase 0.09% ($0.38 PMPM).

Total net annual health expenditures are projected to increase by $38.4 million (0.04%) (Table 1). This change in expenditures is due to a $65.8 million increase in health insurance premiums partially offset by reductions in both enrollee out-of-pocket expenses ($11.1 million) and noncovered expenditures ($16.3 million).

The net increase of $38.4 million could be reduced by a savings of $1.6 million in health care spending, representing the potential short-term (i.e., 1-year) savings resulting from a reduction in low birth weight deliveries and hospitalizations due to acute myocardial infarction (AMI) among those who quit smoking.

Public Health Impacts

CHBRP estimates that AB 1738 would produce a positive public health impact by increasing the number of successful quitters by 5,287 enrollees annually. This is due to the fact that AB 1738 would increase the number of enrollees with coverage for smoking cessation treatments, that there is clear and convincing evidence of the effectiveness of smoking cessation treatment, and that the preponderance of evidence is that full coverage increases smoking cessation rates. This would suggest real improved health outcomes for these new quitters in the long term. Although CHBRP cannot quantify the reduction in harms from secondhand smoke due to lack of data, the medical literature indicates that the additional quitters enabled by AB 1738 would reduce harms from secondhand smoke postmandate.

CHBRP estimates that, for the overall population, any cost increase or physical harms from rare serious adverse events resulting from pharmacotherapy would be outweighed by the benefits of smoking cessation.

Due to lack of data, CHBRP cannot quantify the precise impact of AB 1738 on reducing existing gender disparities in smoking prevalence nor on the relevant health outcomes in the insured population. Therefore, the impact of AB 1738 on reducing gender disparities is unknown.
• Due to lack of data, CHBRP cannot quantify the precise impact of AB 1738 on reducing racial/ethnic disparities in smoking prevalence nor on the relevant health outcomes in the insured population. Therefore, the impact of AB 1738 on reducing racial/ethnic disparities is unknown.

• There is clear and convincing evidence that AB 1738 would contribute to the reduction in premature death from smoking-related conditions such as cancer, low birth weight infants, and cardiovascular and respiratory diseases. However, CHBRP cannot estimate the precise magnitude.

• CHBRP estimates that AB 1738 would increase utilization of smoking cessation treatments and increase quit rates postmandate. This increase would contribute to a reduction in economic loss due to reductions in lost productivity from smoking-related illness and premature death, but the magnitude cannot be estimated.

• CHBRP finds clear and convincing evidence that smoking cessation is a cost-effective preventive treatment that results in long term improvements in multiple health outcomes and reduces both direct medical costs and indirect costs associated with smoking. CHBRP estimates between 37,009 to 65,559 life years would be gained annually under the new mandate. The expected reduction in smoking prevalence and mortality attributable to AB 1738 would bring California closer to achieving Healthy People 2020 goals of 80% of smokers attempting to quit, and 12% rate of smoking among adults (USDHHS, 2010).

Effects of the Affordable Care Act

The federal “Patient Protection and Affordable Care Act” (P.L.111-148) and the “Health Care and Education Reconciliation Act” (H.R.4872) were enacted in March 2010. Together, these laws are referred to as the Affordable Care Act (ACA). The provisions that have gone into effect since 2010—including a federal mandate to cover preventive services with no cost sharing—are reflected in baseline enrollment, expenditures, and premiums for AB 1738. It is unclear, however, to what extent DMHC-regulated plans and CDI-regulated policies are “grandfathered”—in existence before March 2010—and therefore exempt from the ACA’s preventive services requirements. The Introduction of this report discusses potential interactions of the mandated services proposed in AB 1738 and the ACA, including:

• A comparison of services mandated by AB 1738 with preventive services mandated in the ACA beginning September 2010.

• A review of the potential interaction between AB 1738 and essential health benefits in 2014-2015, as defined by the various benchmark plans options so far specified in a federal bulletin.12

It is important to note that CHBRP’s analyses of specific mandate bills typically address the marginal effects of the mandate bill—specifically, how the proposed mandate would impact benefit coverage, utilization, costs, and public health, holding all other factors constant. CHBRP’s estimates of these marginal effects are presented in this report.

---

Table 1. AB 1738 Impacts on Benefit Coverage, Utilization, and Cost, 2012

<table>
<thead>
<tr>
<th>Benefit Coverage</th>
<th>Before Mandate</th>
<th>After Mandate</th>
<th>Increase/Decrease Change After Mandate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total enrollees with health insurance subject to state-level benefit mandates(a)</td>
<td>21,882,000</td>
<td>21,882,000</td>
<td>0</td>
</tr>
<tr>
<td>Total enrollees with health insurance subject to AB 1738</td>
<td>21,882,000</td>
<td>21,882,000</td>
<td>0</td>
</tr>
</tbody>
</table>

**Number of Enrollees with Counseling Coverage**

<table>
<thead>
<tr>
<th>Coverage</th>
<th>Before Mandate</th>
<th>After Mandate</th>
<th>Increase/Decrease</th>
<th>Change After Mandate</th>
</tr>
</thead>
<tbody>
<tr>
<td>No coverage</td>
<td>3,765,607</td>
<td>0</td>
<td>-3,765,607</td>
<td>-100.0%</td>
</tr>
<tr>
<td>Coverage, with cost sharing</td>
<td>735,467</td>
<td>0</td>
<td>-735,467</td>
<td>-100.0%</td>
</tr>
<tr>
<td>Full coverage, no cost sharing</td>
<td>17,380,926</td>
<td>21,882,000</td>
<td>4,501,074</td>
<td>25.9%</td>
</tr>
</tbody>
</table>

**Number of Enrollees with OTC Drug Coverage**

<table>
<thead>
<tr>
<th>Coverage</th>
<th>Before Mandate</th>
<th>After Mandate</th>
<th>Increase/Decrease</th>
<th>Change After Mandate</th>
</tr>
</thead>
<tbody>
<tr>
<td>No coverage</td>
<td>8,417,064</td>
<td>0</td>
<td>-8,417,064</td>
<td>-100.0%</td>
</tr>
<tr>
<td>Coverage, with cost sharing</td>
<td>8,757,726</td>
<td>0</td>
<td>-8,757,726</td>
<td>-100.0%</td>
</tr>
<tr>
<td>Full coverage, no cost sharing</td>
<td>4,707,211</td>
<td>21,882,000</td>
<td>17,174,789</td>
<td>364.9%</td>
</tr>
</tbody>
</table>

**Number of Enrollees with Prescription Smoking Cessation Coverage**

<table>
<thead>
<tr>
<th>Coverage</th>
<th>Before Mandate</th>
<th>After Mandate</th>
<th>Increase/Decrease</th>
<th>Change After Mandate</th>
</tr>
</thead>
<tbody>
<tr>
<td>No coverage</td>
<td>2,176,676</td>
<td>0</td>
<td>-2,176,676</td>
<td>-100.0%</td>
</tr>
<tr>
<td>Coverage, with cost sharing</td>
<td>14,566,190</td>
<td>0</td>
<td>-14,566,190</td>
<td>-100.0%</td>
</tr>
<tr>
<td>Full coverage, no cost sharing</td>
<td>5,139,133</td>
<td>21,882,000</td>
<td>16,742,867</td>
<td>325.8%</td>
</tr>
</tbody>
</table>

**Percentage of Enrollees with Counseling Coverage**

<table>
<thead>
<tr>
<th>Coverage</th>
<th>Before Mandate</th>
<th>After Mandate</th>
<th>Increase/Decrease</th>
<th>Change After Mandate</th>
</tr>
</thead>
<tbody>
<tr>
<td>No coverage</td>
<td>17.2%</td>
<td>0.0%</td>
<td>-17.2%</td>
<td>-100.0%</td>
</tr>
<tr>
<td>Coverage, with cost sharing</td>
<td>3.4%</td>
<td>0.0%</td>
<td>-3.4%</td>
<td>-100.0%</td>
</tr>
<tr>
<td>Full coverage, no cost sharing</td>
<td>79.4%</td>
<td>100.0%</td>
<td>20.6%</td>
<td>25.9%</td>
</tr>
</tbody>
</table>

**Percentage of Enrollees with OTC Drug Coverage**

<table>
<thead>
<tr>
<th>Coverage</th>
<th>Before Mandate</th>
<th>After Mandate</th>
<th>Increase/Decrease</th>
<th>Change After Mandate</th>
</tr>
</thead>
<tbody>
<tr>
<td>No coverage</td>
<td>38.5%</td>
<td>0.0%</td>
<td>-38.5%</td>
<td>-100.0%</td>
</tr>
<tr>
<td>Coverage, with cost sharing</td>
<td>40.0%</td>
<td>0.0%</td>
<td>-40.0%</td>
<td>-100.0%</td>
</tr>
<tr>
<td>Full coverage, no cost sharing</td>
<td>21.5%</td>
<td>100.0%</td>
<td>78.5%</td>
<td>364.9%</td>
</tr>
</tbody>
</table>

**Percentage of Enrollees with Prescription Smoking Cessation Coverage**

<table>
<thead>
<tr>
<th>Coverage</th>
<th>Before Mandate</th>
<th>After Mandate</th>
<th>Increase/Decrease</th>
<th>Change After Mandate</th>
</tr>
</thead>
<tbody>
<tr>
<td>No coverage</td>
<td>9.9%</td>
<td>0.0%</td>
<td>-9.9%</td>
<td>-100.0%</td>
</tr>
<tr>
<td>Coverage, with cost sharing</td>
<td>66.6%</td>
<td>0.0%</td>
<td>-66.6%</td>
<td>-100.0%</td>
</tr>
<tr>
<td>Full coverage, no cost sharing</td>
<td>23.5%</td>
<td>100.0%</td>
<td>76.5%</td>
<td>325.8%</td>
</tr>
</tbody>
</table>

**Utilization and Cost**

**Number of Enrollees who Smoke and Use:**

<table>
<thead>
<tr>
<th>Service</th>
<th>Before Mandate</th>
<th>After Mandate</th>
<th>Increase/Decrease</th>
<th>Change After Mandate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Counseling</td>
<td>159,313</td>
<td>180,268</td>
<td>20,955</td>
<td>13.2%</td>
</tr>
<tr>
<td>OTC drugs</td>
<td>195,100</td>
<td>280,896</td>
<td>85,796</td>
<td>44.0%</td>
</tr>
<tr>
<td>Prescription drugs</td>
<td>91,201</td>
<td>114,329</td>
<td>23,128</td>
<td>25.4%</td>
</tr>
<tr>
<td>Total (at least one or more services)</td>
<td>304,370</td>
<td>387,638</td>
<td>83,268</td>
<td>27.4%</td>
</tr>
</tbody>
</table>
Table 1. AB 1738 Impacts on Benefit Coverage, Utilization, and Cost, 2012 (Cont’d)

<table>
<thead>
<tr>
<th></th>
<th>Before Mandate</th>
<th>After Mandate</th>
<th>Increase/Decrease</th>
<th>Change After Mandate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average Cost per Course of Treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Counseling</td>
<td>$200</td>
<td>$200</td>
<td>$0</td>
<td>0.0%</td>
</tr>
<tr>
<td>OTC drugs</td>
<td>$236</td>
<td>$236</td>
<td>$0</td>
<td>0.0%</td>
</tr>
<tr>
<td>Prescription drugs</td>
<td>$240</td>
<td>$240</td>
<td>$0</td>
<td>0.0%</td>
</tr>
<tr>
<td>Expenditures</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Premium expenditures by private employers for group insurance</td>
<td>$60,279,820,000</td>
<td>$60,319,646,000</td>
<td>$39,826,000</td>
<td>0.0661%</td>
</tr>
<tr>
<td>Premium expenditures for individually purchased insurance</td>
<td>$7,094,708,000</td>
<td>$7,107,133,000</td>
<td>$12,425,000</td>
<td>0.1751%</td>
</tr>
<tr>
<td>Premium expenditures by persons with group insurance, CalPERS HMOs, Healthy Families Program, AIM or MRMIP (b)</td>
<td>$14,706,245,000</td>
<td>$14,716,413,000</td>
<td>$10,168,000</td>
<td>0.0691%</td>
</tr>
<tr>
<td>CalPERS HMO employer expenditures (c)</td>
<td>$3,651,121,000</td>
<td>$3,654,263,000</td>
<td>$3,142,000</td>
<td>0.0861%</td>
</tr>
<tr>
<td>Medi-Cal Managed Care Plan expenditures</td>
<td>$7,637,700,000</td>
<td>$7,637,700,000</td>
<td>$0</td>
<td>0.0000%</td>
</tr>
<tr>
<td>MRMIB Plan expenditures (d)</td>
<td>$1,046,243,000</td>
<td>$1,046,522,000</td>
<td>$279,000</td>
<td>0.0267%</td>
</tr>
<tr>
<td>Enrollee out-of-pocket expenses for covered benefits (deductibles, copayments, etc.)</td>
<td>$8,397,404,000</td>
<td>$8,386,259,000</td>
<td>($11,145,000)</td>
<td>-0.1327%</td>
</tr>
<tr>
<td>Enrollee expenses for noncovered benefits (e)</td>
<td>$16,338,000</td>
<td>$0</td>
<td>($16,338,000)</td>
<td>-100.0%</td>
</tr>
<tr>
<td>Total Expenditures</td>
<td>$102,829,579,000</td>
<td>$102,867,936,000</td>
<td>$38,357,000</td>
<td>0.0373%</td>
</tr>
</tbody>
</table>

Notes: (a) This population includes persons with privately funded and publicly funded (e.g., CalPERS HMOs, Medi-Cal Managed Care Plans, Healthy Families Program, AIM, and MRMIP) health insurance products regulated by DMHC or CDI. Population includes enrollees aged 0 to 64 years and enrollees 65 years or older covered by employer-sponsored insurance.
(b) Premium expenditures by enrollees include employee contributions to employer-sponsored health insurance and enrollee contributions for publicly purchased insurance.
(c) Of the increase in CalPERS employer expenditures, about 58% or $1,821,000 would be state expenditures for CalPERS members who are state employees or their dependents.
(d) MRMIB plan expenditures include expenditures for 874,000 enrollees of the Healthy Families Program, 7,000 enrollees of MRMIP, and 7,000 enrollees of the AIM program.
(e) Includes only those expenses that are paid directly by enrollees to providers for services related to the mandated benefit that are not currently covered by insurance. In addition, this only includes those expenses that will be newly covered postmandate. Other components of expenditures in this table include all health care services covered by insurance.
Key: AIM=Access for Infants and Mothers; CalPERS HMOs=California Public Employees’ Retirement System Health Maintenance Organizations; CDI=California Department of Insurance; DMHC=Department of Managed Health; MRMIB =Managed Risk Medical Insurance Board; MRMIP=Major Risk Medical Insurance Program.
INTRODUCTION

The California Assembly Committee on Health requested on February 17, 2012 that the California Health Benefits Review Program (CHBRP) conduct an evidence-based assessment of the medical, financial, and public health impacts of Assembly Bill (AB) 1738, a bill that would impose a health benefit mandate. In response to this request, CHBRP undertook this analysis pursuant to the provisions of the program’s authorizing statute.13

Analysis of AB 1738

Approximately 21.9 million Californians (59%) have health insurance that may be subject to a health benefit mandate law passed at the state level.14 Of the rest of the state’s population, a portion is uninsured (and so has no health insurance subject to any benefit mandate) and another portion has health insurance subject to other state law or only to federal laws.

Uniquely, California has a bifurcated system of regulation for health insurance subject to state-level benefit mandates. The California Department of Managed Health Care (DMHC)15 regulates health care service plans, which offer benefit coverage to their enrollees through health plan contracts. The California Department of Insurance (CDI) regulates health insurers,16 which offer benefit coverage to their enrollees through health insurance policies.

All DMHC-regulated plans and CDI-regulated policies would be subject to AB 1738. Therefore, the mandate would affect the health insurance of approximately 21.9 million Californians (59%).

Bill Language

The full text of AB 1738 can be found in Appendix A.

AB 1738 would require health care service plans and health insurance policies to provide coverage for at least two courses of treatment within a 12-month period for all tobacco cessation services rated “A” or “B” by the U.S. Preventive Services Task Force (USPSTF). Specifically, AB 1738 mandates the inclusion of the following tobacco cessation services and treatments:

- Telephone, group, or individual counseling (requiring four or more sessions, each of at least 10 minutes duration);
- Food and Drug Administration (FDA)-approved prescription medications;17 and
- FDA-approved over-the-counter (OTC) medications.18

15 DMHC was established in 2000 to enforce the Knox-Keene Health Care Service Plan of 1975; see Health and Safety Code, Section 1340.
16 CDI licenses “disability insurers.” Disability insurers may offer forms of insurance that are not health insurance. This report considers only the impact of the benefit mandate on health insurance policies, as defined in Insurance Code, Section 106(b) or subdivision (a) of Section 10198.6.
17 FDA-approved prescription medications for smoking cessation include Chantix (varenicline tartrate), Zyban (bupropion), and the nicotine replacement therapy, Nicotrol, as a nasal spray and oral inhaler.
18 FDA-approved OTC nicotine replacement products include skin patches, chewing gum, and lozenges.
AB 1738 would prohibit CDI-regulated policies and DMHC-regulated plans from:

- Imposing copayments, coinsurance, or deductibles for tobacco cessation treatments; and
- Imposing prior authorization or stepped care requirements on tobacco cessation treatments.

AB 1738 is cosponsored by the American Heart Association and the American Lung Association. The bill author says that benefit coverage for tobacco cessation treatments and services are inconsistent across health insurance plans and policies. Further, the bill author notes that federal mandates associated with the Affordable Care Act of 2010 (ACA) to require coverage of preventive services and essential health benefits (EHBs) do not apply to all DMHC-regulated plans or CDI-regulated policies, principally because under the ACA, existing (“grandfathered”) plans and policies that do not presently cover smoking cessation services will not be required to begin such coverage. With AB 1738, the bill author’s stated intent is to establish a common baseline for tobacco cessation benefit coverage among DMHC-regulated plans and CDI-regulated policies.

CHBRP has previously analyzed four proposed mandates related to tobacco cessation benefit coverage:

- SB 576 (Ortiz, 2005),
- SB 24 (Torlakson, 2007),
- SB 220 (Yee, 2010), and
- SB 136 (Yee, 2011).

Analytic Approach and Key Assumptions

For this analysis, CHBRP considered two factors that affect the use of smoking cessation services: (a) benefit coverage, and (b) type of smoking cessation treatment used.

Enrollees can have varying degrees of benefit coverage for tobacco cessation, ranging from no coverage to full benefit coverage. In this report, full benefit coverage is defined as benefit coverage for all three smoking cessation treatments (counseling and both prescription and

---

19 Stepped care requires an enrollee to try a first line of treatment (often a generic alternative) prior to receiving coverage for a second line of treatment (often a brand-name medication).
20 The ACA, effective September 23, 2010, requires health insurance policies created after March 23, 2010 to provide benefit coverage for a range of preventive services, including tobacco cessation treatments and services without in-network cost sharing.
21 Plans and policies in existence before March 23, 2010 are considered “grandfathered” plans. “Grandfathered” plans are exempted from a number of provisions stipulated by the ACA. Plans or policies may lose their grandfathered status if they make certain significant changes that reduce benefits or increase costs to consumers.” Available at http://www.healthcare.gov/glossary/g/grandfathered-health.html.
22 In general, tobacco cessation mandates previously analyzed by CHBRP would have required benefit coverage for at least two courses of tobacco cessation treatment, including counseling, prescription and OTC medications. The proposed mandates differed over the level of cost sharing permitted and which plans would be subject to the proposed mandate. The earlier bills—SB 576 and SB 24—would have required a subset of state regulated plans and policies that provided outpatient prescription drug benefits to be subject to the mandate, whereas the two more recent bills—SB 220 and SB 136—would have required that all plans be subject to the mandate.
nonprescription medications) without cost sharing. Furthermore, quitting smoking is a dynamic process, involving different types of assistance and, often, multiple quit attempts (Figure 1). CHBRP uses the 2008 California Tobacco Survey data and the RAND Health Insurance Experiment’s (HIE) estimated impact of cost sharing for well care to estimate premandate and postmandate utilization. The California Health Interview Survey (CHIS) 2009 is used to estimate present number of smokers.

The Medical Effectiveness review examines two topics: the effectiveness of pharmaceutical and counseling treatments for smoking cessation and the effectiveness of health insurance coverage on changing smoking cessation utilization. The standard CHBRP Benefit Coverage, Cost, and Utilization model is applied to the mandate to analyze its 1-year impact. As a preventive service, smoking cessation would be expected to have long-term impacts, and the available literature is reviewed and summarized in the Public Health Impacts section.

The estimated primary impact of AB 1738 is based on data and literature demonstrating increased utilization of smoking cessation treatment(s), as opposed to attempting to quit without any cessation treatment. CHBRP assumes the total number of persons attempting to quit would not change postmandate; however, a shift would occur from persons using newly covered cessation treatments from no treatment use. The literature indicates that persons using cessation treatments experience a higher quit rate than those going “cold turkey” (no treatment use). For the analysis of AB 1738, CHBRP assumes an increased utilization of treatments and a higher quit rate postmandate. While it is possible that the mandate could be the impetus to increase the number of people attempting to quit, such an estimate is not provided in this analysis, as those data are not available. It is possible that the impact of AB 1738 may be higher than CHBRP’s estimates assuming that successful quit rates approach those in many of the randomized controlled trials (RCT). On the other hand, it is often the case that the effects in the “real world” are less than in controlled trials, which would have the effect of reducing quit rates.

AB 1738 includes the requirement that enrollees not be required to enter counseling in order to receive smoking cessation medications. It also stipulates that plans shall not impose prior authorization or stepped-care requirements on smoking cessation treatment. This would constitute a change in utilization requirements for certain managed care plans (including Medi-Cal Managed Care). CHBRP is unable to quantify the effects of this change on projected utilization and costs.

The level of an individual’s consumption of tobacco is one other factor in smoking cessation. Because of lack of overall data on the intensity of consumption, however, CHBRP does not attempt to disaggregate the available data by extent of cigarette consumption.

AB 1738 applies to all DMHC-regulated plans and CDI-regulated policies, which together enroll 21.9 million Californians. As introduced, however, the bill defers to the USPSTF’s “A” and “B”

23 CHBRP examines the impacts of AB 1738 on those plans and policies that are subject to CDI and DMHC regulation. This excludes populations enrolled in self-insured plans, Medi-Cal fee-for-service, Medicare as a primary payer, and others. See http://www.chbrp.org/analysis_methodology/cost_impact_analysis.php for more information regarding the population typically subject to benefit mandates.
recommendations, which apply to pregnant women and adults aged 18 years and older. In this analysis, CHBRP does not address the potential impacts on adolescents aged 12 to 17 years. While a recent Surgeon General report notes that the rate of decline in tobacco use among teens has flattened in recent years, the report also notes that relatively little is known about the effectiveness of clinical interventions for this population segment. In addition, the USPSTF found in 2003 “limited evidence that screening and counseling children and adolescents in the primary care setting are effective” in preventing tobacco use25 and, therefore, does not include “A-” and “B-” level recommendations on tobacco cessation treatments for this cohort.

Existing California Requirements

California activities
The 1988 California Tobacco Tax and Health Promotion Act (Proposition 99) imposed a 25 cent-per-pack state surtax on cigarettes and other tobacco-related products, resulting in additional revenues that were appropriated for tobacco-related research, health care for medically indigent families, and tobacco cessation education and services.26 This cigarette tax will generate an estimated $269 million in 2012-2013 (GBS, 2012).27 One recipient of cigarette tax funds is the California Smokers’ Helpline, which is a free telephone counseling service created in 1992.28 It provides counseling in six languages, including English, Spanish, Korean, Vietnamese, Mandarin, and Cantonese,29 as well as specialized services for teens, pregnant women, and tobacco chewers.

Tobacco tax revenues are also used to fund the California Tobacco Control Program (CTCP). The CTCP provides financing for a wide variety of anti-smoking programs. In addition to funding local health departments’ efforts, the CTCP maintains a competitive grant program for nonprofit organizations engaging in work on tobacco control and smoking intervention at the local level, supplementing its statewide media and advocacy work.30 The CTCP also maintains the Tobacco Education Clearinghouse of California (TECC), offering a library of more than 20,000 tobacco-related materials available for loan as well as professional research assistance and other research and support services.31

Other smoking-related policies in California include a smoke-free workplace law, enacted in 1995, to reduce the public health burden of environmental tobacco smoke (“secondhand smoke”). From 1989 to 2008, smoking prevalence in California decreased from 21.1% to 13.3%

26 Administered through the then-California Department of Health Services Tobacco Control Program. DHS subsequently split into the Department of Health Care Services and the California Department of Public Health, which administers the tobacco program.
27 Altogether, California’s cigarette tax is 87 cents-per-pack of cigarettes. In 2012-13, California will collect an estimated $853 million in tobacco-related taxes.
28 The California Smokers’ Helpline does not provide in-person individual or group counseling or pharmacotherapy.
30 Available at: http://www.cdph.ca.gov/programs/tobacco/Pages/CTCPLocalStatewideProjects.aspx.
31 Available at: http://www.tobaccofreecatalog.org/.
In addition, attempts to quit smoking (i.e., the percentage of smokers reporting a quit attempt in the preceding 12 months) increased from 53.7% to 60.2% between 1996 and 2008 (CDPH, 2010).

California, like the majority of states, also receives payments from tobacco companies to help offset smoking-related Medicaid costs (OAG, 2011). Since 1999, California has received more than $10 billion in payments from tobacco companies as part of the multi-state tobacco settlement, wherein the four major U.S. tobacco firms agreed to compensate state Medicaid programs for smoking-related health costs. California’s total annual share is approximately $700 million, with one-half going to the state and one-half going to local governments. However, beginning with the 2002-2003 budget, the state began to divert its share of tobacco settlement fund revenues from health programs to debt repayment (LAO, 2002), a process that continues.

Requirements in Other States

CHBRP is aware of similar mandates in seven other states (Colorado, Maryland, New Jersey, New Mexico, Oregon, Rhode Island, and Vermont), which require coverage for smoking cessation treatment (ALA, 2011c). Illinois requires health insurers to offer the option of tobacco cessation benefit coverage. North Dakota requires a $150 lifetime smoking cessation benefit for specific group plans (Table 2).

Table 2. Tobacco Cessation Benefit Coverage Mandates in Other States

<table>
<thead>
<tr>
<th>State</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colorado (2010)</td>
<td>Requires health plans to cover tobacco screenings and cessation interventions by primary care providers, according to USPSTF’s “A” and “B” recommendations. The screenings, treatments, and services are not subject to any deductible or coinsurance, though copayments are permitted. (a)</td>
</tr>
<tr>
<td>Illinois (2012)</td>
<td>Requires health insurance plans to offer employers the option of covering at least $500 in tobacco cessation treatments for enrollees aged 18 years and older. (b)</td>
</tr>
<tr>
<td>Maryland (2006)</td>
<td>Requires plans that cover prescription drugs to cover two 90-day courses of nicotine replacement therapy in a policy year. Normal cost sharing applies. Excludes OTC medications. (c)</td>
</tr>
<tr>
<td>New Jersey (2008)</td>
<td>Requires coverage of physician-determined treatment up to limits ranging from $125 to $235, based on age and gender.</td>
</tr>
<tr>
<td>New Mexico (2004)</td>
<td>Requires that all private health insurance plans that provide maternity benefits also provide coverage for smoking cessation treatments for pregnant women. Such treatments are to include: diagnostic services, two 90-day courses of FDA-approved prescription medications, and counseling. Normal cost-sharing applies. (d)</td>
</tr>
<tr>
<td>North Dakota (2008)</td>
<td>Requires “standard” insurance plans for small employers to include coverage for a $150 lifetime smoking cessation benefit. Nonstandard plans are not required to have the cessation benefit. Small employers can select from both standard and nonstandard plans.</td>
</tr>
<tr>
<td>Oregon (2010)</td>
<td>Requires coverage for smoking cessation treatment including both “educational and medical” component following U.S. Public Health Service guidelines. The mandate applies to enrollees aged 15 years and older and must be at least $500 per lifetime. (e)</td>
</tr>
<tr>
<td>Rhode Island (2010)</td>
<td>Requires health insurance plans and policies that cover prescription drugs to cover all FDA-approved tobacco cessation medications – both prescription and OTC – when used in conjunction with 16 half-hour counseling sessions. Normal cost-sharing applies. (f)</td>
</tr>
</tbody>
</table>

32 In 1998, four major U.S. tobacco companies agreed to compensate 46 states, the District of Columbia, and five U.S. territories $246 billion over a 25-year period for smoking-related medical costs in their Medicaid programs.
Table 2. Tobacco Cessation Benefit Coverage Mandates in Other States (Cont’d)

<table>
<thead>
<tr>
<th>State</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vermont</td>
<td>Requires benefit coverage of at least one 3-month supply of FDA-approved tobacco cessation medication—both prescribed and OTC. Normal cost sharing applies. (g)</td>
</tr>
</tbody>
</table>

*Source: California Health Benefits Review Program, 2012.*

*Notes: The ACA may affect cost sharing levels or benefit limits for non-“grandfathered” health insurance plans or policies. Grandfathered plans are exempted from many changes required under the ACA.

(a) Colorado Revised Statutes 10-16-104 (18) (b) (IX)
(b) Illinois Statute 215 ILCS/356z.16
(c) Maryland Insurance Code Section 15-841
(d) New Mexico Administrative Code 13-10-18
(e) Oregon Revised Statutes 743A.170
(f) Rhode Island General Laws Section 27-41-70
(g) Vermont Statutes 8 VSA Section 4100j

*Key:* FDA=U.S. Food and Drug Administration; USPSTF=U.S. Preventive Services Task Force

**State Medicaid coverage of tobacco cessation**

Forty-one state Medicaid programs, including California’s, provide at least partial benefit coverage for tobacco cessation treatments (ALA, 2011b). Six states—Indiana, Massachusetts, Minnesota, Nevada, Oregon and Pennsylvania—offer comprehensive cessation benefits to tobacco users on Medicaid. Additionally, as of October 1, 2010, all state Medicaid programs are required to offer comprehensive tobacco cessation benefits to pregnant women, per ACA requirements (more details follow in the ACA discussion).

One state that provides comprehensive smoking cessation benefits as part of its Medicaid program is Massachusetts. In July 2006, Massachusetts’ health care reform law mandated tobacco cessation coverage for the state’s Medicaid population. The new benefit included behavioral counseling and all medications, including (OTC) medications, approved for tobacco cessation treatment by the FDA. Prior to 2006, MassHealth (the Massachusetts Medicaid program) did not provide tobacco cessation benefits. Between July 1, 2006, and December 31, 2008—after the state heavily promoted the new tobacco cessation program—a total of 70,140 unique Massachusetts Medicaid subscribers used the newly available benefit, which is approximately 37% of all Massachusetts smokers with Medicaid coverage. The crude smoking rate decreased from 38.3% of MassHealth enrollees to 28.3% of enrollees—a 26% decline (Land et al., 2010).

**Effects of Federal Affordable Care Act**

The federal “Patient Protection and Affordable Care Act” (P.L.111-148) and the “Health Care and Education Reconciliation Act” (H.R.4872) were enacted in March 2010. These laws (together referred to as the “Affordable Care Act [ACA]”) are expected to dramatically affect the California health insurance market and its regulatory environment, with most changes becoming effective in 2014.

Provisions of the ACA that go into effect during the transitional years (2010-2013) affect current enrollment (the baseline), expenditures, and premiums. It is important to note that CHBPRP’s analysis of specific mandate bills typically address the marginal effects of the mandate bill—specifically, how the proposed mandate would impact benefit coverage, utilization, costs, and public health, holding all other factors constant. CHBPRP’s estimates of these marginal effects are
presented in this report. Each of the provisions that have gone into effect by January 2012 has been considered, and where data allow, CHBRP has made adjustments to the Cost and Coverage Model to reflect changes in enrollment and/or baseline premiums. These adjustments are discussed in further detail in Appendix D.

Some provisions of the ACA enacted federal health insurance benefit mandates. The mandates relevant to AB 1738 are discussed below.

Effective 2010: Preventive services
The ACA requires that non-grandfathered health plans and policies cover certain preventive services with no cost sharing beginning September 23, 2010. Tobacco cessation-related services and treatments that fall under the ACA’s preventive services requirement are defined as those having an “A” or “B” recommendation from the USPSTF. These services include:

- Tobacco-use counseling and FDA-approved pharmacotherapy for nonpregnant adults. Specifically, the USPSTF recommends that clinicians ask all adults about tobacco use and provide tobacco cessation interventions for those who use tobacco products. Grade A, April 2009 (USPSTF, 2010).
- Tobacco-use counseling for pregnant women. The USPSTF recommends that clinicians ask all pregnant women about tobacco use and provide augmented, pregnancy-tailored counseling to those who smoke. Grade A, April 2009 (USPSTF, 2010).

AB 1738’s requirements, therefore, would broaden the ACA’s preventive services tobacco cessation mandate to include grandfathered DMHC-regulated plans and CDI-regulated policies (Table 3). It is not clear how many DMHC-regulated plans and CDI-regulated policies are grandfathered and therefore not subject to the mandate. The U.S. Departments of Labor and Treasury estimate that by 2013, between 39% and 69% of all employer group plans will have relinquished their grandfathered status.  

---

34 A grandfathered health plan is defined as “A group health plan that was created—or an individual health insurance policy that was purchased—on or before March 23, 2010. Grandfathered plans are exempted from many changes required under the ACA. Plans or policies may lose their ‘grandfathered’ status if they make certain significant changes that reduce benefits or increase costs to consumers. (http://www.healthcare.gov/glossary/g/grandfathered-health.html).  
35 For small employers (3 to 99 employees), the estimated percentage relinquishing grandfathered status is between 49% and 80%; for large employers (more than 100 employees), the estimate is 34% to 64%. U.S. Department of Labor and Department of Treasury, Interim Final Rules for Group Health Plans and Health Insurance Coverage Relating to Status as a Grandfathered Health Plan Under the Patient Protection and Affordable Care Act, (June 17, 2010).
Table 3: Comparison of Benefit Coverage Mandated by AB 1738 and Recommended by the U.S. Preventive Services Task Force, as part of the Affordable Care Act Preventive Services Mandate

<table>
<thead>
<tr>
<th>Benefits Specified</th>
<th>AB 1738</th>
<th>USPSTF “A” or “B” Recommendations (c)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Counseling</td>
<td>Yes (a)</td>
<td>Yes (b)</td>
</tr>
<tr>
<td>FDA-approved prescription medications</td>
<td>Yes</td>
<td>“FDA-approved pharmacotherapy includes nicotine replacement therapy, sustained-release bupropion, and varenicline”</td>
</tr>
<tr>
<td>FDA-approved OTC medications</td>
<td>Yes</td>
<td>“FDA-approved pharmacotherapy” including nicotine replacement therapy</td>
</tr>
</tbody>
</table>

*Source: California Health Benefits Review Program, 2012 (Based on AB 1738 and U.S. Preventive Services Task Force Clinical Guidelines)*

(a) Four sessions, lasting at least 10 minutes each.
(b) USPSTF recommends tobacco cessation counseling for both pregnant and nonpregnant adults. USPSTF finds counseling sessions longer than 3 minutes to be effective, but does not specify a minimum length (USPSTF, 2009). (c) The ACA preventive services mandate defers to the USPSTF “A” and “B” recommendations for tobacco cessation services.

Key: ACA=Affordable Care Act; FDA=U.S. Food and Drug Administration; OTC=over-the-counter.

In addition, effective October 1, 2010, all states are required to extend comprehensive tobacco cessation services to all pregnant women enrolled in Medicaid program (ALA, 2011b). Section 4107 of the ACA mandates coverage of comprehensive tobacco cessation services, defined as counseling and pharmacotherapy without cost sharing, for pregnant women enrolled in Medicaid.

**Effective 2014: Essential health benefits**

The ACA requires non-grandfathered small-group and individual health insurance, including but not limited to qualified health plans (QHPs) sold through the California Exchange, to cover specified categories of benefits, called essential health benefits (EHBs) beginning January 1, 2014. The ACA defines EHBs as including these categories: (1) ambulatory patient services; (2) emergency services; (3) hospitalization; (4) maternity and newborn care; (5) mental health and substance use disorder services, including behavioral health treatment; (6) prescription drugs; (7) rehabilitative and habilitative services and devices; (8) laboratory services; (9) preventive and wellness services and chronic disease management; and (10) pediatric services, including oral and vision care. The Secretary of Health and Human Services (HHS) is charged with defining these categories through regulation and ensuring that the EHB floor “is equal to the scope of benefits provided under a typical employer plan.”

The ACA allows a state to require QHPs sold through an exchange to provide benefits that are “in addition to” EHBs. However, if the state does so, the state must defray the cost of those additionally mandated benefits that exceed EHBs, either by paying the purchaser directly or by paying the QHP.

---

36 ACA Section 1302(b)
In 2014 and 2015, HHS has proposed that each state define its own EHBs for those years by selecting one of a set of specified benchmark plan options. The choice of benchmark plan is expected to dictate which state benefit mandates, if any, will be included in the state’s EHBs.\textsuperscript{37} Any state-mandated benefit enacted after December 31, 2011 may not be part of the EHBs for 2014 and 2015.\textsuperscript{38} If passed, AB 1738 would be effective January 1, 2013. Therefore, if any proposed benefit coverage mandates included in AB 1738 exceed EHBs, as defined in 2014 and 2015, California may be required to defray the cost for QHPs sold through the California Exchange.

HHS has not released final guidance on defining the EHBs or final guidance on how states will defray the costs of state benefit mandates that require QHPs to exceed EHBs.\textsuperscript{39} For further discussion on how state benefit mandates may interact with the EHBs and the benchmark plan regulatory approach, please see CHBRP issue brief, \textit{Interaction between California’s State Benefit Mandates and the Affordable Care Act’s “Essential Health Benefits.”}\textsuperscript{40}

\textit{Effects beginning in 2014: Essential health benefits and AB 1738}

Because the state would be fiscally responsible for mandates exceeding EHBs, CHBRP is providing the following consideration of how the benefit mandate in AB 1738 might interact with EHBs. As mentioned, the 10 EHB categories in the ACA explicitly include “preventive and wellness services and chronic disease management.”

For 2014 and 2015, states will define EHBs by selecting a benchmark plan option, which could include benefit mandates in effect by December 31, 2011, effectively wrapping up those mandates into the definition of EHBs. Because AB 1738 would not be in effect prior to December 31, 2011, it appears that the benefit mandate in AB 1738 would not be part of the EHBs for 2014 and 2015.

However, regardless of the ultimate definition of EHBs for 2014 and 2015, the ACA already requires tobacco cessation benefit coverage for non-grandfathered health plans and policies through its preventive services requirements. As presented in Table 4, it seems likely that at least two of the treatments—counseling and prescription medications—that would also be mandated under AB 1738 would fall “within” EHBs because of the ACA’s preventive services requirement. For the third treatment, OTC medications, the interaction with EHBs is “unclear.” While the USPSTF recommendations do include FDA-approved nicotine replacement therapies (NRT)—some of which are OTC—it is unclear how health insurers are interpreting this requirement.

\textsuperscript{39} It seems likely that states would be required to defray the marginal cost impact associated with the state benefit mandates’ exceeding EHBs. Such a marginal cost may be calculated in a fashion similar to the manner in which CHBRP estimates marginal cost impacts when assessing benefit mandate bills on behalf of the California Legislature.
\textsuperscript{40} Available at http://chbrp.org/publications.html.
<table>
<thead>
<tr>
<th>ACA Essential Health Benefits</th>
<th>Benefits Mandated in AB 1738</th>
<th>Tobacco Cessation Counseling With No Cost Sharing</th>
<th>FDA-approved Prescription Medications With No Cost Sharing</th>
<th>FDA-approved OTC Medications With No Cost Sharing</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 ACA EHB categories</td>
<td>Unclear(a)</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
</tr>
<tr>
<td><strong>HHS' proposed regulatory approach for 2014-2015</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benchmark plan option 1: small group insurance product(b)</td>
<td>Within(c)</td>
<td>Within</td>
<td>Within</td>
<td>Unclear</td>
</tr>
<tr>
<td>Benchmark plan option 2: state employee health benefits plan—CalPERS HMO(b)</td>
<td>Within</td>
<td>Within</td>
<td>Within</td>
<td>Unclear</td>
</tr>
<tr>
<td>Benchmark plan option 2: nongrandfathered state employee health benefits plan—CalPERS self-insured PPO(b)</td>
<td>Within</td>
<td>Within</td>
<td>Within</td>
<td>Unclear</td>
</tr>
<tr>
<td>Benchmark plan option 3: nongrandfathered Federal Employees Health Benefits Program(b)</td>
<td>Within</td>
<td>Within</td>
<td>Within</td>
<td>Unclear</td>
</tr>
<tr>
<td>Benchmark plan option 4: largest commercial HMO(b)</td>
<td>Within</td>
<td>Within</td>
<td>Within</td>
<td>Unclear</td>
</tr>
</tbody>
</table>


Notes: (a) Indicates that it is unclear how the benefit would be included as an EHB under the selected benchmark plan option for 2014 and 2015.
(b) Assumes a non-grandfathered plan or policy (therefore subject to the federal preventive services health benefit mandate).
(c) Indicates that the benefit would likely fall within the definition of EHBs under the selected benchmark plan option for 2014 and 2015.

Key: ACA=Affordable Care Act; CalPERS=California Public Employees’ Retirement System; FDA=U.S. Food and Drug Administration; FEHBP=Federal Employees’ Health Benefits Program; HMO=health maintenance organization; PPO=preferred provider organizations.

**Effects beginning in 2016: Essential health benefits and AB 1738**

As previously mentioned, HHS has not yet defined EHBs for the period after 2014 and 2015. As it relates to AB 1738, it is unclear whether the EHB category “preventive and wellness services and chronic disease management” would require non-grandfathered health plans and policies to include tobacco cessation benefit coverage in 2016 and beyond.

In spite of the uncertainty surrounding EHBs in 2016 and beyond, non-grandfathered plans will continue to be subject to the preventive services requirement in the ACA, as they have since September 2010. As stated earlier, this federal mandate requires coverage of tobacco cessation counseling and FDA-approved medications without cost sharing—although it is unclear whether OTC medications are included as part of tobacco cessation benefit coverage. This federal mandate, and its interaction with AB 1738, would continue to apply post-2016.

**Background on Condition**

Tobacco use is the leading preventable cause of death in the United States and California. An estimated 443,000 deaths per year nationally are attributable to tobacco use, or one in five deaths...
annually. Smoking leads to lung cancer, coronary heart disease, chronic lung disease, stroke, and other cancers (CDC, 2011). Smoking cessation—that is, quitting completely—is the only safe alternative (CDC, 2009). Smoking cessation, however, is a complex process: there are typically multiple quit attempts, degrees of “quitting” (i.e., cutting down consumption), high rates of relapse, and many choices of cessation treatments (CDHS/TCS, 2006). Common forms of smoking cessation treatment include counseling; NRT, such as gum or a patch; and the antidepressant bupropion, as well as prescription cessation medications, such as varenicline. A number of public and private organizations recommend smoking cessation aids as a cost-effective strategy to preventing tobacco-related diseases.

The harms of smoking have been well established for decades, first receiving wide notice with the initial Surgeon General’s report on this topic in 1964. The Surgeon General’s 2004 updated report, *The Health Consequences of Smoking* (CDC, 2004), stated that smoking causes multiple cardiovascular and respiratory diseases as well as cancers and estimated that one in three cases of cancer is attributable to smoking (ACS, 2011). The Surgeon General also reported a causal relationship between smoking and low birth weight infants, Sudden Infant Death Syndrome (SIDS), and preterm births.

**Smoking Prevalence in California**

Despite state-level advances in smoking cessation, smoking prevalence in California remains higher than the *Healthy People 2020* target of 12% for adults (USDHHS, 2010). The 2009 California Health Interview Survey (CHIS, 2012) reported that 13.4% of insured Californians aged 18 to 64 years were current smokers (defined as smoking cigarettes every day or some days) (Table 5). Men demonstrate higher smoking prevalence rates than women; within each sex, there is little variation by age.

**Table 5. Smoking Prevalence Rates Among Currently Insured California Adults (%), 2009**

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>16.8</td>
<td>10.1</td>
<td>13.4%</td>
</tr>
<tr>
<td>18-24</td>
<td>17.1</td>
<td>8.7</td>
<td>12.7</td>
</tr>
<tr>
<td>25-39</td>
<td>20.2</td>
<td>10.2</td>
<td>15.1</td>
</tr>
<tr>
<td>40-64</td>
<td>14.8</td>
<td>10.5</td>
<td>12.5</td>
</tr>
</tbody>
</table>

41 Bupropion SR in strengths of 100 or 150 milligrams is the only antidepressant that the FDA has approved for tobacco cessation, but physicians may prescribe other formulations and strengths of bupropion and other antidepressants (e.g., Prozac) off-label.

42 The U.S. Public Health Service’s *Treating Tobacco Use and Dependence* (Fiore et al., 2008) states that tobacco dependence treatments are “both clinically effective and highly cost-effective relative to other medical and disease prevention interventions.” America’s Health Insurance Plans (AHIP) provides an interactive model for estimating return on investment (ROI) (AHIP, 2011). The National Council on Prevention Policies ranked tobacco-screening and brief intervention (including offer of pharmacotherapy) as one of the three most clinically and cost-effective preventive services (Maciosek et al., 2006).

43 Published by the U.S. Department of Health and Human Services, *Healthy People 2020* establishes a set of health objectives for the Nation to achieve over the first decade of the new century. States, local communities, professional organizations, and others use them to develop programs to improve public health.
Table 5. Smoking Prevalence Rates Among Currently Insured California Adults (%), 2009 (Cont’d)

<table>
<thead>
<tr>
<th>Race/Ethnicity</th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Latino</td>
<td>18.4</td>
<td>6.1</td>
<td>12.2</td>
</tr>
<tr>
<td>White</td>
<td>15.7</td>
<td>12.7</td>
<td>14.1</td>
</tr>
<tr>
<td>African American</td>
<td>18.1</td>
<td>15.7</td>
<td>16.8</td>
</tr>
<tr>
<td>American Indian/Alaskan Native</td>
<td>31.7</td>
<td>28.8</td>
<td>29.9</td>
</tr>
<tr>
<td>Asian</td>
<td>15.6</td>
<td>5.5</td>
<td>10.1</td>
</tr>
<tr>
<td>Native Hawaiian/Pacific Islander</td>
<td>22.1*</td>
<td>26.2*</td>
<td>24.6*</td>
</tr>
<tr>
<td>Two or More Races</td>
<td>21.9</td>
<td>18.1</td>
<td>20.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poverty Status</th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-99% FPL</td>
<td>27.1</td>
<td>14.8</td>
<td>20.0</td>
</tr>
<tr>
<td>100-199% FPL</td>
<td>21.9</td>
<td>12.1</td>
<td>16.9</td>
</tr>
<tr>
<td>200-299% FPL</td>
<td>17.4</td>
<td>10.6</td>
<td>13.7</td>
</tr>
<tr>
<td>300% + FPL</td>
<td>13.7</td>
<td>8.5</td>
<td>11.1</td>
</tr>
</tbody>
</table>

Source: California Health Benefits Review Program, 2012. (Based on 2009 California Health Interview Survey)
Note: Adults aged 18-64 years who are currently insured.
*Statistical issues render this figure unreliable (variance too high or number of respondents too low).
Key: FPL = Federal Poverty Level.

The smoking prevalence rate by race and ethnicity varies; there is nearly a three-fold difference in smoking prevalence rates between the lowest group (Asians, 10.1%) and the highest group (American Indian/Alaska Native, 29.9%) (Table 5). California’s Latino and Asian populations achieve or exceed the Healthy People 2020 target for smoking prevalence at 12.2% and 10.1%, respectively. Within each racial and ethnic group, there are also large differences by sex. Asian men are almost three times more likely to report smoking than Asian women, and smoking prevalence for Latino men is three times that of Latina women. The highest smoking prevalence rate is among American Indian/Alaska Native men (31.7%), whereas the lowest is found in Asian women (5.5%) (CHIS, 2012).

Disparities extend to socioeconomic status as well (Table 5). Both men and women with income less than 200% of the federal poverty level\(^4\) (FPL) are more likely to smoke than those who have higher incomes. The poorest individuals (incomes between 0 and 99% FPL) are almost twice as likely to report smoking as are those with incomes at or above 300% FPL (CHIS, 2012).

Burden of Smoking-Related Disease

In California (Table 6), 19% of heart disease mortality is attributed to smoking, followed by overall mortality from cancer (trachea, bronchus, and lung), chronic obstructive pulmonary disease and stroke, at 6%, 5%, and 5%, respectively (CDPH/CTCP, 2010a).

The health burden of smoking—and therefore the benefits that proceed from AB 1738-related smoking cessation—extends significantly beyond these selected conditions. Characterizing the

\(^4\) The FPL is an income-based criteria used to determine benefit levels for many low-income assistance programs. In 2009, for a family of three, 100% of FPL is equivalent to annual gross income of $18,310; 200% = $36,620; and 300% = $54,930 (USDHHS, 2009).
health burdens and benefits associated with each of the numerous relevant conditions is not feasible; however, certain examples will be given when relevant. The *Impacts on Premature Death and Economic Loss* section of this report will address further the issue of total smoking-related mortality.

**Table 6.** Leading Causes of Tobacco-Related Deaths in California, 2005

<table>
<thead>
<tr>
<th>Leading Causes of Death</th>
<th>Number (%) of Deaths from Ischemic Heart Disease and Other Leading Causes of Death Attributable to Tobacco Use</th>
<th>Age-adjusted Rate/100,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischemic heart disease</td>
<td>45,059 (19%)</td>
<td>176.0</td>
</tr>
<tr>
<td>Cancer of trachea, lung, bronchus</td>
<td>13,350 (6%)</td>
<td>52.7</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary diseases (COPD)</td>
<td>12,562 (5%)</td>
<td>49.8</td>
</tr>
<tr>
<td>Stroke</td>
<td>11,680 (5%)</td>
<td>46.0</td>
</tr>
<tr>
<td>Diabetes</td>
<td>7,689 (3%)</td>
<td>26.8</td>
</tr>
<tr>
<td>Other tobacco-related neoplasms</td>
<td>1,210 (1%)</td>
<td>5.0</td>
</tr>
</tbody>
</table>

*Source: CDPH/CTCP, 2010a.*

Gender and racial/ethnic disparities continue beyond smoking prevalence and extend to smoking-related morbidity and mortality. Despite a lower rate of smoking than men, women experience higher incidence rates of smoking-related disease, including lung cancer and cervical cancer and, according to one study, a 30-fold increase in myocardial infarction risk. In contrast, there was a three-fold higher smoking-related death rate for California men than women from 2000 to 2004 (CDPH/CTCP, 2010b). Ethnic and racial disparities are also well documented. For example, African Americans experience a higher incidence of cardiovascular disease, cancer, and infant mortality, all of which are smoking-related. Native Americans experience the highest rate of infant mortality due to SIDS, which is also causally linked to smoking (Fiore, 2000; Piper et al., 2001). In another example, among cigarette smokers, African American and Native Hawaiian men had the highest incidence of lung cancer (Haimen et al., 2006).

In addition to compromising the health of the smoker, the medical literature indicates secondhand smoke impacts the health of others. The Surgeon General's office has declared that secondhand smoke is associated with an increased risk of lung cancer, heart disease, stroke, asthma, and other respiratory problems, and estimates that nearly 60% of children aged 3 to 11 years and more than 40% of nonsmoking adults are exposed to secondhand smoke (USDHHS, 2006). In its seminal report, *The Health Consequences of Involuntary Exposure to Tobacco Smoke*, the Surgeon General reported a 20% to 30% increase in the lung cancer risk, as well as a 25% to 30% increase in the risk of coronary heart disease, due to secondhand smoke exposure (USDHHS, 2006). Exposure to secondhand smoke is particularly harmful for children. It is associated with a higher risk of SIDS, ear infections, and lower respiratory infections such as pneumonia and bronchitis, and is causally linked with low birth weight (USDHHS, 2006). The American Lung Association estimates that 50,000 deaths each year are attributable to secondhand smoke (ALA, 2011a).
In California, nonsmokers are exposed to smoke primarily at home and in cars, since the majority of workplaces and many public places are smoke-free. In 2006, the California Environmental Protection Agency (EPA) declared secondhand smoke to be a "toxic air contaminant" and estimated that secondhand smoke is responsible for 21 cases of SIDS, 1,600 cases of low birth weight infants, 4,700 preterm deliveries, 31,000 episodes of asthma in children, 400 cases of lung cancer, and 3,600 cardiac deaths each year in the state (EPA, 2006).

The Process of Quitting Smoking

Smoking cessation is a complex process typically requiring multiple quit attempts, degrees of quitting (i.e., cutting down consumption), and high rates of relapse (see Figure 1) (Fiore et al., 2000; Gilpin et al., 1997; CDHS/TCS, 2006). The Surgeon General’s 1990 report characterized smoking cessation as a “dynamic process” (CDC, 1990). The tenacity of smoking addiction is recognized by the medical community, which characterizes it as a chronic disease and recommends repeated courses of treatment as needed to achieve eventual success.

Figure 1. Process of quitting smoking with and without treatment assistance

The percentage of California smokers reporting attempts to quit in the preceding year increased by 12% between 1996 and 2008 (Al-Delaimy et al., 2010). Since 1999, however, the annual quit-attempt rate has remained fairly constant with the most recent California Tobacco Survey (2008) reporting 60% of smokers attempting to quit (Al-Delaimy et al., 2010). Although higher than the national rate of 48.3%, this percentage remains below the Healthy People 2020 target of 80% of smokers who attempt to quit. The 2008 California Tobacco Survey (CTS) showed that one-quarter of persons attempting to quit smoking participate in a formal cessation assistance program (Table 7). Typically, such programs include a combination of counseling, prescription medications, NRT, and physician contact (Javitz, 2004). The CTS reported that NRT (alone or in
combination with counseling or antidepressants) was the treatment used most frequently among persons using assistance and was used by more than 17% of persons reporting quit attempts (Al-Delaimy et al., 2008).

Gender disparities in smoking cessation attempts and quit rates exist, and the literature identifies numerous potential barriers to successful smoking cessation for women. For example, women are twice as likely as men to be concerned about post-cessation weight gain, and these concerns appear associated with lower smoking abstinence rates among those attempting to quit (Clark et al., 2006; Schnoll et al., 2007).

Differences exist in rates of smoking cessation quit attempts by race and ethnicity. In California, 71.8% of African Americans, 66% of Asian/Pacific Islanders, 67% of Hispanics, and 54% of White smokers made smoking cessation quit attempts within 1 year in California (Al-Delaimy et al., 2010).

**Table 7. Smoking Cessation Attempts in California, 2008**

<table>
<thead>
<tr>
<th>Cessation (Quit) Attempts</th>
<th>% of California Smokers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quit attempt of 1 day or longer (b)</td>
<td>60.2</td>
</tr>
<tr>
<td>Successful 90+ days quit (b)</td>
<td>8.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Methods to Quit (Use by Type of Cessation Treatment)</th>
<th>% of California Smokers that Quit</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRT alone (a) (gum, patch, inhalant)</td>
<td>7.7</td>
</tr>
<tr>
<td>Counseling alone</td>
<td>5.9</td>
</tr>
<tr>
<td>Prescription drugs alone</td>
<td>1.8</td>
</tr>
<tr>
<td>Counseling and NRT</td>
<td>4.5</td>
</tr>
<tr>
<td>Counseling and prescription drugs</td>
<td>1.4</td>
</tr>
<tr>
<td>NRT and prescription drugs</td>
<td>2.7</td>
</tr>
<tr>
<td>NRT, counseling, and prescription drugs</td>
<td>2.0</td>
</tr>
</tbody>
</table>

**Attempted To Quit Using One or More Types of Treatments** 26%

**No Use of Any Cessation Treatment During Quit Attempt** 74%

*Source: California Health Benefits Review Program, 2012 (Based on 2008 California Tobacco Survey; Al-Delaimy, 2010).*

(a) CHBPR uses “OTC” to describe all NRTs available OTC. CHBPR defines prescription medication as inclusive of prescription NRT, other smoking cessation medications, and the antidepressant, bupropion.

(B) A quit attempt in the 12 months prior to the CTS.
MEDICAL EFFECTIVENESS

As discussed in the Introduction, AB 1738 defines smoking cessation treatments to include counseling and all medications approved by the FDA for smoking cessation, including all prescription and OTC medications. The medical effectiveness review summarizes findings from literature on two topics: (1) the efficacy of specific types of smoking cessation services, and (2) the effects of health insurance coverage for smoking cessation services.

Types of Smoking Cessation Treatments

Smoking cessation treatments include pharmacotherapy and behavioral interventions, such as counseling and brief advice. Counseling may occur in person or via telephone and may be provided either in individual or group sessions. Counseling may be provided by physicians, nurses, pharmacists, peer counselors, pharmacists, social workers, psychologists, or psychiatrists in a range of inpatient or outpatient settings.

Pharmacological agents for smoking cessation are commonly divided into those most frequently used in initial attempts to quit smoking ("first-line agents") and those most frequently used when initial attempts to quit smoking have not been successful ("second-line agents"). First-line agents are medications approved by FDA for smoking cessation. Second-line agents are medications that have a greater risk of side effects than first-line agents and have not been approved by the FDA for smoking cessation but which have been found to be effective for that purpose (Fiore et al., 2008).

Research Approach and Methods

Studies of the effects of smoking cessation treatments and coverage for these treatments were identified through searches of PubMed, the Cochrane Library, the Cumulative Index of Nursing and Allied Health Literature, EconLit, PsycInfo, and SCOPUS. Websites maintained by the following organizations that produce and/or index meta-analyses and systematic reviews were also searched: the Agency for Healthcare Research and Quality, the International Network of Agencies for Health Technology Assessment, the National Health Service Centre for Reviews and Dissemination, the National Institute for Health and Clinical Excellence, and the Scottish Intercollegiate Guideline Network.

The search was limited to abstracts of studies published in English from February 2011 to present because CHBRP had previously conducted thorough literature searches on these topics in 2005, 2007, 2010, and 2011 for SB 576, SB 24, SB 220, and SB 136, respectively. A total of 41 studies were included in the medical effectiveness review for AB 1738: 10 studies from the SB 576 review, 11 additional studies from the SB 24 review, 13 studies from the SB 220 review, 1 study from the SB 136 review, and 6 new studies for AB 1738. A more thorough description of the methods used to conduct the medical effectiveness review and the process used to grade the evidence for each outcome measure is presented in Appendix B: Literature Review Methods.

The literature on behavioral and pharmacological treatments to improve smoking cessation rates and continued abstinence is extensive, including numerous meta-analyses of randomized
controlled trials (RCTs), the strongest form of evidence for CHBRP analyses. Accordingly, CHBRP relied to the extent feasible on these meta-analyses. Where meta-analyses were not available, CHBRP drew upon individual RCTs and nonrandomized studies with comparison groups. Findings from the literature review are summarized in Tables 8 and 9, which appear at the end of the Medical Effectiveness section. Appendix C includes a table describing the studies that CHBRP reviewed.

Methodological Considerations

CHBRP considers it highly unlikely that the conclusions this report draws about the efficacy of smoking cessation treatments will be diminished or altered with the publication of new individual studies. This is because of the magnitude of the literature, the consistently positive results with respect to specific treatments, and the quality of the research designs. CHBRP published analyses of the efficacy of smoking cessation treatments for SB 576 in 2005, SB 24 in 2007, SB 220 in 2010, and SB 136 in 2011 that reached much the same conclusion as the present analysis.

The rates of abstinence from smoking reported by the meta-analyses and systematic reviews summarized in this report may be greater than those that would be achieved in “real-world” settings if AB 1738 were enacted. Most of the meta-analyses and systematic reviews synthesized findings from RCTs. Most of these RCTs used strict inclusion/exclusion criteria to maximize their ability to determine whether counseling or pharmacotherapy increases smoking cessation. They may exclude some smokers who would have coverage for these services under AB 1738. In addition, smokers who take the initiative to enroll in RCTs are probably more highly motivated to quit than the average smoker. Greater motivation may lead to higher rates of abstinence from smoking among persons enrolled in both the intervention and control groups of RCTs than would occur in the “real world.” Clinician researchers may also work harder than other clinicians to ensure that smokers use recommended amounts of counseling and/or pharmacotherapy. One study that examined commonly used exclusion criteria in tobacco cessation clinical trials reported that persons who smoke fewer cigarettes per day, lack motivation to quit, have cardiovascular disorders or depression, or use alcohol or drugs were most often excluded from such trials (Le Strat et al., 2011). A recent population-based study found smoking cessation treatment to be as effective as that reported in RCTs (Boudrez et al., 2011), while another population-based study found no effect of smoking cessation treatments on smoking relapse rates among adult smokers who previously smoked (Alpert et al., 2012).

As discussed below, nonrandomized studies conducted in California found that NRT is less effective than what the findings of RCTs suggest, especially for light smokers (Pierce and Gilpin, 2002).

Outcomes Assessed

In most studies reviewed, abstinence from smoking is the primary outcome measured to evaluate the efficacy of smoking cessation interventions. Although measurement of continuous abstinence is desirable, studies have used varying definitions of relapse, which creates difficulty in evaluating the effects of treatments on prolonged abstinence rates. However, because most
relapses occur within the first 3 months after smoking cessation, many meta-analyses and systematic reviews of the literature only include those studies with follow-up of at least 5 months (Fiore et al., 2008). Thus, in evaluating the effectiveness of specific behavioral and pharmacological treatments, the medical effectiveness analysis includes only studies that assessed abstinence from smoking for at least 5 months. The majority of studies rely on self-reported abstinence while some use biochemically validated measures of abstinence that are likely to be more accurate.

For studies of the impact of coverage for smoking cessation services, CHBRP assessed effects on two outcomes: (1) use of smoking cessation services, and (2) abstinence from smoking. CHBRP’s decision to analyze both of these outcomes reflects the causal pathway by which coverage for smoking cessation services could affect abstinence from smoking. As discussed below, CHBRP found a large body of evidence indicating that use of smoking cessation counseling and pharmacotherapy increases the likelihood that smokers will abstain from smoking. Coverage for smoking cessation services could increase the likelihood that smokers will use these services and, thus, increase the likelihood that they will abstain from smoking.

Study Findings

Effects of Counseling

The principal behavioral intervention for smoking cessation is counseling, provided in person to individuals or groups or to individuals over the telephone. The evidence summarized in meta-analyses indicates that counseling increases smoking cessation.

Individual counseling

Fiore et al. (2008) reviewed the effect of individual counseling versus no intervention on smoking cessation rates at 5 months. Of note, of the 58 studies incorporated into the meta-analyses, all provided evidence at Level I (well-implemented RCTs or cluster randomized trials) or II (randomized trials or cluster randomized trials with major weaknesses in design). Fiore et al. concluded that individual counseling was associated with a statistically significant effect on smoking cessation of at least 5 months’ duration (odds ratio = 1.7) when compared to no intervention. Mottillo et al. (2009) evaluated the effects of individual counseling across 23 RCTs and found a significant effect on biochemically validated cessation of at least 6 months (odds ratio = 1.5).

Rice and Stead (2008) evaluated the evidence from 31 RCTs comparing individual advice by a nursing professional to no intervention. Advice from a nursing professional was found to have a

---

45 The Fiore et al. (2008) report incorporates findings from meta-analysis performed for the Fiore et al. (2000) report and includes new meta-analysis performed on studies regarding new treatments for tobacco cessation (e.g., varenicline) that were published since Fiore et al. (2000) was issued.

46 Odds ratios and risk ratios both compare the likelihood of an event. An odds ratio compares the relative odds of an event in each group while a risk ratio (sometimes called the relative risk) compares the probability of an event in each group. A sample interpretation of an odds ratio = 2 is as follows: Among patients receiving a smoking cessation treatment their odds of smoking cessation are 2 times as large as the odds of patients not receiving a smoking cessation treatment.
favorable and statistically significant effect on smoking cessation at 6 or 12 months (odds ratio = 1.3).

Lancaster and Stead (2008) evaluated the evidence from 22 RCTs and quasi-randomized trials of face-to-face individual counseling from a health care worker not involved in routine clinical care versus minimal intervention. They reported that such counseling was associated with a favorable impact on smoking cessation at 6 months (odds ratio = 1.4).

**Group counseling**

Stead and Lancaster (2009) summarized the information in eight RCTs comparing group smoking cessation programs to self-help materials or no intervention, finding that group programs have a favorable effect on smoking cessation at 6 months (odds ratio = 2.7). A meta-analysis by Fiore et al. (2008) found that participation in group smoking cessation counseling was associated with a modest increase in smoking cessation compared to no intervention (odds ratio = 1.3). Mottillo et al. (2009) evaluated the effects of group counseling across 12 RCTs and found significant effect on biochemically validated cessation of at least 6 months (odds ratio = 1.8).

**Counseling provided over the telephone**

Three meta-analyses have assessed the efficacy of telephone-based smoking cessation counseling versus minimal intervention. Telephone counseling interventions have been classified into two categories: (1) proactive counseling in which all counseling is initiated by counselors, and (2) reactive counseling in which smokers initiate counseling by calling a counseling service, usually through a toll-free telephone number (Stead et al., 2009). California and a number of other states operate quitline counseling services under which smokers initiate counseling and may choose to receive additional, proactive calls from counselors (Fiore et al., 2008; Stead et al., 2009).

Stead et al. (2009) reviewed the results of 44 RCTs and quasi-randomized trials of proactive telephone counseling versus minimal intervention, reporting that telephone proactive counseling was associated with a favorable effect on smoking cessation at 6 months (odds ratio = 1.5).

Stead et al. (2009) also reviewed the results of nine RCTs and quasi-randomized trials of quitline telephone counseling versus minimal intervention, reporting that quitline counseling was associated with a favorable effect on smoking cessation at 6 months (odds ratio = 1.3). Fiore et al. (2008) analyzed the results of nine RCTs examining the effects of quitline telephone counseling to minimal or no intervention. At 5 months, the odds of smoking cessation were 1.6 higher for smokers in the quitline intervention group compared to the controls.

Mottillo et al. (2009) evaluated the effects of telephone counseling across 10 RCTs of both proactive and reactive telephone counseling interventions. This meta-analysis found that telephone counseling had a statistically significant effect on biochemically validated cessation of at least 6 months (odds ratio = 1.6).

---

47 In the Stead et al., 2009, and Stead, Bergson et al., 2008 meta-analyses, the authors report relative risk ratios. However, in order to report outcomes in a manner consistent with the other meta-analyses, CHBRP converted the relative risk ratios to odds ratios.
Tzelepis et al. (2011) pooled the findings from 13 RCTS on proactive telephone counseling and reported an increase in continuous abstinence at 6 to 9 months (risk ratio = 1.6) and at 12 to 18 months (risk ratio = 1.4) when compared to no intervention control or self-help materials. These positive patterns remained when these RCTs were analyzed by whether the participants were recruited in an active (e.g., fax referral by provider) or passive (e.g., through mass media) channel.

**Brief counseling**
Fiore et al. (2008) summarized seven RCTs on advice by physicians of 3 minutes or less versus no advice and reported a modest increase in the odds of smoking cessation at 5 months (odds ratio = 1.3).

Stead, Bergson, et al. (2008) summarized 17 RCTs and quasi-randomized trials evaluating the effects of minimal48 physician advice versus no advice or usual care and observed that minimal advice was associated with a favorable effect on cessation either at 6 or 12 months (odds ratio = 1.6).

Mottillo et al. (2009) summarized nine RCTs on the effects of brief advice delivered during a regular clinical visit compared to only self-help materials or no treatment. They found the odds of biochemically validated cessation to be 1.5 times higher in the counseling group at 6 months; however, this was not statistically significant.

Aveyard et al. (2011) pooled the results of 11 RCTs on the effects of brief physician advice to quit smoking based on medical reasons and found an increase in smoking cessation of at least 6 months when compared to no advice or usual care (risk ratio = 1.5). A separate pooled analysis of four RCTs found that the offer of NRT in addition to brief advice increased abstinence when compared to brief advice alone (risk ratio = 1.5).

### Summary of findings regarding effects of counseling
Overall, the meta-analyses of counseling interventions provide clear and convincing evidence that individual, group, and telephone counseling increase rates of smoking cessation. The magnitude of the average increase in successful smoking cessation ranges from 2 to 13 percentage points relative to no counseling or self-help materials.49

**Counseling intensity**
Three meta-analyses analyzed the effects of the intensity of counseling on abstinence from smoking. In the first of the meta-analyses, Fiore et al. (2008) reviewed seven studies that assessed the effects of low-intensity counseling (3-10 minutes) and higher intensity (>10

---

48 The amount of contact time for physician advice varied across the trials. Contact time varied from less than 5 minutes to advice lasting less than 20 minutes; a few studies did not specify the length of contact time other than a report of “brief advice.”

49 The range in increase of percentage points does not include estimates from the Fiore et al. (2008) meta-analyses as the Fiore et al. (2008) report does not include the data necessary to calculate such increases in a manner consistent with other meta-analyses included in our review.
minutes) compared to no counseling. The authors reported a favorable effect of low intensity and higher intensity when compared to no counseling (odds ratio = 1.6 and 2.3, respectively) on rates of cessation at 5 months. In a second meta-analysis, Fiore et al. (2008) compared the effect of the number of treatment sessions on abstinence from smoking across 46 trials. The number of treatment sessions was categorized into a control group, having had 0 to 1 sessions, and three treatment groups having 2 to 4 sessions, 4 to 8 sessions, and >8 sessions, respectively. The authors report increasingly favorable effects in a stepwise fashion with increasing number of sessions (odds ratio = 1.4 for 2 to 4 sessions; 1.9 for 4 to 8 sessions; 2.3 for >8 sessions, respectively, when compared to receiving 0 to 1 session). An important limitation of the analyses by Fiore et al. (2008) of the effects of longer counseling sessions and more counseling sessions is that the authors made indirect comparisons across RCTs and did not examine any RCTs that directly compared low-intensity to high-intensity counseling.

In the Lancaster and Stead (2008) meta-analysis of five studies that directly compared brief counseling to more intensive counseling, there was no difference in 6-month cessation rates among individuals who received brief counseling compared to individuals who received more intensive counseling.

Stead, Bergson, et al. (2008) summarized 15 RCTs and quasi-randomized trials that directly compared the impact of more intensive versus minimal advice and found a modest and statistically significant difference favoring more intensive advice (odds ratio = 1.5).

Overall, the preponderance of evidence indicates that smokers who receive more intensive counseling are more likely to abstain from smoking than those who receive less intensive counseling.

Relative effectiveness of different types of health professionals in providing counseling
Two meta-analyses have examined whether different types of health professionals are more or less effective in providing smoking cessation counseling (Fiore et al., 2008; Mojica et al., 2004). The Mojica et al. (2004) meta-analysis synthesized a larger number of studies, including those included in the Fiore et al. (2008) meta-analysis. Mojica et al. (2004) concluded that psychologists, physicians, and nurses are all effective in delivering smoking cessation counseling and that none of the three types of health professionals was substantially more effective than the others. A systematic review of studies on counseling delivered by community pharmacy personnel suggest a positive effect on cessation rates; however, the strength of the evidence is limited because only two RCTs have been published on this topic (Sinclair et al., 2008).

The preponderance of evidence suggests that multiple types of health professionals can provide effective smoking cessation counseling.

Effects of Pharmacotherapy

Pharmacological agents for smoking cessation are commonly divided into those used in initial attempts to quit smoking (“first-line agents”), followed by those used when initial attempts to quit have not been successful (“second-line agents”). First-line agents are medications approved by the FDA for smoking cessation that generally have less severe side effects than second-line
medications. Second-line medications are medications that are not approved by the FDA for smoking cessation but which have been found to be effective (Fiore et al., 2008). First-line agents for smoking cessation include the following: NRT administered by gum, patch, nasal spray, lozenge, and inhaler; varenicline, a nicotine receptor partial agonist\(^{50}\); and the non-nicotine agent bupropion SR, an antidepressant useful in treating certain addiction syndromes. Second-line agents include clonidine and nortriptyline.

First-line agents

NRT. The large majority of CHBRP findings on NRT are drawn from three meta-analyses (Eisenberg et al., 2008; Fiore et al., 2008; Stead, Perera, et al., 2008). These three meta-analyses include some of the same studies; however, the stringency of inclusion criteria differed among them. The Eisenberg et al. (2008) meta-analysis only included studies that reported biochemically validated abstinence and used a placebo for a control. The Fiore et al. (2008) analyses included studies that measured biochemically or self-report abstinence and used a placebo for a control. The Stead, Perera, et al. (2008) analyses included studies that measured biochemically or self-report abstinence and used either a placebo or no treatment for a control.

Nicotine gum. Independently, Fiore et al (2008), Stead, Perera, et al. (2008), and Eisenberg et al. (2008) synthesized the literature on the effect of nicotine gum on smoking cessation rates. Fiore et al. (2008) pooled four RCTs on the effects of using nicotine gum for more than 14 weeks and reported that use of nicotine gum compared to placebo was associated with a favorable effect on smoking cessation rates at the end of 6 months (odds ratio = 2.2). Fiore et al. (2008) also pooled nine RCTs on shorter-term gum use (6 to 14 weeks) and reported a 1.5 increase in the odds of cessation at 6 months. Stead, Perera, et al. (2008) integrated results from 53 RCTs, again showing that using nicotine gum increases the likelihood a person will abstain from smoking (odds ratio = 1.4). Eisenberg et al. (2008) reached the same conclusions in a meta-analysis of 22 RCTs that reported biochemically verified abstinence at 6 months or more following initiation of treatment (odds ratio = 1.7)

Overall, nicotine gum has a favorable effect on smoking cessation rates. The magnitude of the average increase in successful smoking cessation ranges from 5 to 7 percentage points.

Nicotine patch. Four teams of researchers have conducted meta-analyses of the substantial literature on nicotine patches. Fiore et al. (2008) performed three separate meta-analyses. The first pooled four studies on high-dose nicotine patch use (>25 mg) and reported a 2.3 increase in odds of smoking cessation at 6 months compared to placebo. The second pooled eight studies on long-term nicotine patch use (>14 weeks) and the third meta-analysis pooled 25 studies on shorter-term (6 to 14 weeks) nicotine patch use. For both longer and shorter term use of the patch, there was an increase of 1.9 in the odds of cessation. Stead, Perera, et al. (2008) summarized the results from 41 RCTs of the effect of the nicotine patch compared to placebo or no treatment on smoking cessation after 6 months, reporting that the patch was associated with a favorable outcome (odds ratio = 1.6). Eisenberg et al. (2008) also found the patch to be associated with greater odds of biochemically verified abstinence at or over 6 months (odds ratio

---

\(^{50}\) The nicotine receptor partial agonist simulates the effects of nicotine to reduce cravings and the pleasurable effect of smoking cigarettes.
2.1) in meta-analyses of 36 RCTs. Myung et al. (2007) reached the same conclusions when evaluating biochemically verified abstinence at 12 months in 16 RCTs (odds ratio = 1.8).

Overall, on the basis of a large literature, the nicotine patch has been found to have a favorable effect on smoking cessation rates, increasing these by approximately 5 to 6 percentage points.

**Nicotine lozenge.** Stead, Perera, et al. (2008) found six RCTs on the effect of nicotine lozenges on cessation in comparison to placebo or no treatment. This mode of administration of NRT was associated with a favorable outcome in terms of smoking cessation rates at 6 months following treatment (odds ratio = 2.0; difference in abstinence rates = 8 percentage points). Eisenberg et al. (2008) also found a twofold increase in the odds of cessation at or over 6 months when using a nicotine tablet compared to placebo in six RCTs that reported biochemically verified abstinence.

**Nicotine inhaler.** Fiore et al. (2008), Stead, Perera, et al. (2008), and Eisenberg et al. (2008) pooled findings from RCTs on the effect of nicotine inhalers on smoking cessation rates. The Fiore et al. (2008) meta-analysis found six RCTs and observed that nicotine inhaler use was associated with a higher rate of smoking cessation at the end of 6 months when compared to either placebo or no treatment (odds ratio = 2.1). Stead and colleagues found four RCTs meeting their inclusion criteria. They observed a favorable outcome in smoking cessation at 6 months when compared to either placebo or no treatment (odds ratio = 1.9). In a meta-analysis of four studies by Eisenberg et al. (2008), the use of an inhaler compared to placebo showed a twofold increase in the odds of cessation at or beyond 6 months, but the results were not statistically significant.

The preponderance of the limited number of RCTs on the efficacy of nicotine inhalers suggest that they have a favorable effect on smoking cessation rates, increasing these by approximately 8 percentage points.

**Nicotine nasal spray.** Fiore et al. (2008), Stead, Perera, et al. (2008), and Eisenberg et al. (2008) analyzed the literature on the effectiveness of nicotine nasal spray. Although there are fewer RCTs on nicotine nasal spray than on nicotine gum or nicotine patches, the results are similar. Specifically, Fiore et al. (2008) pooled four RCTs comparing nicotine nasal spray to placebo or no treatment, and indicated that this mode of administration of NRT is associated with a favorable outcome with respect to smoking cessation at the end of 6 months (odds ratio = 2.3). Stead, Perera, et al. (2008) pooled four studies, reporting a favorable outcome at the end of 6 months (odds ratio = 2.0) and Eisenberg et al. (2008) reported an increase of 2.4 in the odds of cessation at 6 months or more. Use of nicotine nasal spray is associated with a 12 percentage point increase in smoking cessation rates.

Thus, although the literature is not that voluminous, it appears that nicotine nasal spray has a favorable effect on smoking cessation rates.
Summary of findings regarding effects of NRT. There is clear and convincing evidence that all forms of NRT increase abstinence from smoking when compared to a placebo or no treatment. The evidence favoring nicotine patches is especially robust. Use of NRT is associated with a 5 to 12 percentage point increase in the likelihood that a person will abstain from smoking relative to a placebo.  

Bupropion SR (brand name: Zyban). Meta-analyses conducted by Fiore et al. (2008), Hughes et al. (2010), and Eisenberg et al. (2008) evaluated the evidence on the effect of bupropion, an antidepressant agent approved for use in smoking cessation. Fiore et al. (2008) analyzed data from 24 RCTs and reported that bupropion had a favorable effect on smoking cessation rates when compared to placebo or no treatment at the end of 6 months (odds ratio = 2.0). Hughes et al. (2010) included 36 RCTs comparing bupropion to either placebo or no treatment, and reported a favorable effect on smoking cessation rates at the end of 6 months (risk ratio = 1.7). Eisenberg et al. (2008) analyzed data from 16 RCTs and found similar effects of bupropion SR on biochemically confirmed abstinence at or beyond 6 months (odds ratio = 2.1). Adverse effects of bupropion have been reported and may include an increase in the risk for seizures and suicidal thoughts or behavior (FDA, 2009; GlaxoSmithKline, 2009).

Summary of findings regarding effects of bupropion. There is clear and convincing evidence that bupropion is associated with a statistically significant increase in the likelihood of abstaining from smoking of 8 to 9 percentage points relative to a placebo.

Varenicline (brand name: Chantix). Fiore et al. (2008), Cahill et al. (2011), and Eisenberg et al. (2008) evaluated the evidence on the effect of varenicline compared to a placebo on smoking cessation. Fiore et al. (2008) reviewed four smoking cessation RCTs at 6 months; varenicline was found to have a favorable effect. A dose of 2 milligrams per day was associated with a greater effect than a dose of 1 milligram per day (odds ratios = 3.1 and 2.1, respectively). At 6-month follow-up or greater, both Cahill et al. (2011) and Eisenberg et al. (2008) found varenicline to increase the likelihood of quitting smoking compared to placebo (Cahill: relative risk = 2.3, Eisenberg: odds ratio = 2.4). Adverse effects of varenicline may include an increase in the risk for depressed mood, agitation, changes in behavior, and suicidal thoughts or behavior (FDA, 2009; FDA, 2011).

---

51 The range of risk differences (i.e., percentage point differences in smoking cessation rates) does not include estimates from the Fiore et al. (2008) meta-analyses as the Fiore at al. (2008) report does not include the data necessary to calculate such increases in a manner consistent with other meta-analyses included in our review. Estimates from Eisenberg et al. (2008) are not included for nicotine lozenge, nicotine inhaler, and nicotine nasal spray because the article did not contain the data necessary to calculate risk differences.

52 Bupropion SR in strengths of 100 or 150 milligrams is the only formulation of bupropion approved by the FDA for smoking cessation. Fiore et al. (2008) and Hughes et al. (2010) do not indicate whether their meta-analyses were limited to RCTs on the efficacy of bupropion SR. Some of the RCTs included in their meta-analyses may have evaluated other formulations of bupropion. Eisenberg et al. (2008) only included RCTs that examined bupropion SR.

53 The range of risk differences (i.e., percentage point differences in smoking cessation rates) does not include estimates from the Fiore et al. (2008) meta-analyses as the Fiore at al. (2008) report does not include the data necessary to calculate such increases in a manner consistent with other meta-analyses included in our review.

54 Cahill et al. (2011) reported that trials included in their meta-analysis on varenicline were funded and managed by Pfizer Inc., the manufacture of varenicline.
Summary of findings regarding effects of varenicline. There is clear and convincing evidence that varenicline is associated with a statistically significant increase in the likelihood of abstaining from smoking of 11 to 18 percentage points relative to a placebo.\(^{55}\)

The comparative effectiveness of varenicline to bupropion on smoking cessation has also been studied. Eisenberg et al. (2008) reported that varenicline has a favorable effect relative to bupropion SR (odds ratio = 2.2). Cahill et al. (2011) and Hughes et al. (2010) reached a similar conclusion.\(^{56}\)

Summary of findings regarding effects of first-line therapies. There is clear and convincing evidence that all forms of first-line therapy, including the multiple modes of administration of NRT, bupropion SR, and varenicline, increase smoking cessation rates. However, population surveys undertaken in California have found that NRT is less effective in facilitating long-term abstinence outside RCTs and that having a smoke-free home improves effectiveness of both NRT and bupropion SR (see page 39).

Second-line therapy

In this section, the focus of attention is on second-line pharmacological agents (i.e., agents used when initial attempts to quit are not successful)—specifically, clonidine (an antihypertensive medication) and nortriptyline (an antidepressant medication)—on which meta-analyses have been published in English-language journals.

Clonidine. Fiore et al. (2008) analyzed the effects of clonidine compared to placebo on smoking cessation in three RCTs. The findings at 6 months indicate that clonidine is superior to placebo for smoking cessation (odds ratio = 2.1). Gourlay et al. (2008) performed a meta-analysis on six RCTs and found a positive effect of clonidine on 3-month cessation rates when compared to placebo (odds ratio = 1.6).

Nortriptyline. In a meta-analysis of four studies, the use of nortriptyline almost doubled the likelihood of smoking cessation at 6 months compared to placebo (Fiore et al., 2008). Hughes et al. (2010) found a similar result in a meta-analysis of six studies that compared nortriptyline to either placebo or no pharmacotherapy at 6 months or greater (odds ratio = 2.0).

\(^{55}\) The range of risk differences (i.e., percentage point differences in smoking cessation rates) does not include estimates from the Fiore et al. (2008) meta-analyses as the Fiore et al. (2008) report does not include the data necessary to calculate such increases in a manner consistent with other meta-analyses included in our review.\(^{56}\) Hughes et al. (2010) do not indicate whether their meta-analyses were limited to RCTs on that assessed bupropion SR in strengths of 100 or 150 milligrams, the only formulation of bupropion approved by the FDA for smoking cessation. Some of the RCTs included may have evaluated other formulations of bupropion. Eisenberg et al. (2008) only included RCTs that examined bupropion SR.
**Summary of findings regarding effect of second-line therapies.** Meta-analyses of the small number of studies on clonidine and nortriptyline provide clear and convincing evidence that they are effective in increasing smoking cessation rates relative to a placebo by approximately 10 to 11 percentage points.  

**Effects of Combination Therapies**

In this section, CHBRP presents the findings from meta-analyses that examined the effect of (1) adding medication to counseling, and (2) using a combination of medications for smoking cessation. Fiore et al. (2008) pooled nine studies that compared the combination of counseling and medication to counseling alone. Results showed that adding medication to counseling significantly increased the odds of cessation (odds ratio = 1.7). These authors also pooled data from three studies on the effect of using the NRT patch plus NRT gum or spray compared to placebo. Using this combination resulted in a tripling in the likelihood of cessation at 6 months. Similarly, when combining the NRT patch with bupropion or with an NRT inhaler, the odds of cessation more than doubled when compared with placebo. Lastly, Shah et al. (2008) compared the effects of using the NRT patch with another first-line medication compared to a single medication. At 6 months, the odds of cessation were 1.5 times higher among those taking combined medications compared to a single medication.

**Summary of findings regarding effects of combination therapies.** The preponderance of evidence from studies of combination therapy suggests that combination therapies have a favorable effect on smoking cessation rates when compared to placebo or single medications, increasing these approximately 10 percentage points.

**Generalizability of pharmacotherapy findings to Californians affected by AB 1738**

Two nonrandomized population studies have assessed the effectiveness of pharmacotherapy for smoking cessation in California (Gilpin et al., 2006; Pierce and Gilpin, 2002). Although population studies do not provide as strong evidence of the efficacy of pharmacotherapy as RCTs, they provide important insights into its effectiveness when administered outside of RCTs, which typically enroll motivated, compliant participants. These two studies are of particular interest to CHBRP because they analyzed data from the California Tobacco Survey (CTS), a survey of a large, representative sample of Californians. The first study found that after NRT became an OTC drug, it continued to improve short-term rates of abstinence from smoking among moderate-to-heavy smokers (≥15 cigarettes/day) relative to no use of pharmacotherapy, but no longer produced the long-term gains that had been observed when NRT was only available by prescription. The long-term gains may have disappeared because many smokers

---

57 The range of risk differences (i.e., percentage point differences in smoking cessation rates) does not include estimates from the Fiore et al. (2008) meta-analyses as the Fiore et al. (2008) report does not include the data necessary to calculate such increases in a manner consistent with other meta-analyses included in our review.

58 Fiore et al. (2008) do not indicate whether their meta-analysis was limited to RCTs on the efficacy of bupropion for smoking cessation assessed bupropion SR in strengths of 100 or 150 milligrams, the only formulation of bupropion approved by the FDA for smoking cessation. Some of the RCTs included may have evaluated other formulations of bupropion.

59 The range of risk differences (i.e., percentage point differences in smoking cessation rates) does not include estimates from the Fiore et al. (2008) meta-analyses as the Fiore et al. (2008) report does not include the data necessary to calculate such increases in a manner consistent with other meta-analyses included in our review.
used NRT for a shorter period of time than recommended (Pierce and Gilpin, 2002). The authors also found that OTC NRT was not effective for light smokers (<15 cigarettes/day).

The second study reported that moderate-to-heavy smokers who used bupropion SR (with or without NRT) were more likely to abstain from smoking than were smokers who did not use this drug. This study also found that bupropion SR and NRT were especially effective when used by smokers who had smoke-free homes and had no other smokers in their households (Gilpin et al., 2006). The findings from these two studies suggest that NRT may be less effective when used OTC outside of an RCT and that both NRT and bupropion SR are more likely to be effective for smokers who have smoke-free homes.

One prospective population-based study found no difference in smoking relapse rates between former smokers who used NRT with or without behavioral support (Alpert, 2012). However, findings from this study have little relevance to the analysis of AB 1738 because it included only persons who had quit smoking and examined relapse rates and not cessation rates.

Efficacy of Treatments for Major Subpopulations

Some meta-analyses have assessed the effect of smoking cessation counseling and pharmacotherapy on smoking cessation rates among subgroups of smokers, including pregnant women, persons in inpatient settings, and persons with various medical conditions, including coronary heart disease and chronic obstructive pulmonary disease (COPD).

Pregnant women
Lumley et al. (2009) assessed the effects of smoking cessation treatments (behavioral and/or pharmacotherapy) in pregnant women. A review of 65 RCTs demonstrated a significant reduction (6%) in smoking during late pregnancy. During the postpartum period, the results of 14 RCTs suggest that prenatal interventions promote continued cessation up to 1 to 5 months post-delivery but cease to be effective from 6 to 12 months post-delivery. Fiore et al. (2008) reviewed eight RCTs of smoking cessation counseling interventions in pregnant women and reported biochemically confirmed cessation rates to be higher (odds ratio = 1.8) in the intervention group when measured in late pregnancy, but found no continued effect of the intervention when measured at 5 months postpartum. Filion et al. (2011) analyzed eight RCTs on the independent effect of smoking cessation counseling interventions, including brief advice or individual, group, or telephone counseling among pregnant women. The trials offered only one type of counseling intervention and that was not part of a multicomponent intervention. Results showed no difference in continued abstinence rates at 6 months among women who received counseling in isolation when compared to usual care compare group (odds ratio = 1.1).

Coleman et al. (2010) analyzed five RCTS on the independent effects of NRT on smoking cessation among pregnant women. Of the five RCTS, two compared any form of NRT with behavioral treatment to behavioral treatment alone. Three RCTs compared any form of NRT with behavioral treatment to placebo NRT with behavioral treatment. Pooled results of the five RCTs found no evidence for NRT being effective in pregnancy (risk ratio = 1.6). In subgroup analysis, pooled estimates of the two nonplacebo-controlled trials found a favorable effect for NRT, while the estimates for the three placebo-controlled trials found no effect. In another RCT,
Coleman et al. (2012) analyzes the effects of NRT patches on smoking cessation among pregnant women. Women received behavioral treatments and were randomly assigned to receive an NRT patch or a visibly identical placebo. Results showed no significant difference in rates of smoking cessation among the groups (odds ratio = 1.3); however, these findings are limited because less than 10% of the women reported using the patch or placebo for more than a month. The 2008 U.S. Public Health Service (PHS) guidelines did not make a recommendation regarding medication in pregnant women as there is inconclusive evidence on the safety and effectiveness of smoking cessation medication use during pregnancy.

Inpatient and chronic conditions
Rigotti et al. (2008) analyzed the results of 17 RCTs and quasi-randomized trials to evaluate the impact of inpatient smoking cessation counseling plus follow-up post-hospitalization of at least 1 month versus usual care, reporting that the inpatient contact plus follow-up had a favorable effect on smoking cessation rates (odds ratio = 1.7).

Barth et al. (2008) analyzed the results of 16 RCTs in patients with coronary heart disease and found that behavioral interventions including counseling and advice increased the odds of quitting smoking (odds ratio = 1.7) after 6 to 12 months.

Strassmann et al. (2009) analyzed the effects of smoking cessation counseling in patients with COPD in six RCTs. At 6 months, the odds of cessation were not statistically different from the controls.

Nayan et al. (2011) examined the effect of smoking cessation treatments in patients with various types of cancer. The pooled results from four RCTs found no difference in 6-month abstinence rates among cancer patients who received behavioral and/or pharmacotherapy smoking cessation treatments compared to those who received usual care (risk ratio = 1.2). In a secondary analysis, pooled results of three RCTs showed a favorable effect for combined behavioral and pharmacotherapy treatments compared to usual care controls (risk ratio = 1.4).

There is less robust literature on the effect of combining smoking cessation medications with counseling on smoking cessation rates among smokers with multiple types of medical conditions. In one meta-analysis including RCTs among hospitalized patients, using NRT or bupropion did not increase cessation beyond the effects of counseling alone (Rigotti et al., 2008). Other RCTs on medication use among patients with COPD and patients admitted to the emergency department for chest pain were conditioned on also receiving counseling interventions (Bock et al., 2008; Strassman et al., 2009). Finding from these trials indicate that pharmacotherapy and counseling are effective in reducing smoking rates among these subgroups. 60

The above subpopulation studies are heterogeneous in population, study design, and findings vary within or across subpopulations. However, when considering consistency among studies with stronger designs, results demonstrate findings that are in a favorable direction.

60 Nicotine gum and nicotine inhalers are not recommended for persons with cardiac conditions because of their rapid delivery and high concentrations of nicotine. However, these persons can safely use nicotine patches, which deliver nicotine more slowly.
Summary of findings regarding effects on subpopulations. Overall, the preponderance of evidence from the meta-analyses of counseling interventions indicates that smoking cessation treatments are effective among multiple subpopulations of smokers.

Effects of Health Insurance Coverage for Smoking Cessation Treatments

CHBRP reviewed evidence of the medical effectiveness of health insurance coverage for smoking cessation treatments on two outcomes:

- Use of smoking cessation treatments, including NRT, bupropion, and counseling, and
- Abstinence from smoking.

These studies included a meta-analysis, RCTs, and nonrandomized studies that had comparison groups. Studies of the provision of free counseling and medications by state telephone counseling programs were excluded because these programs are available to all persons in states that operate them regardless of whether they have health insurance (Bauer et al., 2006; Bush et al., 2008; Cummings et al., 2010; Swartz et al., 2005).

Three nonrandomized studies were excluded from the review because they did not have comparison groups and did not present or analyze information about use of smoking cessation treatments by the study population prior to coverage (Boudrez et al., 2011; Burns et al., 2005; Ringen et al., 2002). It is not possible to determine whether the rates of use of smoking cessation treatments reported in such studies are different from rates of use in the study population prior to coverage or from rates observed among persons who do not have coverage.

One RCT (Twardella and Brenner, 2007) was excluded from the review because persons enrolled in the two arms of the trial in which participants received coverage for smoking cessation medications were treated by physicians who had been trained in the provision of smoking cessation treatments. In this study, the effects of coverage for smoking cessation medications cannot be separated from the effects of physician education. This study is not useful for the analysis of AB 1738 because this bill addresses only coverage for smoking cessation treatments; it would not mandate physician education in smoking cessation treatment.

Use of Smoking Cessation Treatments

One meta-analysis was found that assessed the impact of coverage for smoking cessation treatments on use of these services (Kaper, Wagena, Severens, et al., 2005). This meta-analysis

---

61 The content of the Kaper, Wagena, Severens, et al. (2005) was updated by Reda et al. in 2009. In the Reda et al. (2009) update, the authors defined the categories of coverage differently than in the Kaper, Wagena, Severens, et al. (2005) study. In the Reda et al. (2009) study, full coverage was defined as financial coverage for both pharmacotherapy and behavioral interventions; partial coverage was defined as financial coverage for pharmacotherapy or behavioral intervention. While financial coverage was not explicitly defined in the Kaper, Wagena, Severens, et al. study (2005), the aim and analyses examine the different levels of financial coverage, such that full coverage was a benefit covered at 100% and partial coverage a benefit for which the user paid a share of the cost (e.g., a copayment). As the Kaper, Wagena, Severens, et al. (2005) design more closely resembles the intent of the CHBRP analysis, it is cited.
synthesized the results of six studies. Five of these studies had been published in peer-reviewed journals (Boyle et al., 2002; Curry et al., 1998; Dey et al., 1999; Hughes et al., 1991; Schauffler et al., 2001), and one was a conference paper that was subsequently published (Kaper, Wagena, Willemsen, et al., 2005). The authors reported separate estimates for counseling, NRT, and bupropion. They compared the effects of full coverage to no coverage, and full coverage to partial coverage.

Counseling
The meta-analysis pooled the results of two RCTs that assessed the effect of full coverage for smoking cessation treatments versus no coverage on receipt of counseling. In the pooled analysis, the authors found no statistically significant difference in the percentage of persons obtaining counseling (Kaper, Wagena, Severens, et al., 2005). One of the studies included in the meta-analysis reported that full coverage was associated with a statistically significant increase in use of counseling (Kaper, Wagena, Willemsen, et al., 2005), and the other study found no difference (Schauffler et al., 2001). In both studies, few persons with full coverage obtained counseling. One study reported that 5% of persons with full coverage received counseling, and the other study reported that 1% used it.

The lack of consistent findings across the two studies suggests that the evidence of the impact of full coverage for smoking cessation counseling relative to no coverage is ambiguous.

One nonrandomized study included in the meta-analysis compared the effects of full and partial coverage for smoking cessation counseling on receipt of counseling (Curry et al., 1998). The authors found that persons who had coverage for 100% of the costs of counseling were more likely to obtain it than were persons who had coverage for only 50% of the costs.

Some health plans require persons to receive smoking cessation counseling in order to be covered for pharmacotherapy. One RCT conducted in California found that persons with coverage for counseling were more likely to receive it if coverage for smoking cessation medications was contingent on participation in counseling (Halpin et al., 2006).

Nicotine replacement therapy (NRT)
The meta-analysis included five studies of the effects of full coverage versus no coverage on use of NRT (Kaper, Wagena, Severens, et al., 2005). The pooled findings from the meta-analysis indicate that full coverage was associated with a statistically significant increase in use of NRT. The authors of the meta-analysis estimated that 18% of persons who had full coverage for NRT used it versus 13% of persons who did not have coverage (Kaper, Wagena, Willemsen, et al., 2005). Estimates of use from the five studies included in the meta-analysis ranged from 4% (Kaper, Wagena, Willemsen, et al., 2005) to 97% (Dey et al., 1999). Three RCTs included in the meta-analysis also reported statistically significant increases in use of NRT (Hughes et al., 1991; Kaper, Wagena, Willemsen, et al., 2005; Schauffler et al., 2001). One study that did not report results of tests of statistical significance nevertheless reported a large increase in use (Dey et al., 1999). One nonrandomized study reported no statistically significant difference (Boyle et al.,

62 For purposes of this report, full coverage for smoking cessation treatments is defined as coverage of 100% of costs associated with smoking cessation medications and/or counseling without a deductible, copayment, or coinsurance. Partial coverage is defined as a benefit for which the user pays a share of the cost (e.g., a copayment).
2002). The difference between Boyle et al.’s (2002) findings and those of the other studies may reflect a difference in the amount of information subjects in the intervention groups received regarding their coverage for NRT.\textsuperscript{63} One study examined persons enrolled in two California health maintenance organizations (HMOs) and reported that 25\% of persons in the full-coverage group used NRT versus 14\% of persons in the no-coverage group (Schauffler et al., 2001).

Overall, the preponderance of the evidence suggests that persons who have full coverage for NRT are more likely to use it than are persons who do not have coverage.

Two studies included in the meta-analysis compared full and partial coverage for NRT. One study found that persons who had coverage for 100\% of the costs of NRT were more than three times as likely to obtain it as persons who had coverage for only 50\% of the costs (7\% vs. 2\%) (Curry et al., 1998). Another study found that 75\% of persons who had full coverage for nicotine gum obtained at least one box of gum versus 58\% of persons who had only partial coverage (Hughes et al., 1991). Thus, there is consistent evidence that persons with full coverage for nicotine gum are more likely to use it than are persons with partial coverage. The latter study may have found that a much higher percentage of persons used NRT because it was an RCT, whereas the former study was an observational study. Smokers who enroll in RCTs may be more highly motivated to use NRT and other smoking cessation treatments than the average smoker regardless of their level of coverage for NRT.

One study compared partial coverage for nicotine gum to no coverage (Hughes et al., 1991). The authors found that persons who had partial coverage were more likely to use the gum than were persons who did not have coverage (58\% vs. 47\%).

\textit{Bupropion}

The meta-analysis synthesized the results of two studies that investigated the impact of full versus no coverage on use of bupropion. The authors concluded that persons with full coverage for bupropion were more likely to use it than were persons with no coverage, but that the difference was not statistically significant (Kaper, Wagena, Severens, et al., 2005).\textsuperscript{64} One of the studies included in the meta-analysis reported a statistically significant difference in use of bupropion that favored full coverage (Kaper, Wagena, Willemsen, et al., 2005). A nonrandomized study also found an increase in the use of bupropion SR, but the increase was not statistically significant (Boyle et al., 2002). The rates of use among persons with full coverage

\textsuperscript{63} In the RCTs conducted by Hughes et al. (1991); Kaper, Wagena, Willemsen, et al. (2005); and Schauffler et al. (2001), study personnel informed participants randomized to the intervention group orally or in writing that they had coverage for NRT and explained the procedures they needed to follow to use their coverage. The provision of such information increased awareness of coverage for NRT among smokers in the intervention group, which may have increased their likelihood of using NRT. In contrast, participants enrolled in Boyle et al.’s (2002) study did not receive information from study personnel regarding their coverage. One year after coverage for NRT became available to smokers in the intervention, only 30\% of them knew that they had coverage for it (Boyle et al., 2002).

\textsuperscript{64} Although bupropion SR (brand name: Zyban) at strengths of 100 or 150 milligrams is the only formulation of bupropion approved by FDA for smoking cessation, one of the studies included in the meta-analysis (Kaper, Wagena, Willemsen, et al., 2005) does not state whether smokers in the intervention group received coverage for bupropion SR or another formulation of bupropion. In the other study (Boyle et al., 2002), smokers in the intervention group received coverage for bupropion SR.
ranged from 4% (Kaper, Wagena, Willemsen, et al., 2005) to 24% (Boyle et al., 2002). 65 No studies compared the effects of full versus partial coverage for bupropion or the effects of partial versus no coverage.

In summary, the preponderance of evidence suggests that persons who have full coverage for bupropion are more likely to use this drug than persons who do not have coverage.

**Varenicline**

No studies examined the impact of coverage on use of varenicline.

### Summary of findings regarding effects of coverage on use of smoking cessation treatments.

The preponderance of evidence suggests that persons who have coverage for NRT or bupropion are more likely to use these forms of pharmacotherapy for smoking cessation than persons who do not have coverage. There is also evidence that persons who have partial coverage for NRT are more likely to use it than persons who have no coverage. Findings regarding the effect of coverage on use of smoking cessation counseling are ambiguous. No studies have assessed the impact of coverage on use of varenicline.

### Abstinence from Smoking

Eight studies have examined the effects of full coverage of smoking cessation treatments versus no coverage on abstinence from smoking. The results of five of these studies were synthesized in the meta-analysis (Kaper, Wagena, Severens, et al., 2005), including four studies published in peer-reviewed journals (Boyle et al., 2002; Dey et al., 1999; Hughes et al., 1991; Schauffler et al., 2001) and one conference paper that was subsequently published (Kaper, Wagena, Willemsen, et al., 2005). Three articles were published after the meta-analysis was completed (Kaper et al., 2006; 66 Land et al., 2010; Petersen et al., 2006).

The authors of the meta-analysis concluded that persons who had full coverage for smoking cessation treatments were more likely to have quit smoking at 6 months post-treatment than were persons who had no coverage and that the difference was statistically significant (Kaper, Wagena, Severens, et al., 2005). They estimated that 5% of persons who had full coverage had quit smoking versus 4% of persons with no coverage. Two RCTs included in the meta-analysis reported that that full coverage was associated with a statistically significant increase in the percentages of persons who had abstained from smoking (Kaper, Wagena, Willemsen, et al., 2005; Schauffler et al., 2001). Three studies, two RCTs (Dey et al., 1999; Hughes et al., 1991)

65 As discussed in the previous footnote, the difference between the findings of Kaper, Wagena, Willemsen, et al. (2005) and Boyle et al. (2002) may be due a difference in the amount of information study personnel provided to smokers in the intervention group regarding their coverage for smoking cessation services. In Kaper, Wagena, Willemsen, et al.’s (2005) study, members of the study team mailed a leaflet to smokers in the intervention group that described the types of smoking cessation services for which they could receive reimbursement (bupropion, NRT, and counseling) and the procedures for submitting claims. In contrast, participants enrolled in Boyle et al.’s (2002) study did not receive information from study personnel regarding their coverage.

66 Kaper et al., 2006 reports findings from the same study as Kaper, Wagena, Willemsen, et al., 2005. The difference between the two studies is that Kaper, Wagena, Willemsen, et al., 2005, presents findings for use of tobacco cessation services and abstinence from smoking at 6 months after intervention, whereas Kaper et al., 2006 presents additional findings regarding abstinence from smoking at 2 years after intervention.
and one nonrandomized study (Boyle et al., 2002) found no statistically significant difference in abstinence from smoking. In one of these studies, persons with full coverage were more likely to abstain from smoking, but the small sample size limited the authors’ ability to detect statistically significant differences (Hughes et al., 1991). In another study, the lack of a statistically significant difference in abstinence from smoking is probably due to the lack of difference in use of NRT and bupropion SR between smokers who had coverage for them and those who did not (Boyle et al., 2002).

Three articles published after the meta-analysis reported that full coverage for smoking cessation treatments was associated with statistically significant increases in abstinence from smoking relative to no coverage. A second publication from Kaper and colleagues’ RCT found that persons who had full coverage were more likely to abstain from smoking for 2 years after the study was completed than were those without full coverage (Kaper et al., 2006). An article reported findings from a nonrandomized study that concluded that women enrolled in Medicaid were more likely to abstain from smoking during and after pregnancy if they resided in states in which Medicaid covered both smoking cessation counseling and medication than if they lived in states in which Medicaid did not cover either of these treatments (Petersen et al., 2006). A third article presented findings from an interrupted time series analysis of the impact of implementing smoking cessation coverage for adults enrolled in Massachusetts’ Medicaid program (Land et al., 2010). The authors found a statistically significant decrease in the prevalence of smoking among adult Medicaid beneficiaries following implementation of the benefit.\(^67\)

Among studies of full coverage versus no coverage that enrolled men and women with a wide range of ages and incomes, rates of abstinence from smoking ranged from 4% to 19% among the full coverage group versus 4% to 8% in the no coverage groups (Boyle et al., 2002; Hughes et al., 1991). One study examined persons enrolled in two California HMOs and reported that 18% of persons in the full-coverage group abstained from smoking versus 13% of persons in the no-coverage group (Schauffler et al., 2001). The study of women enrolled in Medicaid who resided in states in which Medicaid covered smoking cessation counseling and medications found that 51% quit smoking during pregnancy versus 39% of women who resided in states with no Medicaid coverage for such smoking cessation treatments (Petersen et al., 2006).

Overall, the preponderance of evidence suggests that full coverage for smoking cessation services increases abstinence from smoking relative to no coverage.

Three studies examined the effects of full versus partial coverage for smoking cessation treatments on abstinence from smoking. One study found that persons with full coverage for NRT were three times more likely to abstain from smoking than persons with partial coverage, but the difference was not statistically significant (Hughes et al., 1991). Another study found no difference in rates of abstinence from smoking between persons who had 100% coverage for

\(^{67}\) One important limitation of the two studies of Medicaid beneficiaries is that their authors analyzed data sources that only contained information about smoking status. They did not have access to data on use of smoking cessation counseling or pharmacotherapy and, thus, could not determine whether differences in abstinence from smoking across states or over time were due to differences in use of these treatments, which would be facilitated by coverage, versus factors unrelated to health insurance coverage, such as differences in stigma associated with smoking during pregnancy or cigarette taxes. For example, the implementation of coverage for smoking cessation services in the Massachusetts Medicaid program coincided with a $1 per pack increase in the state’s cigarette tax.
NRT and counseling, and persons who had 50% coverage (Curry et al., 1998). Hughes et al. (1991) may have found a higher rate of abstinence from smoking than Curry et al. (1998) because it was an RCT. Smokers who enroll in RCTs may be more highly motivated to quit smoking than many smokers included in observational studies. For example, Curry et al. (1998) examined data on all smokers who had the two types of coverage regardless of their interest in quitting and their motivation to quit. In contrast, smokers who participated in Hughes et al.’s (1991) RCT chose to participate in the study, which suggests that they were motivated to attempt to quit smoking.

A third study reported the results of an RCT in which the subjects were enrolled in individual preferred provider organization (PPO) plans in California (Halpin et al., 2006). The RCT had three arms: (1) coverage for only NRT and bupropion SR (no coverage for counseling), (2) coverage for pharmacotherapy and counseling, and (3) coverage for pharmacotherapy if persons also obtained counseling. The authors found no statistically significant differences in rates of abstinence from smoking across the three groups. The rates of abstinence were 19% for coverage of pharmacotherapy only, 13% for coverage of pharmacotherapy drugs and counseling, and 18% for coverage of pharmacotherapy if counseling was used.

The lack of consistent findings across these three studies suggests that evidence of the impact of full versus partial coverage on abstinence from smoking is ambiguous.

Two studies compared persons with partial coverage for smoking cessation treatments with persons who had no coverage. One study of men and women of various ages with various levels of income reported that persons with partial coverage for NRT were no more likely to abstain from smoking than persons with no coverage (Hughes et al., 1991). The study of women enrolled in Medicaid found that women who lived in states in which Medicaid provided coverage for either pharmacotherapy or counseling but not both were more likely to quit smoking during pregnancy than women in states in which Medicaid did not cover either of these services, but found no difference in the likelihood of abstaining from smoking after delivery (Petersen et al., 2006).

Thus, the evidence of the effects of partial versus no coverage on abstinence from smoking is ambiguous.

**Summary of findings regarding effects of coverage on abstinence from smoking.** The preponderance of evidence suggests that full coverage for smoking cessation treatments increases abstinence from smoking relative to no coverage. The evidence of the effects of full versus partial coverage on abstinence from smoking is ambiguous, as is the evidence of the effects of partial versus no coverage.

**Summary of Findings**

**Efficacy of Smoking Cessation Treatments**

The literature on the efficacy of behavioral interventions (e.g., counseling, brief advice) and pharmaceuticals for smoking cessation is large and includes numerous meta-analyses of RCTs,
the strongest form of evidence for CHBRP analyses. These meta-analyses provide clear and convincing evidence that behavioral and pharmacological treatments and combinations of the two improve quit rates and increase the likelihood of sustained abstinence from smoking. These conclusions about the efficacy of smoking cessation interventions are not likely to be diminished or altered with the publication of new studies, because of the large quantity of literature summarized in the meta-analyses.

*Behavioral interventions*

- There is clear and convincing evidence that use of multiple types of counseling increases smoking cessation.

- Individual, group, and telephone counseling by physicians and other health professionals increases smoking cessation.

- Brief counseling interventions (as little as a few minutes) are effective, and the preponderance of evidence suggests that more intensive counseling is associated with larger effects.

- Psychologists, physicians, pharmacists, and nurses are all effective in providing smoking cessation counseling.

- RCTs that enrolled smokers at high risk for adverse health outcomes (e.g., persons with coronary heart disease, pregnant women) report similar findings to RCTs that enrolled smokers who were not at increased risk relative to other smokers.

*Pharmacotherapy*

- Pharmacological agents for smoking cessation are commonly divided into those used in initial attempts to quit smoking (“first-line agents”), followed by those used when initial attempts to quit have not been successful (“second-line agents”). First-line agents for smoking cessation include the following: NRT administered by gum, patch, lozenge, nasal spray, and inhaler; varenicline, a nicotine receptor partial agonist; and the non-nicotine agent bupropion SR, an antidepressant useful in treating certain addiction syndromes. Second-line agents include clonidine and nortriptyline.

- Among first-line agents:
  - There is clear and convincing evidence that NRT administered by gum, lozenge, patch, nasal spray, and inhaler increases smoking cessation.
  - There is also clear and convincing evidence that varenicline and bupropion increase smoking cessation.

---

68 The nicotine receptor partial agonist simulates the effects of nicotine to reduce cravings and the pleasurable effect of smoking cigarettes.

69 Although bupropion SR at strengths of 100 or 150 milligrams is the only formulation of bupropion approved by the FDA for smoking cessation, meta-analyses regarding the efficacy of bupropion for smoking cessation do not indicate whether all of the RCTs they included in their analyses assessed bupropion SR. Some of the RCTs included may have evaluated other formulations of bupropion or other strengths of the medication.
There is a preponderance of evidence that varenicline is more effective than bupropion.

There is a preponderance of evidence that smokers who receive a combination of pharmacological agents are more likely to abstain from smoking than persons who receive a single pharmacological agent.

Among second-line agents:

- There is clear and convincing evidence that clonidine and nortriptyline also increase smoking cessation relative to placebo.

- There is a preponderance of evidence that smokers who receive both counseling and pharmacological agents are more likely to abstain from smoking than smokers who only receive counseling.

### Effects of Coverage for Smoking Cessation Treatments

The evidence base from which conclusions can be drawn about the effects of coverage on utilization of smoking cessation treatments and abstinence from smoking is much less robust than the evidence base regarding the efficacy of these treatments.

#### Use of smoking cessation treatments

- The preponderance of evidence suggests that persons who have full coverage for NRT and/or bupropion are more likely to use these smoking cessation medications than are persons who do not have coverage for them.

- The evidence of the effect of full coverage for smoking cessation counseling relative to no coverage is ambiguous.

- Findings from studies suggest that persons who have more generous coverage for NRT and/or counseling are more likely to use these smoking cessation treatments than are persons who have less generous coverage for them.

#### Abstinence from smoking

- The preponderance of evidence suggests that full coverage for smoking cessation counseling and pharmacotherapy is associated with improved abstinence from smoking relative to no coverage for smoking cessation treatments.

- The evidence of the effect of more generous coverage for smoking cessation counseling and pharmacotherapy relative to less generous coverage on abstinence from smoking is ambiguous.

---

70 For purposes of this report, full coverage for smoking cessation treatments is defined as coverage of all three modalities of smoking cessation.
Table 8. Summary of Findings from Studies of the Effectiveness of Smoking Cessation Treatments 
Counseling vs. No Treatment or Minimal Treatment

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual Counseling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking cessation rate at 5 months or more</td>
<td>5 meta-analyses</td>
<td>• Statistically significant: 5 meta-analyses</td>
<td>• Better: 5 of 5 meta-analyses</td>
<td>• Pooled odds ratios ranged from 1.1 to 1.7</td>
<td>• Generalizable: 4 of 5 meta-analyses</td>
<td>• Clear and convincing evidence that individual counseling increases the odds of abstinence from smoking relative to no treatment or minimal intervention</td>
</tr>
<tr>
<td>Group Counseling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking cessation rate at 5 months or more</td>
<td>3 meta-analyses</td>
<td>• Statistically significant: 3 of 3 meta-analyses</td>
<td>• Better: 3 of 3 meta-analyses</td>
<td>• Pooled odds ratios ranged from 1.3 to 2.7</td>
<td>• Generalizable: 3 of 3 meta-analyses</td>
<td>• Clear and convincing evidence that group counseling increases the odds of abstinence from smoking relative to no treatment</td>
</tr>
<tr>
<td>Counseling Provided Over the Phone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking cessation rate at 5 months or more</td>
<td>4 meta-analyses</td>
<td>• Statistically significant: 4 of 4 meta-analyses</td>
<td>• Better: 4 of 4 meta-analyses</td>
<td>• Pooled odds and risk ratios ranged from 1.3 to 1.6</td>
<td>• Generalizable: 4 of 4 meta-analyses</td>
<td>• Clear and convincing evidence that counseling provided over the phone increases the likelihood of abstinence from smoking relative to no treatment or minimal intervention</td>
</tr>
<tr>
<td>Brief Counseling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking cessation rate at 5 months or more</td>
<td>4 meta-analysis</td>
<td>• Statistically significant: 4 of 4 meta-analyses</td>
<td>• Better: 4 of 4 meta-analyses</td>
<td>• Pooled odds and risk ratios ranged from 1.3 to 1.6</td>
<td>• Generalizable: 4 of 4 meta-analyses</td>
<td>• The preponderance of evidence indicates that brief counseling increases the likelihood of abstinence from smoking relative to no treatment or self-help materials</td>
</tr>
</tbody>
</table>

71 One meta-analysis, Stead et al. (2009), reported pooled effects from two analyses. One analysis pooled findings from RCTs on the effectiveness of proactive telephone counseling (i.e., counseling in which all calls are initiated by a counselor). The other pooled findings from RCTs on the effectiveness of quitline telephone counseling (i.e., counseling in which the initial call is made by a smoker who may choose to schedule additional, proactive calls initiated by a counselor). Both analyses found statistically significant effects that favored telephone counseling.
Table 8. Summary of Findings from Studies of the Effectiveness of Smoking Cessation Treatments (Cont’d)

### Intensity of Counseling

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
<th>Conclusion</th>
</tr>
</thead>
</table>
| Smoking cessation rate at 5 months or more   | 3 meta-analyses | • Statistically significant: 2 of 3 meta-analyses\(^{72}\)  
• Not statistically significant: 1 of 3 meta-analyses | • Better: 3 of 3 meta-analyses | • Pooled odds ratios ranged from 1.1 to 2.3 | • Generalizable: 4 of 4 meta-analyses | • Preponderance of evidence suggests that there is a dose-response relationship, where more intensive counseling increases the odds of abstinence from smoking relative to less intensive treatment |

### Nicotine Gum vs. Placebo or No Treatment

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking cessation rate at 5 months or more</td>
<td>3 meta-analyses</td>
<td>• Statistically significant: 3 of 3 meta-analyses(^{73})</td>
<td>• Better: 3 of 3 meta-analyses</td>
<td>• Pooled odds ratios from meta-analyses ranged from 1.4 to 2.2</td>
<td>• Generalizable: 3 of 3 meta-analyses</td>
<td>• Clear and convincing evidence that nicotine gum increases the odds of abstinence from smoking relative to placebo or no treatment</td>
</tr>
</tbody>
</table>

\(^{72}\) One meta-analysis, Fiore et al. (2008), reported findings from two analyses regarding the intensity of counseling. One analysis compared pooled effects of RCTs that assessed the effects of low-intensity counseling (3 to 10 minutes) and higher intensity (>10 minutes) compared to no counseling. The other analysis compared the effect of the number of treatment sessions on abstinence from smoking across 46 trials. The number of treatment sessions was categorized into a control group, having had 0 to 1 sessions, and 3 treatment groups: having 2 to 4 sessions, 4 to 8 sessions, and >8 sessions. Findings from these analyses suggest that the likelihood that a person will abstain from smoking increases as the length of counseling sessions and the number of counseling sessions increases.

\(^{73}\) One meta-analysis, Fiore et al. (2008), reported findings from two analyses of the efficacy of nicotine gum. One analysis pooled findings from RCTs that compared use of nicotine gum for 6 to 14 weeks to a placebo. The other analysis compared use of nicotine gum for more than 14 weeks to a placebo. Both analyses found statistically significant differences favoring nicotine gum.
Table 8. Summary of Findings from Studies of the Effectiveness of Smoking Cessation Treatments (Cont’d)

### Nicotine Patch vs. Placebo or No Treatment

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking cessation rate at 5 months or more</td>
<td>4 meta-analyses</td>
<td>Statistically significant: 4 of 4 meta-analyses&lt;sup&gt;74&lt;/sup&gt;</td>
<td>Better: 4 of 4 meta-analyses</td>
<td>Pooled odds ratios from meta-analyses ranged from 1.6 to 2.3</td>
<td>Generalizable: 4 of 4 meta-analyses</td>
<td>Clear and convincing evidence that nicotine patch increases the odds of abstinence from smoking relative to placebo or no treatment</td>
</tr>
</tbody>
</table>

### Nicotine Lozenge vs. Placebo or No Treatment

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking cessation rate at 5 months or more</td>
<td>2 meta-analyses</td>
<td>Statistically significant: 2 of 2 meta-analyses</td>
<td>Better: 2 of 2 meta-analyses</td>
<td>Pooled odds ratios from meta-analyses were 2.0 and 2.1</td>
<td>Generalizable: 2 of 2 meta-analyses</td>
<td>Clear and convincing evidence that nicotine lozenge increases the odds of abstinence from smoking relative to placebo or no treatment</td>
</tr>
</tbody>
</table>

### Nicotine Inhaler vs. Placebo or No Treatment

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking cessation rate at 5 months or more</td>
<td>3 meta-analyses</td>
<td>Statistically significant: 2 of 3 meta-analyses Not statistically significant: 1 of 3 meta-analyses</td>
<td>Better: 3 of 3 meta-analyses</td>
<td>Pooled odds ratios from meta-analyses were 1.9 and 2.2</td>
<td>Generalizable: 3 of 3 meta-analyses</td>
<td>Preponderance of evidence indicates that nicotine inhaler increases the odds of abstinence from smoking relative to placebo or no treatment</td>
</tr>
</tbody>
</table>

<sup>74</sup> One meta-analysis, Fiore et al. (2008), reported findings from three analyses of the efficacy of nicotine patches. The first pooled RCTs on high-dose nicotine patch use (>25 mg) compared to placebo. The second pooled RCTs on long-term nicotine patch use (>14 weeks) compared to a placebo and the third meta-analysis pooled studies on shorter-term (6 to 14 weeks) nicotine patch use compared to a placebo. All three analyses found statistically significant differences favoring nicotine patches.
Table 8. Summary of Findings from Studies of the Effectiveness of Smoking Cessation Treatments (Cont’d)

<table>
<thead>
<tr>
<th>Nicotine Nasal Spray vs. Placebo or No Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Outcome</strong></td>
</tr>
<tr>
<td>Smoking cessation rate at 5 months or more</td>
</tr>
</tbody>
</table>

**Bupropion** vs. Placebo or No Treatment

| **Outcome** | **Research Design** | **Statistical Significance** | **Direction of Effect** | **Size of Effect** | **Generalizability** | **Conclusion** |
| Smoking cessation rate at 5 months or more | 3 meta-analyses | Statistically significant: 3 of 3 meta-analyses | Better: 3 of 3 meta-analyses | Pooled odds ratios from meta-analyses range from 1.7 to 2.1 | Generalizable: 3 of 3 meta-analyses | Clear and convincing evidence that bupropion increases the odds of abstinence from smoking relative to placebo or no treatment |

**Varenicline vs. Placebo**

| **Outcome** | **Research Design** | **Statistical Significance** | **Direction of Effect** | **Size of Effect** | **Generalizability** | **Conclusion** |
| Smoking cessation rate at 5 months or more | 3 meta-analyses | Statistically significant: 3 of 3 meta-analyses | Better: 3 of 3 meta-analyses | Pooled odds ratios ranged from 2.3 to 3.1 | Generalizable: 3 of 3 meta-analyses | Clear and convincing evidence that varenicline increases the odds of abstinence from smoking relative to placebo |

---

75 Bupropion SR in strengths of 100 or 150 milligrams is the only formulation of bupropion approved by the FDA for smoking cessation. Two of the meta-analyses on the efficacy of bupropion for smoking cessation -- Fiore et al. (2008) and Hughes et al. (2010) -- do not indicate whether their meta-analyses included only RCTs that assessed the efficacy of bupropion SR. Some of the RCTs included may have evaluated other formulations of bupropion. The third meta-analysis -- Eisenberg et al. 2008 -- only included RCTs that examined bupropion SR.
Table 8. Summary of Findings from Studies of the Effectiveness of Smoking Cessation Treatments (Cont’d)

### Varenicline vs. Bupropion

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking cessation rate at 5 months or more</td>
<td>3 meta-analyses</td>
<td>• Statistically significant: 3 of 3 meta-analyses</td>
<td>• Better: 3 of 3 meta-analyses</td>
<td>• Pooled odds ratio ranged from 1.5 and 2.2</td>
<td>• Generalizable: 3 of 3 meta-analyses</td>
<td>• Clear and convincing evidence that varenicline increases the odds of abstinence from smoking relative to bupropion</td>
</tr>
</tbody>
</table>

### Clonidine vs. Placebo

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking cessation rate at 3 months or more</td>
<td>2 meta-analyses</td>
<td>• Statistically significant: 2 of 2 meta-analyses</td>
<td>• Better: 2 of 2 meta-analyses</td>
<td>• Pooled odds ratio ranged from 1.6 and 2.1</td>
<td>• Generalizable: 2 of 2 meta-analyses</td>
<td>• Clear and convincing evidence that clonidine increases the odds of abstinence from smoking compared to placebo</td>
</tr>
</tbody>
</table>

### Nortriptyline vs. Placebo

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking cessation rate at 5 months or more</td>
<td>2 meta-analyses</td>
<td>• Statistically significant: 2 of 2 meta-analyses</td>
<td>• Better: 2 of 2 meta-analyses</td>
<td>• Pooled odds ratio ranged from 1.8 and 2.3</td>
<td>• Generalizable: 2 of 2 meta-analyses</td>
<td>• Clear and convincing evidence that nortriptyline increases the odds of abstinence from smoking compared to placebo</td>
</tr>
</tbody>
</table>

---

76 Two of the meta-analyses—Cahill et al. (2011) and Hughes et al. (2010)—do not indicate whether their meta-analyses were limited to RCTs on that assessed bupropion SR in strengths of 100 or 150 milligrams, the only formulation of bupropion approved by the FDA for smoking cessation. Some of the RCTs included may have evaluated other formulations of bupropion. The third meta-analysis—Eisenberg et al. 2008—only included RCTs that examined bupropion SR.
Table 8. Summary of Findings from Studies of the Effectiveness of Smoking Cessation Treatments (Cont’d)
Combination Therapies

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking cessation rate at 5 months or more</td>
<td>2 meta-analyses</td>
<td>Statistically significant: 2 of 2 meta-analyses</td>
<td>Better: 2 of 2 meta-analyses</td>
<td>Pooled odds ratio ranged from 1.5 and 3.6</td>
<td>Generalizable: 2 of 2 meta-analyses</td>
<td>Clear and convincing evidence that there is a dose-response relationship, where more combinations of specific therapies increases the odds of abstinence from smoking relative to placebo of a single medication</td>
</tr>
<tr>
<td>Smoking cessation rate at later pregnancy or delivery</td>
<td>1 meta-analysis</td>
<td>Statistically significant: 1 of 3 meta-analyses</td>
<td>Better: 3 of 3 meta-analyses</td>
<td>Pooled risk ratios from 1.1 to 7.8</td>
<td>Generalizable: 3 of 3 meta-analyses and 1 or 1 RCT</td>
<td>Evidence that NRT increases the likelihood of abstinence among pregnant women from smoking relative to placebo, behavioral, or no treatment is ambiguous/conflicting</td>
</tr>
<tr>
<td>Smoking cessation of at least 6 months (limited to cancer patients)</td>
<td>1 meta-analysis</td>
<td>Statistically significant: 1 or 2 meta-analyses</td>
<td>Better: 2 or 2 meta-analysis</td>
<td>Pooled risk ratios from 1.2 to 1.4</td>
<td>Generalizable: 2 of 2 meta-analyses</td>
<td>Evidence that smoking cessation treatments in patients with various types of cancer is ambiguous/conflicting</td>
</tr>
</tbody>
</table>

Sources: Aveyard et al., 2011; Cahill et al., 2011; Eisenberg et al., 2008; Fiore et al., 2008; Gourlay et al., 2008; Hughes et al., 2010; Lancaster and Stead, 2008; Mottillo et al., 2009; Myung et al., 2007; Nayan et al., 2011; Rice and Stead, 2008; Shah et al., 2008; Stead and Lancaster, 2009; Stead, Bergson, et al., 2008; Stead, Perera, et al., 2008; and Stead et al., 2009.

77 Coleman et al., (2010) included RCTS on any NRT use, including gum, patches among pregnant women.
78 Coleman et al., (2012) conducted a RCT that examined the effects of behavioral treatment with NRT patch compared to NRT patch or placebo NRT patch.
### Table 9. Summary of Findings from Studies of the Effects of Coverage for Smoking Cessation Treatments on Use of Treatments and Abstinence from Smoking

**Full Coverage for Smoking Cessation Treatments vs. No Coverage—Use of Cessation Treatments**

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Research Design&lt;sup&gt;70&lt;/sup&gt;</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use of Counseling</td>
<td>• Level I: 2 studies</td>
<td>• Statistically significant: 1 of 2 studies</td>
<td>• Better (i.e., more likely to use counseling cessation services): 1 of 2 studies</td>
<td>• Ranged from no difference to 5 times as likely to obtain</td>
<td>• Highly generalizable = 1 of 2 studies</td>
<td>• The evidence of the effect of full coverage for tobacco cessation counseling on use of counseling is ambiguous</td>
</tr>
<tr>
<td></td>
<td>• Not statistically significant: 1 of 2 studies</td>
<td>• No difference: 1 of 2 studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use of NRT</td>
<td>• Level I: 3 studies</td>
<td>• Statistically significant: 3 of 5 studies</td>
<td>• Better (i.e., more likely to use NRT): 4 of 5 studies</td>
<td>• Ranged from 0.07 times less likely to use to 1.02 times more likely</td>
<td>• Highly generalizable = 1 of 5 studies</td>
<td>• Preponderance of evidence suggests that full coverage for NRT increases use of NRT</td>
</tr>
<tr>
<td></td>
<td>• Level II: 1 study</td>
<td>• Not statistically significant: 1 of 5 studies</td>
<td>• No difference: 1 of 5 studies</td>
<td></td>
<td>• Somewhat generalizable = 4 of 5 studies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Level III: 1 study</td>
<td>• Not reported: 1 of 5 studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

<sup>70</sup> Level I = Well-implemented RCTs and cluster RCTs; Level II = RCTs and cluster RCTs with major weaknesses; Level III = Nonrandomized studies that include an intervention group and one or more comparison groups and time series analyses; Level IV = Case series and case reports; and Level V = Clinical/practice guidelines based on consensus or opinion.
Table 9. Summary of Findings from Studies of the Effects of Coverage for Smoking Cessation Treatments on Use of Treatments and Abstinence from Smoking (Cont’d)

**Full Coverage for Smoking Cessation Treatments vs. No Coverage—Use of Cessation Treatments (Cont’d)**

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use of bupropion (^{80}) (2 studies)</td>
<td>Level I: 1 study</td>
<td>Statistically significant: 1 of 2 studies</td>
<td>Better (i.e., more likely to obtain bupropion): 2 of 2 studies</td>
<td>Changes in usage rates ranged from 0.24 times more likely to 0.63 times more likely</td>
<td>Somewhat generalizable = 2 of 2 studies</td>
<td>Preponderance of the evidence suggests that full coverage for bupropion increases use of this drug for tobacco cessation</td>
</tr>
<tr>
<td></td>
<td>Level III: 1 study</td>
<td>Not statistically significant: 1 of 2 studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^{80}\) Although bupropion SR (brand name: Zyban) at strengths of 100 or 150 milligrams is the only formulation of bupropion approved by FDA for smoking cessation, one of the studies included in the meta-analysis (Kaper, Wagena, Willemsen, et al., 2005) does not state whether smokers in the intervention group received coverage for bupropion SR or another formulation of bupropion. In the other study (Boyle et al., 2002), smokers in the intervention group received coverage for bupropion SR.
Table 9. Summary of Findings from Studies of the Effects of Coverage for Smoking Cessation Treatments on Use of Treatments and Abstinence from Smoking (Cont’d)

**Full Coverage for Smoking Cessation Treatments vs. Partial Coverage—Use of Cessation Treatments**

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use of counseling</td>
<td>• Level III: 1 study</td>
<td>• Statistically significant: 1 of 1 study</td>
<td>• Better (i.e., more likely to obtain counseling): 1 of 1 study</td>
<td>• 3 times as likely to obtain</td>
<td>• Somewhat generalizable = 1 of 1 study</td>
<td>• Single study suggests that persons who have full coverage for counseling are more likely to obtain it than persons with partial coverage</td>
</tr>
<tr>
<td>Use of NRT</td>
<td>• Level II: 1 study, Level III: 1 study</td>
<td>• Statistically significant: 2 of 2 studies</td>
<td>• Better (i.e., more likely to use NRT): 2 of 2 studies</td>
<td>• Change in usage rates ranged from 0.3 times to 2.5 times more likely to use</td>
<td>• Somewhat generalizable = 2 of 2 studies</td>
<td>• Clear and convincing evidence that persons with full coverage for NRT are more likely to use it than people with partial coverage</td>
</tr>
</tbody>
</table>

**Full Coverage for Smoking Cessation Treatments vs. No Coverage—Abstinence from Smoking**

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstinence from smoking (7 studies)</td>
<td>• Level I: 3 studies, Level II: 1 study, Level III: 3 studies</td>
<td>• Statistically significant: 5 of 7 studies, Not statistically significant: 2 of 7 studies</td>
<td>• Better (i.e., more likely to stop smoking): 5 of 7 studies, No effect: 1 of 7 studies, Worse: 1 of 7 studies</td>
<td>• Ranged from no difference to 1.7 times as likely to quit</td>
<td>• Highly generalizable = 1 of 7 studies, Somewhat generalizable = 6 of 7 studies</td>
<td>• Preponderance of evidence suggests that coverage for tobacco cessation services increases abstinence from smoking</td>
</tr>
</tbody>
</table>
Table 9. Summary of Findings from Studies of the Effects of Coverage for Smoking Cessation Treatments on Use of Treatments and Abstinence from Smoking (Cont’d)

**Full Coverage for Smoking Cessation Treatments vs. Partial Coverage—Abstinence from Smoking**

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstinence from smoking (3 studies)</td>
<td>Level I: 1 study</td>
<td>Not statistically significant: 3 of 3 studies</td>
<td>Better (i.e., more likely to stop smoking): 1 of 3 studies</td>
<td>Ranged from no difference to 2 times as likely to quit</td>
<td>Highly generalizable = 1 of 3 studies</td>
<td>The evidence of the impact of full versus partial coverage on abstinence from smoking is ambiguous</td>
</tr>
<tr>
<td></td>
<td>Level II: 1 study</td>
<td></td>
<td>No effect: 2 of 3 studies</td>
<td></td>
<td>Somewhat generalizable = 2 of 3 studies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Level III: 1 study</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Sources*: Boyle et al., 2002; Curry et al., 1998; Dey et al., 1999; Halpin et al., 2006; Hughes et al., 1991; Kaper, Wagena, Willemsen, et al., 2005; Kaper et al., 2006; Land et al., 2010; Petersen et al., 2006; and Schauffler et al., 2001.
AB 1738 would require DMHC-regulated health plans and CDI-regulated insurance policies to provide two courses of treatment in a 12-month period for smoking cessation without copayments, coinsurance, or deductibles. A course of treatment is defined as coverage for counseling (including telephone, group, and individual) and FDA-approved pharmacotherapy, whether by prescription or OTC. According to CHBRP’s estimates, there are 21.9 million insured Californians currently enrolled in either DMHC-regulated health plans or CDI-regulated insurance policies, including 14.3 million adults aged 18 years and older.

Although AB 1738 does not specify a targeted age group, the bill as introduced defers to the USPSTF “A” and “B” recommendations, which applies to adults aged 18 and older and pregnant women. Therefore, CHBRP made the simplifying assumption to focus on the adult population for the benefit coverage impact analysis. OTC and prescription smoking cessation treatments have been proven efficacious and are regularly utilized by adult smokers, but the efficacy and usage rates for these treatments have not been firmly established for adolescents (Grimshaw and Stanton, 2010). Instead, the literature points to school-based counseling programs administered by nurses (Fritz et al., 2008; Joffe et al, 2009). Additionally, smoking cessation in adolescents is associated with deeper psychological issues linked with peer and parental relationships (McVea et al., 2009). Thus, this report will focus on coverage for adults.

This section will present first the current, or baseline, costs and coverage related to smoking cessation treatment for adults, and then the estimated utilization, cost, and benefit coverage impacts of AB 1738. For further details on the underlying data sources and methods, please see Appendix D at the end of this document.

**Current (Baseline) Benefit Coverage, Utilization and Cost**

**Current Coverage of the Mandated Benefit**

Current coverage of smoking cessation services was determined by a survey of the seven largest providers of health insurance in California. CHBRP surveys the largest major health plans and insurers regarding coverage. Responses to this survey represent 26.3% of the privately funded, CDI-regulated market and 66.8% of the privately funded, DMHC-regulated market. Combined, responses to this survey represent 58.4% of the privately funded market subject to state mandates.

Currently, enrollees in DMHC-regulated health plans or CDI-regulated insurance policies may have coverage for smoking cessation treatment by a physician or other clinical staff as part of a regular physician visit, which is subject to a copayment ($15) per office visit. Additionally, 23.5% have full coverage and 66.6% have partial coverage, (a total of 90.1%), for prescription smoking cessation treatments (e.g., bupropion, varenicline, or inhalant forms of NRT) through outpatient prescription drug benefits with copayments ranging from $10 to $50. While 82.8% have full or partial (79.4% full coverage, 3.4% partial coverage) coverage for personal counseling through telephone or other counseling services, a smaller number, 61.5% (21.5% full coverage, 40.0% partial coverage), have coverage for OTC treatments. Enrollee out-of-pocket
expenses for covered benefits (partial coverage) ranges from a $50 per enrollee per lifetime reimbursement to a $20 copayment per visit

California’s Medi-Cal Managed Care Program, which covers 9.8% (1.4 million) of adults subject to the mandate, provides comprehensive smoking cessation benefits at no charge to Medi-Cal enrollees.

Contracting health plans administer smoking cessation benefits including a broad scope of pharmacological aids (including OTC medications) and coverage for smoking cessation programs that provide counseling, classes, and self-help materials. If AB 1738 were enacted, 100% of insured adults would have mandate-compliant coverage for all of these smoking cessation services.

Current Utilization Levels

According to the most recent California-specific data available, the 2008 California Tobacco Survey (CTS), 60.2% of California smokers made at least one quit attempt in a year. Among those who made a quit attempt, 26% participated in a formal cessation assistance program (see Table 5 in Introduction). In 2009, the USPSTF recommended that clinicians ask all adults about tobacco use and provide tobacco cessation interventions, including counseling and medication to those who smoke. Typically, formal cessation assistance programs include a combination of counseling, prescription medications, and physician contact (Javitz, 2004). CHBRP used the 2008 CTS data and found that 7.7% smokers who made an attempt to quit used NRT alone, 5.9% used counseling only, 1.8% used a pharmaceutical smoking cessation method alone; 10.6% used a combination of two or more treatments, giving a total of 26.0% of enrollees using one or more services. The rest (74.0%) did not use any formal assistance during a quit attempt in the year before the survey.

Though previous studies, including an RCT in California HMOs, showed utilization rates of smoking cessation services among those with or without coverage (see details in the Medical Effectiveness section), CHBRP decided to use the 2008 CTS data as a baseline to estimate the premandate utilization because these data were weighted to represent a complete utilization pattern of all Californians. Because CTS data did not provide utilization information by insurance coverage, CHBRP decided to use the estimate of elasticity of demand for well care from the RAND Health Insurance Experiment (HIE) to model the impact of cost sharing on use of smoking cessation treatments. An RCT conducted in the late 1970s and early 1980s, HIE remains the most authoritative study on the topic of the effects of cost sharing on health care utilization. The RAND HIE found that consumers enrolled in fee-for-service plans who paid a larger share of costs were less likely to use health care services and used smaller amounts of services than consumers who paid a smaller share of costs (Newhouse, 1993). The RAND HIE tested the effects of cost sharing on the use of medical services and developed utilization rates for no copays, or 25%, 50%, or 95% coinsurance (Newhouse, 1993). The results indicate that an increase from zero copay to 25% coinsurance reduces utilization rates by about 25%. CHBRP used an average of 20% reduction to estimate current utilization levels based on the proportion of enrollees with any levels of copayments.
Premandate, of the 1.92 million adult smokers enrolled in DMHC- or CDI-regulated plans or policies with smoking cessation coverage, 304,400 used one or more smoking cessation treatments, with 252,000 using treatments covered through their existing insurance and 52,400 enrollees using treatments for which they were uninsured. Additional detail is provided in Appendix D.

**Current Average Cost of Smoking Cessation Services**

Currently, the average cost per course of smoking cessation treatment is $200 for counseling, $236 for OTC, and $240 for prescriptions. The average costs for counseling assume four sessions in either group or individual settings, each a minimum of 10 minutes. Use of the free statewide quit telephone helpline is not included in this estimate as the quit line is universally available to all smokers regardless of insurance and the cost is already reflected in baseline estimates. The estimates in this report focus on the marginal impact of new insurance coverage, which is assumed to be zero for quit telephone helpline. This analysis assumes that the available supply of services would meet the increased demand, and that costs for the service would not increase.

**The Extent to Which Costs Resulting From Lack of Coverage Are Shifted to Other Payers, Including Both Public and Private Entities**

CHBRP estimated no shift in costs among private or public payers as a result of current coverage. In the long term, to the extent that smokers are more likely to require custodial nursing home services, reductions in smoking may produce reductions in nursing home expenditures under the Medi-Cal program (Warner et al., 2004). In contrast, because quitters will live longer, they incur health care expenditures including custodial care during more years of life (Warner et al., 2004). These potential savings or costs were not estimated in the current analysis, since the CHBRP cost model examines the short-term impact of the proposed benefit coverage mandate. However, CHBRP examines the relevant literature and anticipated long-term cost impact of AB 1738 later in this section (see “Impact on Long-Term Costs”).

**Public Demand for Benefit Coverage**

As a way to determine whether public demand exists for the proposed mandate (based on criteria specified by CHBRP’s authorizing statute), CHBRP must report on the extent to which collective bargaining entities negotiate for and the extent to which self-insured plans currently have coverage for the benefits specified under the proposed mandate. On the basis of conversations with the largest collective bargaining agents in California, CHBRP determined that no evidence exists that unions currently include such detailed provisions (specific to smoking cessation) during the negotiations of their health insurance policies. In general, unions tend to negotiate for broader contract provisions such as coverage for dependents, premiums, deductibles, and coinsurance levels. In order to determine whether any local unions engage in negotiations in such detail, they would need to be surveyed individually. ³⁸¹ Currently, CalPERS’ plans vary in coverage for tobacco cessation, though generally, most provide some coverage. Some plans also place dollar limits on the maximum level of tobacco cessation benefit coverage available; others

---

³⁸¹ Personal communication with the California Labor Federation, March 26, 2012.
do not. Plans also vary in the level cost sharing for prescription drugs, and OTC medications are generally not covered. The plans also vary in the types of requirements for enrolling in a behavioral intervention program.

**Impacts of Mandated Benefit Coverage**

How Would Changes in Benefit Coverage Related to the Mandate Affect the Availability of the Newly Covered Treatment/Service, the Health Benefit of the Newly Covered Treatment/Service, and the Per-Unit Cost?

**Impact on access and health treatment/service availability**

On the basis of the responses from health plans and insurers in California, CHBRP estimated that the percentage of enrollees with mandate-compliant benefit coverage would increase 20.6 percentage points, from 79.4% who currently have mandate-compliant coverage to 100% for counseling; 78.5 percentage points, from 21.5% who currently have mandate-compliant coverage to 100% for OTC treatments; and 76.5 percentage points, from 23.5% who currently have mandate-compliant coverage to 100% for prescription smoking cessation treatments (see Table 1 in Executive Summary) in the CDI- and DMHC-regulated markets.

**Impact on per-unit cost**

As there is no evidence in the literature that increasing coverage for smoking cessation treatments increases the prices of those treatments, CHBRP assumes that the unit cost of covered smoking cessation services would stay the same after the mandate.

**How Would Utilization Change As a Result of the Mandate?**

On the basis of findings from the literature (Curry et al., 1998; Kaper, Wagena, Severens, et al., 2005; Land, et al., 2010; Schauffler et al., 2001), utilization is expected to increase as a result of increasing coverage for smoking cessation treatment. Using CHBRP’s adjustment of the RAND HIE, CHBRP estimated that those without coverage would have expenditures equal to 45% of those with full coverage, whereas those with partial coverage would have expenditures equal to 80% of those with full coverage. CHBRP estimated that AB 1738 would increase the utilization of all smoking cessation treatments.

Postmandate, of the 1.92 million insured adult smokers, CHBRP estimated that the utilization of counseling services would increase by 13.2%, OTC treatments by 44.0%, and prescription treatments by 25.4%. Utilization of one or more smoking cessation treatments would increase by 27.5%, representing an additional 83,300 insured adult smokers using smoking cessation treatments postmandate. (Details of the calculations are provided in Appendix D.) The estimated increases similar to the findings of two meta-analyses published more recently (Gollust et al., 2008; Kaper et al., 2006) as well as previous studies (Curry et al., 1998; Schauffler et al., 2001).

**To What Extent Would the Mandate Affect Administrative and Other Expenses?**

This mandate would likely increase the administrative expenses for health plans, especially in the first few years, but this increase is expected to be in proportion to the increase in health care costs. Claims administration costs may go up slightly due to an increase in claims for smoking
cessation. Health plans and insurers would have to modify some insurance contracts and enrollee materials to reflect the new services. In addition, health plans and insurers would need to determine how to administer the smoking cessation benefits to comply with the mandate to cover OTC smoking cessation treatments and counseling services. If AB 1738 were enacted, the mandate would eliminate the prior authorization requirements that currently exist in some managed care plans (beyond the first treatment). Health plans and insurers include a component for administration and profit in their premiums. The estimated impact of this mandate on premiums includes the assumption that plans and insurers will apply their existing administration and profit loads to the marginal increase in health care costs produced by the mandate. Therefore, although there may be administrative costs associated with the mandate, administrative costs as a proportion of the premium would not change.

Impact of the Mandate on Total Health Care Costs

Changes in total expenditures
AB 1738 would increase total net annual expenditures by $38.4 million or 0.04% for this insured population (see Table 1 in Executive Summary). This is due to a $65.8 million total increase in health insurance premiums and enrollee expenses for newly covered benefits, partially offset by a reduction in enrollee expenditures for previously noncovered benefits ($16.3 million) and a reduction in enrollee expenditures for enrollee out-of-pocket expenses ($11.1 million).

Potential cost offsets or savings in the short term
Potential cost offsets in the short term include potential savings from a reduction in low birth weight deliveries and in hospitalizations due to acute myocardial infarction (AMI) among those who quit smoking. However, estimating savings are $1.6 million for the 1-year timeframe of the CHBRP cost model.

Impact on long-term costs
Many of the health benefits associated with smoking cessation are reductions in long-term risk of serious disease. The 2008 Surgeon General's Clinical Practice Guideline update of Treating Tobacco Use and Dependence identified effective, experimentally validated tobacco dependence treatments and practices and found that virtually all cessation analyses included in the guideline used long-term outcome data (Fiore et al, 2008). Long-term health risks associated with tobacco use include: heart attacks and strokes, lung and other cancers (e.g., larynx, oral cavity, pharynx, esophagus, pancreas, stomach, kidney, bladder, cervix, and acute myelocytic leukemia), COPD (chronic bronchitis and emphysema), osteoporosis, long-term disability, and need for extended care (Fiore et al, 2008). Reducing the incidence of serious smoking-related disease, such as lung cancer, through tobacco cessation treatments could result in reductions in the health care costs associated with treating these diseases in the future. For example, Kuticova et al (2005) conducted a case-control cohort study on a claims database of employees, dependents, and retirees of multiple large U.S. employers and found that the monthly healthcare costs of lung cancer patients was $6,181 higher than those with no cancer.
Impacts for Each Category of Payer Resulting from the Benefit Mandate

Changes in expenditures and per member per month (PMPM) amounts by payer category

Increases in insurance premiums vary by market segment. Note that the total population in Table 11 reflects the full 21.9 million enrollees in DMHC-regulated health plans or CDI-regulated insurance policies that are included in the mandate under AB 1738. The premium increases are estimated to be spread among all enrollees in all plans or policies, regardless of whether they have prescription drug coverage or whether the enrollees would possibly use smoking cessation treatments.

Increases in per member per month (PMPM) premiums for the newly mandated benefit coverage vary by market segment (Table 11). Increases as measured by percentage changes in PMPM premiums are estimated to range from a low of 0.00% (for DMHC-regulated Medi-Cal HMO plans) to a high of 0.28% (for CDI-regulated individual policies) in the affected market segments. Increases as measured by PMPM premiums are estimated to range from $0.00 to $0.58.

In the privately funded large-group market, the increase in premiums is estimated to range from $0.26 PMPM among DMHC-regulated plan contracts to $0.39 PMPM among CDI-regulated policies (Table 11). For enrollees with privately funded small-group insurance policies, health insurance premiums are estimated to increase by approximately $0.29 PMPM for DMHC contracts to $0.46 PMPM for CDI policies. In the privately funded individual market, the health insurance premiums are estimated to increase by $0.29 PMPM and by $0.58 PMPM in the DMHC- and CDI-regulated markets, respectively.

In the publicly funded DMHC-regulated health plans, CHBRP estimates that premiums would decrease slightly or remain flat for Medi-Cal HMOs and MRMIB (including Healthy Families), with the impact ranging from 0.00% to 0.03% ($0.00 to $0.03). For CalPERS HMOs, CHBRP estimates that premiums would increase 0.09% ($0.38).

The largest portion of the shift in benefit expenditures would be from privately insured individuals’ out-of-pocket expenses to third parties, and in turn to the employers and employees who pay premiums to the third parties. For example, in the large-group HMO market, $0.12 of the out-of-pocket expenses (measured as PMPM costs) would be expected to shift to the health plan or insurer. Individuals who currently purchase smoking cessation services, mostly OTC medications, would realize the greatest savings under the mandate, because full coverage for OTC medications would be available to them without cost sharing under the mandate.

Impacts on the Uninsured and Public Programs as a Result of the Cost Impacts of the Mandate

CHBRP estimates premium increases of less than 1% for each market segment. CHBRP does not anticipate loss of health insurance, changes in availability of the benefit beyond those subject to the mandate, changes in offer rates of health insurance, changes in employer contribution rates, changes in take-up of health insurance by employees, or purchase of individual market policies, due to the small size of the increase in premiums after the mandate. This premium increase would not have a measurable impact on number of persons who are uninsured.
CHBRP’s method for estimating the impact of premium increases on the number of individuals who drop their private insurance is described on CHBRP’s website. 82

Impact on public programs as a result of premium increases
CHBRP estimates that the mandate would produce no measurable impact on enrollment in publicly funded insurance programs or on utilization of covered benefits in the publicly funded insurance market.

82 See http://www.chbrp.org/analysis_methodology/cost_impact_analysis.php
Table 10. Baseline (Premandate) Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2012

<table>
<thead>
<tr>
<th></th>
<th>DMHC-Regulated</th>
<th>CDI-Regulated</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Privately Funded Plans (by market)</td>
<td>CDI-Regulated Privately Funded Policies (by market)</td>
</tr>
<tr>
<td></td>
<td>Large Group</td>
<td>Small Group</td>
</tr>
<tr>
<td>Total enrollees in plans/policies subject to state Mandates (a)</td>
<td>10,538,000</td>
<td>2,231,000</td>
</tr>
<tr>
<td>Total enrollees in plans/policies subject to AB 1738</td>
<td>10,538,000</td>
<td>2,231,000</td>
</tr>
<tr>
<td>Average portion of premium paid by Employer</td>
<td>$367.66</td>
<td>$292.19</td>
</tr>
<tr>
<td>Average portion of premium paid by Employee</td>
<td>$72.69</td>
<td>$95.87</td>
</tr>
<tr>
<td>Total Premium</td>
<td>$440.36</td>
<td>$388.06</td>
</tr>
<tr>
<td>Enrollee expenses for covered benefits (Deductibles, copays, etc.)</td>
<td>$24.33</td>
<td>$38.10</td>
</tr>
<tr>
<td>Enrollee expenses for benefits not covered (e)</td>
<td>$0.05</td>
<td>$0.07</td>
</tr>
<tr>
<td>Total Expenditures</td>
<td>$464.74</td>
<td>$426.22</td>
</tr>
</tbody>
</table>


Note: (a) This population includes persons insured with private funds (group and individual) and insured with public funds (e.g., CalPERS HMOs, Medi-Cal Managed Care Plans, Healthy Families Program, AIM, MRMIP) enrolled in health plans or policies regulated by the DMHC or CDI. Population includes enrollees aged 0 to 64 years and enrollees 65 years or older covered by employment sponsored insurance.
(b) Of these CalPERS HMO members, about 58% or 495,000 are state employees or their dependents.
(c) Medi-Cal Managed Care state expenditures for members over 65 years of age include those who also have Medicare coverage.
(d) MRMIB Plan state expenditures include expenditures for 874,000 enrollees of the Healthy Families Program, 7,000 enrollees of MRMIP and 7,000 enrollees of the AIM program.
(e) Includes only those expenses that are paid directly by enrollees to providers for services related to the mandated benefit that are not currently covered by insurance. In addition this only includes those expenses that will be newly covered, post-mandate. Other components of expenditures in this table include all health care services covered by insurance
Table 11. Impacts of the Mandate on Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2012

<table>
<thead>
<tr>
<th></th>
<th>Privately Funded Plans (by market)</th>
<th></th>
<th>CalPERS HMOs (b)</th>
<th>DMHC-Regulated</th>
<th>CDI-Regulated</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Large Group</td>
<td>Small Group</td>
<td>Individual</td>
<td>Large Group</td>
<td>Small Group</td>
<td>Individual</td>
</tr>
<tr>
<td>Total enrollees in plans/policies subject to state Mandates (a)</td>
<td>10,538,000</td>
<td>2,231,000</td>
<td>695,000</td>
<td>854,000</td>
<td>201,000</td>
<td>3,539,000</td>
</tr>
<tr>
<td>Total enrollees in plans/policies subject to AB 1738</td>
<td>10,538,000</td>
<td>2,231,000</td>
<td>695,000</td>
<td>854,000</td>
<td>201,000</td>
<td>3,539,000</td>
</tr>
<tr>
<td>Average portion of premium paid by Employer</td>
<td>$0.2206</td>
<td>$0.2189</td>
<td>$0.0000</td>
<td>$0.3066</td>
<td>$0.0000</td>
<td>$0.0000</td>
</tr>
<tr>
<td>Average portion of premium paid by Employee</td>
<td>$0.0437</td>
<td>$0.0716</td>
<td>$0.2875</td>
<td>$0.0767</td>
<td>$0.0000</td>
<td>$0.0000</td>
</tr>
<tr>
<td>Total Premium</td>
<td>$0.2645</td>
<td>$0.2905</td>
<td>$0.2875</td>
<td>$0.3833</td>
<td>$0.0000</td>
<td>$0.0000</td>
</tr>
<tr>
<td>Enrollee expenses for covered benefits (Deductibles, copays, etc.)</td>
<td>-$0.0674</td>
<td>-$0.0502</td>
<td>-$0.0714</td>
<td>-$0.0121</td>
<td>$0.0000</td>
<td>$0.0000</td>
</tr>
</tbody>
</table>
Table 11. Impacts of the Mandate on Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2012 (Cont’d)

<table>
<thead>
<tr>
<th></th>
<th>Privately Funded Plans (by market)</th>
<th>CalPERS HMOs (b)</th>
<th>DMHC-Regulated</th>
<th>CDI-Regulated</th>
<th>Privately Funded Policies (by market)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Large Group</td>
<td>Small Group</td>
<td>Individual</td>
<td>65 and Over (c)</td>
<td>Under 65</td>
<td>Large Group</td>
</tr>
<tr>
<td>Enrollee expenses for benefits not covered (e)</td>
<td>-$0.0517</td>
<td>-$0.0671</td>
<td>-$0.0482</td>
<td>-$0.1317</td>
<td>$0.0000</td>
<td>$0.0000</td>
</tr>
<tr>
<td>Total Expenditures</td>
<td>$0.1454</td>
<td>$0.1732</td>
<td>$0.1679</td>
<td>$0.2395</td>
<td>$0.0000</td>
<td>$0.0000</td>
</tr>
<tr>
<td>Percentage Impact of Mandate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insured Premiums</td>
<td>0.0601%</td>
<td>0.0749%</td>
<td>0.0679%</td>
<td>0.0861%</td>
<td>0.0000%</td>
<td>0.0000%</td>
</tr>
<tr>
<td>Total Expenditures</td>
<td>0.0313%</td>
<td>0.0406%</td>
<td>0.0332%</td>
<td>0.0511%</td>
<td>0.0000%</td>
<td>0.0000%</td>
</tr>
</tbody>
</table>

Note: (a) This population includes persons insured with private funds (group and individual) and insured with public funds (e.g., CalPERS HMOs, Medi-Cal Managed Care Plans, Healthy Families Program, AIM, MRMIP) enrolled in health plans or policies regulated by the DMHC or CDI. Population includes enrollees aged 0 to 64 years and enrollees 65 years or older covered by employment-sponsored insurance.
(b) Of these CalPERS HMO members, about 58% or 495,000 are state employees or their dependents.
(c) Medi-Cal Managed Care state expenditures for members over 65 years of age include those who also have Medicare coverage.
(d) MRMIB Plan state expenditures include expenditures for 874,000 enrollees of the Healthy Families Program, 7,000 enrollees of MRMIP and 7,000 enrollees of the AIM program.
(e) Includes only those expenses that are paid directly by enrollees to providers for services related to the mandated benefit that are not currently covered by insurance. In addition this only includes those expenses that will be newly covered, post-mandate. Other components of expenditures in this table include all health care services covered by insurance.
PUBLIC HEALTH IMPACTS

AB 1738 would require DMHC-regulated plans and CDI-insurance policies to cover smoking cessation treatments rated A or B by the USPSTF and eliminate cost sharing between the enrollee and the plan or policy for such treatments. Covered treatments include counseling, OTC NRT, and prescription medications. Use of these treatments individually or in combination can assist smokers with the task of quitting smoking, maintaining abstinence, and positively impacting California’s 13.4% smoking prevalence rate in the insured adult population (CHIS, 2012).

The literature on the harms of smoking and subsequent health improvements from cessation are well documented through decades of research. The evidence presented in this report about the efficacy and improved outcomes from sustained abstinence from smoking are unlikely to be diminished or altered with the publication of new studies. This section presents the estimated marginal public health impact of AB 1738, including the additional enrollees attempting to quit, successful quitters, potential for reduction in gender and racial/ethnic disparities in health outcomes, premature death, societal economic losses, and long-term outcomes of smoking-related diseases.

Public Health Outcomes

Improving the quit rate of smokers affects long- and short-term health outcomes. For example, smoking cessation will reduce rates of low birth weight babies and AMI. However, the benefits to heart disease and AMI are not fully realized in the immediate 12 months postmandate that CHBPRP commonly models. In the short term, the proportion of low birth weight infants (expressed as a percentage of all live births) would drop by an estimated 10.4% in 1 year if all pregnant smoking women quit smoking (Ventura et al., 2003). Additionally, a Cochrane review reported similar conclusions for pregnant women who quit smoking during pregnancy (Table 12) (Lumley et al., 2009). However, there is little evidence about the efficacy of NRT and smoking cessation counseling for pregnant women, and further research is needed (Coleman, et al., 2011; Filion et al., 2011).

Coronary artery disease (CAD) represents an example of both short- and long-term benefits from smoking cessation. CAD can be reversed substantially within 1 to 2 years of cessation, and after 10 to 15 years of cessation, risk of all-cause mortality returns to close to that of a never smoker (CDC, 1990; Lightwood and Glantz, 1997). A study on the Massachusetts Medicaid program found a decline in hospitalizations for AMI and other acute coronary heart disease diagnoses 2.5 years after a comprehensive smoking cessation benefit was implemented (Table 12) (Land et al., 2010). The authors also estimated that the smoking prevalence among subscribers decreased by 10 percentage points in this time period (Land et al., 2010). Similarly, in a recent study, evidence-based smoking cessation counseling coupled with supportive follow-up contact in smokers hospitalized with AMI was found to create 50,230 new quit attempts in the year implemented and would prevent 1,380 non-fatal AMIs and 7,860 deaths overall (Lapado et al., 2011).
Table 12. Improved Perinatal and Adult Health Outcomes Due to Smoking Cessation

<table>
<thead>
<tr>
<th>Improved Health Outcomes Due to Smoking Cessation</th>
<th>Birth Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perinatal Outcomes from Lumley et al., Study</td>
<td></td>
</tr>
<tr>
<td>Low birth weight</td>
<td>RR = 0.94</td>
</tr>
<tr>
<td></td>
<td>(CI = 0.93 – 0.96)</td>
</tr>
<tr>
<td>Preterm birth</td>
<td>RR=0.86</td>
</tr>
<tr>
<td></td>
<td>(CI = 0.74 – 0.98)</td>
</tr>
<tr>
<td>Mean birth weight (grams)</td>
<td>59.9g</td>
</tr>
<tr>
<td></td>
<td>(CI = 10.44g – 95.4g)</td>
</tr>
<tr>
<td>Adult Outcomes from Land et al., Study</td>
<td>% Decline in Hospitalizations</td>
</tr>
<tr>
<td>Acute myocardial infarction</td>
<td>46%</td>
</tr>
<tr>
<td></td>
<td>(CI = 2% - 70%)</td>
</tr>
<tr>
<td>Acute coronary heart disease</td>
<td>49%</td>
</tr>
<tr>
<td></td>
<td>(CI = 6% - 72%)</td>
</tr>
</tbody>
</table>

Source: California Health Benefits Review Program, 2011. (Based on Lumley et al., 2009, and Land et al., 2010.)
Note: RR = risk ratio or relative risk. A risk ratio or relative risk < 1.0 means a decreased risk of disease attributable to smoking cessation. CI = confidence interval

As presented in the Medical Effectiveness section, there is clear and convincing evidence that the smoking cessation treatments mandated by AB 1738 are medically effective, and coverage for these treatments demonstrably improve smoking cessation rates. The preponderance of evidence shows that full coverage for smoking cessation treatment improves rates of smoking cessation. Some studies demonstrate an approximate doubling of the odds for successfully quitting among persons with full or partial (e.g., copays) insurance benefits for smoking cessation compared to persons without such benefits (see Medical Effectiveness section). Smoking cessation rates are greatest in those populations with access to full coverage compared to partial coverage (e.g., copays) and no treatment, and reductions in smoking prevalence are also found among groups with complete coverage compared to groups with no coverage (Kaper, Wagena, Severens et al., 2005).

As presented in the Benefit Coverage, Utilization, and Cost Impacts section, CHBRP estimates AB 1738 would increase enrollee coverage for smoking cessation treatments, which would result in 27.4% increase in utilization (of one or more treatments). As a result of this increased utilization, it is estimated that AB 1738 would provide an additional 83,268 enrollees who attempt to quit annually, of whom 5,287 enrollees would successfully quit (see Appendix F for explanation of calculation).

AB 1738 would decrease the financial burden of some enrollees who use smoking cessation treatments and are newly covered under this mandate. For enrollees whose previously uncovered expenses decreased, the change would reduce the financial hardship associated with smoking cessation treatment for those persons.

Additionally, postmandate, a reduction in harms from secondhand smoke would be realized in both the short term and long term. For example, reductions in maternal exposure to secondhand smoke would result in decreased incidence of SIDS and low birth weight deliveries, and reductions in exposure to parental smoking would result in decreases in lower respiratory illnesses, middle ear infections, “wheeze” illnesses, and asthma in infants, children and
adolescents (USDHHS, 2006). In addition, a reduction in exposure to secondhand smoke as an adult would decrease the risk of developing lung cancer and coronary heart disease.

CHBRP estimates that due to clear and convincing evidence of the effectiveness of smoking cessation treatment, the preponderance of evidence that full coverage increases smoking cessation rates, and the increased number of enrollees with coverage for smoking cessation treatments, AB 1738 would produce a positive public health impact by increasing the number of successful quitters by 5,287 enrollees annually. This would suggest real improved health outcomes for these new quitters in the long term. Although CHBRP cannot quantify the reduction in harms from secondhand smoke due to lack of data, the literature indicates that the additional quitters enabled by AB 1738 would reduce harms from secondhand smoke postmandate.

Potential harms from smoking cessation treatment
While smoking cessation treatment is typically well tolerated, there is evidence to suggest that an increase in the use of smoking cessation treatment may have a harmful effect on a small proportion of users. That is, some may experience side effects from prescription medications (hypertension, neuropsychotic symptoms, insomnia, increased seizure risk, etc.) or NRT (nausea, irregular heartbeat, soft tissue irritation around site of administration, etc.) (FDA, 2010). Serious adverse events are rare, but they may result in increased health care costs to treat the events. However, the risk of adverse events of mild to moderate intensity resulting from smoking cessation medication is low compared to the adverse health outcomes related to smoking (Hays and Ebbert, 2010).

CHRBP estimates that, for the overall population, any cost increase or physical harms from rare serious adverse events from pharmacotherapy would be outweighed by the benefits of smoking cessation.

Impact on Gender and Racial Disparities

Several competing definitions of “health disparities” exist. CHBRP relies on the following definition: A health disparity/inequality is a particular type of difference in health or in the most important influences of health that could potentially be shaped by policies; it is a difference in which disadvantaged social groups (such as the poor, racial/ethnic minorities, women or other groups that have persistently experienced social disadvantage or discrimination) systematically experience worse health or greater health risks than more advantaged groups (Braveman, 2006).

CHRBP investigated the effect that AB 1738 would have on health disparities by gender, race, and ethnicity. Since AB 1738 would only affect the insured population, a literature review was conducted to determine whether there are gender, racial, or ethnic disparities associated with the prevalence, treatment, and outcomes for smoking and cessation outside of disparities attributable to differences between insured and uninsured populations.
Impact on Gender Disparities

Gender disparities in the prevalence of smoking exist in California. As presented in Table 5 of the Introduction, 16.8% of insured men smoke and 10.1% of insured women smoke (CHIS, 2012). The CTS found that a higher percentage of men than women made any kind of quit attempt in 2008 (63% and 56%, respectively), but that women were more likely to use NRT than men (21.4% versus 14.5%) (Al-Delaimy et al., 2010). CHBRP found no studies that reported insurance status, type of cessation method used, and quit rates by gender, which are all necessary components to calculating the public health impact of AB 1738.

Due to lack of data, CHBRP cannot quantify the impact of AB 1738 on reducing existing gender disparities in smoking prevalence nor on the relevant health outcomes in the insured population. Therefore, the impact of AB 1738 on reducing gender disparities is unknown.

Impact on Racial/Ethnic Disparities

Evaluating the impact on racial and ethnic health disparities is particularly important because racial and ethnic minorities report having poorer health status and more risk factors (KFF, 2007). One important contributor to racial and ethnic health disparities is differences in the prevalence of insurance, where minorities are more likely than Whites to be uninsured. However, coverage disparities still exist within the insured population and may contribute to gaps in access and/or utilization among those covered (Kirby et al., 2006; Lille-Blanton and Hoffman, 2005; Rosenthal et al., 2008). To the extent that racial/ethnic groups are disproportionately distributed among policies with more or less coverage, a mandate bringing all policies to parity may impact an existing disparity.

Racial and ethnic disparities in the prevalence of smoking exist in California. As presented in Table 5 of the Introduction, there is nearly a 3-fold difference in smoking prevalence between the lowest group (Asians, 10.1%) and the highest group (American Indian/Alaska Native, 29.9%) (CHIS, 2012).

There is evidence that utilization of cessation treatments differs across racial and ethnic groups. For example, one study found that African American smokers are more likely to attempt to quit but are less likely to use a cessation treatment (Piper et al., 2010). Related to these conclusions is California-specific data from the 2008 CTS that indicated that non-Hispanic Whites are less likely to make a quit attempt (54%) than African Americans (72%) and Hispanics (68%) (Al-Delaimy et al., 2010). Others reported that minority smokers may be less likely to use cessation aids when available (Fu, 2008; King, 2007). The 2008 CTS shows that non-Hispanic Whites and African Americans were more likely to use NRT (22.5% and 18.4%, respectively) compared to Hispanics (9.2%) and Asians (9.8%). Other studies recommended that further investigation of targeted- versus generic-cessation interventions is warranted for racial and ethnic minority populations (Fiore et al., 2000; Lawrence et al., 2003; Sanderson et al., 2011; Carlsten et al., 2011). More recent research found that minority groups are less likely than Whites to have prescribed or to use NRT to quit smoking (Trinidad et al., 2011). CHBRP found no studies that
reported insurance status, type of cessation method used, and quit rates by race/ethnicity, which are all necessary components to calculating the public health impact of AB 1738.

Sanderson et al. (2011) conducted a literature review of published studies examining tobacco cessation treatments among ethnic/racial and minority populations in the United States over the past two decades. This review provides evidence that racial and ethnic minority populations have interest in quitting smoking. There is also evidence that different racial and ethnic groups use different smoking cessation pharmacotherapy treatments. For example, there is support for nicotine patch use among Latino smokers and nicotine patch, nicotine nasal spray, and bupropion for African-American smokers. No studies in this review assessed non-daily smoking, and given the use of light or non-daily smoking among minority populations, there is a greater need to assess the smoking level, adherence to smoking cessation treatment, and outcomes that may be associated with quitting smoking among light smokers. Although decades of research exist, there is still a need to study tobacco cessation treatments among racial and ethnic minority populations (Sanderson et al., 2011).

CHBRP estimates that AB 1738 would have limited impact on reducing racial/ethnic disparities in utilization of cessation treatments.

Due to lack of data, CHBRP cannot quantify the impact of AB 1738 on reducing racial/ethnic disparities in smoking prevalence nor on the relevant health outcomes in the insured population. Therefore, the impact of AB 1738 on reducing racial/ethnic disparities is unknown.

Impacts on Premature Death and Economic Loss

Premature death is often defined as death before the age of 75 years (Cox, 2006). The overall impact of premature death due to a particular disease can be measured in years of potential life lost prior to age 75 years and summed for the population (generally referred to as “YPLL”) (Cox, 2006; Gardner and Sanborn, 1990). In California, it is estimated that there are nearly 102,000 premature deaths each year accounting for more than 2 million YPLL (CDPH, 2011; Cox, 2006). In order to measure the impact of premature mortality across the population impacted by a proposed mandate, CHBRP first collects baseline mortality rates. Next, the medical effectiveness literature is examined to determine whether the proposed mandated benefit impacts mortality. When a reduction in mortality is projected, a literature review is conducted to determine whether the YPLL has been established for the given condition. Some diseases and conditions do not result in death, and a mortality outcome is therefore not relevant.

Economic loss associated with disease is generally presented in the literature as an estimation of the value of the YPLL in dollar amounts (i.e., valuation of a population’s lost years of work over a lifetime). For CHBRP analyses, a literature review is conducted to determine whether lost productivity has been established in the literature. In addition, morbidity associated with the disease or condition of interest can also result in lost productivity, either by causing the worker to miss days of work due to their illness or due to their role as a caregiver for someone else who is ill.


Premature Death

The literature provides substantial evidence regarding reduced mortality resulting from smoking cessation. This report focuses on additional years of life gained by smoking cessation, which represents a summary measure of the increased longevity due to prevention of premature death from the numerous health conditions associated with smoking.

Several studies found that smoking cessation is as effective as other medical treatments for smoking-attributable diseases. Two separate studies concluded that quitting results in a similar reduction in morbidity and mortality that would be achieved through pharmaceutical interventions commonly prescribed for heart disease patients (Critchley and Capewell, 2003; Suskin et al., 2001).

California-specific data show the societal effects of premature death and morbidity attributable to smoking. The CDC estimated that in 2004 in California, 2,012 years of potential life were lost to maternal smoking-related low birth weight infants who died (CDC, 2010b), and the average annual smoking-attributable mortality rate was 249 per 100,000, resulting in 34,492 deaths (CDC, 2010a).

Taylor and colleagues (2002) estimated the life extension achieved by smoking cessation. Cessation at age 35 years results in a predicted additional 7 to 8 years of life for men and a predicted additional 6 to 7 years of life for women. In contrast, cessation at age 65 years results in significantly fewer predicted life years gained (1 to 2 years for men and 2 to 3 years for women), but nevertheless illustrates the benefits of cessation at any age. California’s Department of Health Services (now the California Department of Public Health) reported that in 1999, on average, 12.4 years of potential life were lost per smoker due to smoking-related disease (Max et al., 2004).

The actual years of life gained due to smoking cessation will vary with the age at which the smoker quits and other factors; a precise accounting of this effect would require information about the underlying population that is unavailable. Nevertheless, the following estimates are valuable for showing the approximate magnitude of benefit in years of life gained across the state attributable to the AB 1738 mandate. In addition, these figures are consistent with those developed by the Centers for Disease Control and Prevention (CDC). The CDC estimates that smokers aged 35 years and older in California annually experience 484,022 YPLL due to smoking, or 13.2 years of life lost per death (CDC, 2010b). Using the studies by Taylor et al. (2002) and Max et al, (2004) to estimate a range of years gained from quitting (7.0 to 12.4 years), CHBRP estimates that the passage of AB 1738 would produce 37,009 to 65,559 years of potential life gained in the first year after enactment83 for California smokers who successfully quit using smoking cessation treatments.

---

83 Total additional quitters (5,287) * 7 years = 37,009 years. Total additional quitters (5,287) * 12.4 years = 65,559 years.
There is clear and convincing evidence that AB 1738 would contribute to the reduction in premature death from smoking-related conditions such as cancer, low birth weight infants who died, and cardiovascular and respiratory diseases; however, the precise magnitude of this reduction could not be estimated by CHBRP.

In California, it is estimated that secondhand smoke is responsible for 21 cases of SIDS, 1,600 cases of low birth weight infants, 4,700 preterm deliveries, 31,000 episodes of asthma in children, 400 cases of lung cancer, and 3,600 cardiac deaths each year in the state (EPA, 2006). In the United States, secondhand smoke causes 46,000 premature deaths resulting from heart disease as well as 3,400 lung cancer deaths each year (CDC, 2008). To the extent that smokers quit, a corresponding improvement in health outcomes for nonsmokers exposed to secondhand smoke would likely result.

**Economic Loss**

Quantitative assessments of the disease burden imposed by smoking can be an important complement to the epidemiologic data presented. In-depth modeling of indirect costs (e.g., effects of quality of life, years of life gained, loss of productivity) by full insurance coverage of smoking cessation treatments is beyond the scope of this report. However, according to the California Department of Public Health, $8.5 billion (47%) of smoking-related health care costs in California were due to lost productivity from smoking-attributed early death or illness (not including burn or secondhand smoke deaths) (CDPH/CTCP, 2010a). Furthermore, there is evidence that other indirect costs are reduced by smoking cessation. For example, smokers who successfully quit report improved quality of life relative to current smokers (Mulder et al., 2001).

The cost of low birth weight deliveries can be significant due to increased complications during the birth, extended hospitalization for mothers and infants, and increased need for neonatal intensive care. The SAMMEC Maternal and Child Health reports California’s 2003 smoking-attributable neonatal expenditures at $11.8 million (CDC, 2010b) and a study by Adams and colleagues showed that maternal smoking increases the risk of neonatal intensive care unit admissions by 20% (Adams et al., 2002).

Other studies report that the cost for treating high blood pressure associated with heart disease ranges from $5,000 to $45,000 per additional life year gained, whereas smoking cessation treatment is estimated to cost a few hundred to a few thousand dollars per additional life year gained (Warner et al., 2004). Placing smoking cessation into a preventive treatment context demonstrates that cost effectiveness of smoking cessation is comparable or superior to other commonly used preventive services. For example, mammography screening is estimated to cost $20,000 per life year saved (Warner et al., 2004). Should some smokers quit, a corresponding increase in productivity would likely result.

On an annual basis, secondhand smoke costs the United States nearly $5 billion in medical expenses associated with diseases related to tobacco exposure (lung cancer, asthma, CAD, etc.), as well as an additional $4.6 billion in lost wages (Behan et al., 2005) One study found that exposure to parental smoking is associated with 5.4 million excess cases of disease (including low birth weight, ear infections, asthma, and burns) resulting in a total cost of $4.6 billion per
year for direct medical expenditures. Loss of life costs associated with exposure to parental smoking is estimated to result in an excess of $8 billion (Aligne et al., 1997).

CHBRP estimates that AB 1738 would increase utilization of smoking cessation treatments and increase quit rates postmandate. A higher rate of successful quitters would reduce economic loss associated with lost productivity from smoking-related illness and premature death but the magnitude cannot be estimated. Additionally, CHBRP estimates that enrollee out-of-pocket expenses for covered benefits would be reduced by $11.1 million, and out-of-pocket expenses for previously noncovered smoking cessation treatments would be reduced by about $16.3 million.

Long-Term Public Health Impacts

CHBRP’s modeling focuses on cost and utilization estimates for the immediate 12 months postmandate. However, many health outcomes resulting from smoking cessation are not immediately apparent; smoking cessation is a classic public health example of an intervention that results in a diverse set of long-term benefits. Estimating the long-term impact of AB 1738 is challenging, precisely because smoking (and treatment for cessation) have far-reaching effects on direct and indirect costs and the large number of health outcomes that affect individuals, employers, health plans, the government, and society. There are potential long-term savings resulting from quitting, including the potential impact of total annual costs of treatment for smoking cessation declining in future years because there are fewer smokers. It is also possible that smoking cessation costs could increase in the future due to the diminishing effectiveness of smoking cessation strategies for those heavy smokers who continue to smoke despite treatments. This effect would likely be minimal, given that the treatments covered by the mandate are limited to two in a 12-month period.

It is clear from the literature that the increase in smoking cessation coverage would lead to improved health outcomes over the long term that would lead to long-term savings not measured in the CHBRP model. Medical care contributes the largest proportion of the direct costs of smoking, and individuals personally bear additional medical costs related to smoking. The CDC reports that, on average, men who smoke incur $15,800 (in 2002 dollars) more in lifetime medical expenses than nonsmokers, and women who smoke incur $17,500 more than nonsmokers (CDC, 2002). Additionally, fewer low birth weight infants can also save costs, as those children tend to use more medical care later in life.

To place these costs in their proper context, cost-effectiveness studies generally report their findings in costs per quality-adjusted life year (QALY), as recommended by the Panel on Cost Effectiveness in Health and Medicine (USPHS, 1996). For example, Warner and colleagues (2004) found that successful quitters gain on average 7.1 years of life at a net cost of $3,417 per additional year of life gained, or $24,261 per successful quitter. Cromwell and colleagues (1997) found that implementation of smoking cessation guidelines would have a net cost of $3,779 per quitter, $2,587 per additional life year gained, and $1,915 per QALY (a year in perfect health is considered equal to 1.0 QALY) saved.
Depending on the parameters used, the costs of achieving and maintaining lifetime smoking cessation can be greater than the long-term savings related to disease reduction. This is true in part because most of the savings occur years after cessation, so those costs are discounted heavily when converted into present value dollars. In addition, the costs per lifetime quitter are higher because smoking cessation is not 100% effective, so costs are incurred by individuals who are not successful in quitting, and because most quitters require multiple attempts before they quit. Many of these studies also include general medical costs accrued from increased life expectancy, which can reduce the perceived cost effectiveness of smoking cessation. To address the latter issue, Solberg et al. (2006) modeled the cost effectiveness of multiple cessation counseling sessions over multiple years and included cost savings from smoking-attributable illnesses but not medical costs unrelated to smoking. Using these variables, they estimated 2.47 million QALYs were saved at a cost savings of $500 per smoker receiving the intervention. If no financial savings from tobacco-attributable illnesses are factored, the cessation treatment is still found to be cost-effective at $1,100/QALY saved. If financial savings from averted smoking-related illnesses are included, the authors reported a cost savings of $65 per smoker (Solberg et al., 2006).

Bertram et al. (2007) found that smoking cessation services ranged from a cost of $7,900 to $17,000 for each disability-adjusted life year. Additionally, Bolin et al. (2009) performed a cost-utility analysis of an additional 12-week treatment course of varenicline for those who had already received one treatment as compared with those receiving only one 12-week course of treatment. The authors concluded that the incremental cost per QALY gained for the additional treatment (including indirect costs of productivity and increased consumption related to survival) was about Euro 25,000 (or about U.S. $35,550 at March 2011 conversion rates).

It is generally accepted that interventions that cost less than $50,000 per QALY, such as mammography, are viewed by society as cost effective (Fiore, 1998). According to these standards, smoking cessation programs are highly cost effective in the long term, producing significant reductions in mortality and morbidity at a net cost that is well below the $50,000/QALY threshold. In addition, Kahende et al. (2009) performed a meta-analysis of the economic literature and found that in nearly every case smoking cessation programs are either cost saving or highly cost effective.

In addition to gaining short-term savings in health expenditures, those who quit smoking may experience measurable long-term improvements in health status. Medical care contributes the largest proportion of the direct costs of smoking, and individuals personally bear additional medical costs related to smoking. A number of studies have examined the long-term cost consequences of reductions in tobacco use, and all generally find that smoking cessation is cost effective.

CHBRP finds clear and convincing evidence that smoking cessation is a cost-effective preventive treatment that results in improvements in multiple long-term health outcomes and reduces both direct medical costs and indirect costs associated with smoking.
Conclusion

AB 1738 would likely have a positive impact on public health in California, based on (1) the scientific evidence of the medical effectiveness of smoking cessation treatments, (2) the likely increase in utilization of smoking-cessation treatments and successful smoking cessation associated with AB 1738, (3) the favorable impact of smoking cessation on both short- and long-term health outcomes, and (4) the cost effectiveness of smoking cessation. Overall smoking-attributable mortality would also be reduced, with between 7 and 12.4 years of life gained for each quitter attributable to the mandate, totaling between 16,548 to 29,314 life-years gained annually under the new mandate. The expected reduction in smoking prevalence and smoking-related mortality attributable to AB 1738 would bring California closer to achieving Healthy People 2020 goals (USDHHS, 2010).
APPENDICES

Appendix A: Text of Bill Analyzed

On February 17, 2012 the Assembly Committee on Health requested that CHBRP analyze AB 1738.

INTRODUCED BY Assembly Member Huffman

FEBRUARY 16, 2012

An act to add Section 1367.667 to the Health and Safety Code, and to add Section 10123.25 to the Insurance Code, relating to health care coverage.

LEGISLATIVE COUNSEL’S DIGEST

AB 1738, as introduced, Huffman. Health care coverage: tobacco cessation.

Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law also provides for the regulation of health insurers by the Department of Insurance. Existing law requires health care service plan contracts and health insurance policies to provide coverage, and not impose cost-sharing requirements, for certain preventive services, including evidence-based items or services with a rating of "A" or "B" in the current recommendations of the United States Preventive Services Task Force, as specified.

This bill would require health care service plan contracts and health insurance policies issued, amended, renewed, or delivered on or after January 1, 2013, to provide coverage for 2 courses of treatment in a 12-month period for tobacco cessation preventive services rated "A" or "B" by the United States Preventive Services Task Force, and would prohibit plans and insurers from charging a copayment, coinsurance, or deductible for those services. The bill would also prohibit a plan or insurer from requiring enrollees to enter counseling in order to receive tobacco cessation medications or from imposing prior authorization or stepped-care requirements on tobacco cessation treatments.

Because a willful violation of the bill's provisions relative to health care service plans would be a crime, the bill would impose a state-mandated local program.

The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

THE PEOPLE OF THE STATE OF CALIFORNIA DO ENACT AS FOLLOWS:

SECTION 1. The Legislature hereby finds and declares the following:
(a) It is the intent of the Legislature that this act diminish the statewide economic and personal cost of tobacco addiction by making tobacco cessation treatments available to all smokers.
(b) Cigarette smoking and other uses of tobacco remain the leading cause of preventable death in California, as well as the cause of many other serious health problems, including heart disease, emphysema, and other chronic illnesses.
(c) The treatment of tobacco-related diseases continues to impose a significant burden on California's health care system, including local and state-funded health care systems. Tobacco use costs Californians billions of dollars a year in medical expenses and lost productivity.
(d) Providing tobacco cessation counseling and medication is one of the most clinically effective and cost-effective health services available, second only to inoculations.
(e) Reducing the smoking rate in California by one percentage point will result in approximately $91 million saved over five years from fewer smoking-caused heart attacks and strokes.
(f) The United States Public Health Service Clinical Practice Guideline entitled Treating Tobacco Use and Dependence has identified the medications and counseling that are scientifically proven to be effective in helping smokers quit.

SEC. 2. Section 1367.667 is added to the Health and Safety Code, to read:
1367.667. (a) (1) A health care service plan contract issued, amended, renewed, or delivered on or after January 1, 2013, shall cover a minimum of two courses of treatment in a 12-month period for all tobacco cessation preventive services rated "A" or "B" by the United States Preventive Services Task Force, which shall include counseling and over-the-counter medication and prescription pharmacotherapy approved by the federal Food and Drug Administration.

(2) No copayment, coinsurance, or deductible shall be applied to the benefits covered under this section.
(3) As used in this section, "course of treatment" shall be defined to consist of the following:
   (A) As applied to counseling, at least four sessions of counseling, which may be telephone, group, or individual counseling with each session lasting at least 10 minutes.
   (B) As applied to a prescription or over-the-counter medication, the duration of treatment approved by the federal Food and Drug Administration for that medication.
(4) Enrollees shall not be required to enter counseling in order to receive tobacco cessation medications.
(5) A health care service plan shall not impose prior authorization or stepped-care requirements on tobacco cessation treatments.
(b) This section shall not apply to Medicare supplement plan contracts or to specialized health care service plan contracts.

SEC. 3. Section 10123.25 is added to the Insurance Code, to read:
10123.25. (a) (1) A health insurance policy issued, amended, renewed, or delivered on or after January 1, 2013, shall cover a minimum of two courses of treatment in a 12-month period for all tobacco cessation preventive services rated "A" or "B" by the United States Preventive Services Task Force, which shall include counseling and over-the-counter medication and prescription pharmacotherapy approved by the federal Food and Drug Administration.
(2) No copayment, coinsurance, or deductible shall be applied to the benefits covered under this section.

(3) As used in this section, "course of treatment" shall be defined to consist of the following:
   (A) As applied to counseling, at least four sessions of counseling, which may be telephone, group, or individual counseling with each session lasting at least 10 minutes.
   (B) As applied to a prescription or over-the-counter medication, the duration of treatment approved by the federal Food and Drug Administration for that medication.

(4) Insureds shall not be required to enter counseling in order to receive tobacco cessation medications.

(5) A health insurer shall not impose prior authorization or stepped-care requirements on tobacco cessation treatments.
   (b) This section shall not apply to Medicare supplement policies or to specialized health insurance policies.

SEC. 4. No reimbursement is required by this act pursuant to Section 6 of Article XIII B of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIII B of the California Constitution.
Appendix B: Literature Review Methods

Appendix B describes methods used in the medical effectiveness literature review for AB 1738. This literature review updates the reviews conducted for SB 576 in 2005, SB 24 in 2007, SB 220 in 2010, and SB 136 in 2011. The search was conducted to retrieve literature on the effectiveness of smoking cessation treatments (including counseling, brief advice, and pharmacotherapy) and the impact of coverage for smoking cessation treatments on use of services and abstinence from smoking.

Studies of the effects of smoking cessation treatments were identified through searches of the Cochrane Library and website maintained by the USPSTF and the FDA. CHBRP limited the search for literature on the effects of smoking cessation treatments because it is unlikely that the conclusions this report draws about the efficacy of smoking cessation treatments will be diminished or altered with the publication of new individual studies. This is because of the magnitude of the literature, the consistently positive results with respect to specific treatments, and the quality of the research designs. CHBRP published analyses of the efficacy of smoking cessation treatments for SB 576 in 2005, SB 24 in 2007, SB 220 in 2010, and SB 136 in 2011 that reached much the same conclusion as the present analysis. Studies of the effects of coverage for these treatments were identified though search of PubMed, the Cochrane Library, the Cumulative Index of Nursing and Allied Health Literature, and EconLit. Websites maintained by the following organizations that produce and/or index meta-analyses and systematic reviews were also searched: the Agency for Healthcare Research and Quality, the International Network of Agencies for Health Technology Assessment, the National Health Service Centre for Reviews and Dissemination, the National Institute for Health and Clinical Excellence, and the Scottish Intercollegiate Guideline Network, the Employee Benefits Research Institute, and the National Compensation Survey.

The search was limited to studies published in English from 2011 to present, because CHBRP had previously conducted thorough literature searches on these topics in 2005, 2007, 2010, and 2011 for SB 576, SB 24, SB 220, and SB 136, respectively.

The literature on behavioral and pharmacological treatments to improve smoking cessation rates and continued abstinence is extensive, including numerous meta-analyses of RCTs, the strongest form of evidence available for CHBRP analyses. Accordingly, CHBRP relied to the extent feasible on these meta-analyses. Where meta-analyses were not available, CHBRP drew upon individual RCTs.

In contrast, less research has been completed on the impact of coverage for smoking cessation treatments on the use of these treatments and abstinence from smoking. The review on the impact of coverage included nonrandomized studies with comparison groups as well as RCTs and a meta-analysis.

One reviewer screened the title and abstract of each citation retrieved by the literature search to determine eligibility for inclusion. The reviewer acquired the full text of articles that were deemed eligible for inclusion in the review and reapplied the initial eligibility criteria.
Abstracts for 342 articles, meta-analyses, evidence-based guidelines, and systematic reviews were identified. Twenty-two meta-analyses, systematic reviews, and evidence-based guidelines were retrieved and reviewed.

Evidence Grading System

In making a “call” for each outcome measure, the medical effectiveness lead and the content expert consider the number of studies as well the strength of the evidence. To grade the evidence for each outcome measured, the team uses a grading system that has the following categories:

- research design,
- statistical significance,
- direction of effect,
- size of effect, and
- generalizability of findings.

The grading system also contains an overall conclusion that encompasses findings in these five domains. The conclusion is a statement that captures the strength and consistency of the evidence of an intervention’s effect on an outcome. The following terms are used to characterize the body of evidence regarding an outcome:

- clear and convincing evidence,
- preponderance of evidence,
- ambiguous/conflicting evidence, and
- insufficient evidence.

The conclusion states that there is “clear and convincing” evidence that an intervention has a favorable effect on an outcome if most of the studies included in a review have strong research designs and report statistically significant and clinically meaningful findings that favor the intervention.

The conclusion characterizes the evidence as “preponderance of evidence” that an intervention has a favorable effect if most, but not all five, criteria are met. For example, for some interventions, the only evidence available is from nonrandomized studies. If most such studies that assess an outcome have statistically and clinically significant findings that are in a favorable direction and enroll populations similar to those covered by a mandate, the evidence would be classified as a “preponderance of evidence favoring the intervention.” In some cases, the preponderance of evidence may indicate that an intervention has no effect or an unfavorable effect.

The evidence is presented as “ambiguous/conflicting” if their findings vary widely with regard to the direction, statistical significance, and clinical significance/size of the effect.

The category “insufficient evidence” of an intervention’s effect indicates that available evidence is not sufficient to determine whether or not a health care service is effective. It is used when no
research studies have been completed or when only a small number of poorly designed studies are available. It is not the same as “evidence of no effect.” A health care service for which there is insufficient evidence might or might not be found to be effective if more evidence were available.

The search terms used to locate studies relevant to AB 1738 were as follows:

**MeSH Terms**

Tobacco Use Cessation
Smoking/Prevention and Control Smoking/Therapy
Tobacco Use Disorder/Prevention and Control Tobacco Use Disorder/Therapy
Humans
Delivery of Health Care
Harms
Health Behavior
Health Knowledge, Attitudes, Practice
Health Services Accessibility
Health Services, Indigenous
Mass Screening
Health Services Needs And Demand
Patient Acceptance of Health Care
Patient Selection
Quality of Health Care
Quality of Life
Socioeconomic Factors
African Continental Ancestry Group
American Native Continental Ancestry Group
Asian Continental Ancestry Group
Ethnic Groups
Medically Underserved Area
Minority Groups
Oceanic Ancestry Group
Poverty Areas
Rural Health
Rural Health Services
Rural Population
Urban Health
Urban Health Services
Urban Population
Vulnerable Populations
Health Status Disparities
Healthcare Disparities
Minority Health
Costs and Cost Analysis
Economics [Subheading]
Smoking Cessation
Infant Health

Publication Types

Comparative Study
Evaluation Studies
Meta-analysis
Multicenter Study
Practice Guideline
Randomized Controlled Trial
Review Systematic Review
Appendix C: Summary Findings on Medical Effectiveness

Appendix C describes the meta-analyses, systematic reviews, and individual studies on smoking cessations treatments that were analyzed by the medical effectiveness team. Tables C-1a through C-1c present information regarding the citation, type of study, intervention and comparison groups, population studied, and the location at which a study was conducted. Table C-1a lists studies that assessed the effects of smoking cessation counseling. Table C-1b lists studies of the effectiveness of OTC and prescription medications for smoking cessation. Table C-1c lists studies of the impact of coverage for smoking cessation treatments. The studies listed in these tables include studies cited in CHBRP’s reports on SB 576, SB 24, SB 220, and SB 136 regarding coverage for smoking cessation treatments that were introduced in 2005, 2007, 2010, and 2011, respectively, as well as six additional studies that have been published since the SB 136 report in 2011. In some cases, more recent versions of studies cited in the SB 576, SB 24, SB 220 and SB 136 reports are listed.84

Table C-1a. Summary of Published Studies on Effectiveness of Smoking Cessation Treatments (Counseling)

<table>
<thead>
<tr>
<th>Citation</th>
<th>Type of Trial</th>
<th>Intervention vs. Comparison Group</th>
<th>Population Studied</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aveyard et al., 2011</td>
<td>Meta-analysis</td>
<td>Brief physician advice to quit based on medical grounds with or without offering NRT vs. no intervention or advice alone</td>
<td>Smokers who consulted a physician for medical care</td>
<td>N/A</td>
</tr>
<tr>
<td>Barth et al., 2008</td>
<td>Meta-analysis</td>
<td>Counseling, support and advice, with or without provision of written materials vs. usual care</td>
<td>Patients with coronary heart disease who smoke</td>
<td>N/A</td>
</tr>
<tr>
<td>Bock et al., 2008</td>
<td>Randomized controlled trial</td>
<td>Counseling via motivational interviewing and pharmacotherapy vs. usual care</td>
<td>Smokers admitted to emergency room for chest pain after 6-month follow-up</td>
<td>Emergency department of a urban university-affiliated hospital</td>
</tr>
<tr>
<td>Filion et al., 2011</td>
<td>Meta-analysis</td>
<td>Counseling vs. usual care</td>
<td>Pregnant smokers</td>
<td>N/A</td>
</tr>
</tbody>
</table>

84 In some cases, more current versions of meta-analyses and systematic reviews included in the SB 576, SB 24, and SB 220 reports were included in the literature review for the SB 136 report. For example, Cahill et al. (2011) is an update of a Cochrane review that these authors previously published in 2008. In addition, the U.S. Public Health Service (PHS) issued a new version of its evidence-based guideline for treatment of tobacco dependence in 2008 (Fiore et al., 2008). The new version included meta-analyses that incorporated findings from studies published since the previous version of the PHS guideline was released in 2000.
<table>
<thead>
<tr>
<th>Citation</th>
<th>Type of Trial</th>
<th>Intervention vs. Comparison Group</th>
<th>Population Studied</th>
<th>Location</th>
</tr>
</thead>
</table>
| Fiore et al., 2008             | Meta-analysis  | Individual counseling vs. no intervention  
Group counseling vs. no intervention  
Quitline telephone counseling vs. minimal or no intervention  
Brief advice vs. no advice | Smokers after 5-month follow-up            | N/A 85                       |
| Lancaster and Stead, 2008      | Meta-analysis  | Face-to-face individual counseling from a health care worker not involved in routine clinical care vs. minimal intervention | Smokers after 6-month follow-up      | N/A            |
| Lumley et al., 2009            | Meta-analysis  | Behavioral and or pharmacotherapy vs. usual care                                                 | Pregnant women who smoke. Follow-up during late pregnancy and 1-5 months post delivery | N/A            |
| Mojica et al., 2004            | Meta-analysis  | Relative effectiveness of smoking cessation counseling interventions delivered by psychologists, physicians, and nurses | Smokers after 5-month follow-up      | N/A            |
| Motillo et al., 2009           | Meta-analysis  | Individual counseling vs. no intervention  
Group counseling vs. no intervention  
Telephone counseling vs. no intervention  
Brief advice vs. no intervention | Smokers after 6-month follow-up            | N/A            |
| Rice and Stead, 2008           | Meta-analysis  | Advice by a nursing professional vs. no intervention                                            | Adult smokers over 18 years, after 6-month follow-up | N/A            |
| Rigotti et al., 2008           | Meta-analysis  | Intensive intervention (inpatient contact plus follow up for at least 1 month) vs. usual care   | Hospital inpatients after 6-month follow-up | N/A            |
| Sinclair et al., 2008          | Meta-analysis  | Smoking cessation intervention provided by community pharmacy personnel compared to usual pharmacy support or less intensive program. | Pharmacy customers who smoke and express a desire to stop smoking | N/A            |
| Stead et al., 2009             | Meta-analysis  | Proactive telephone counseling vs. minimal intervention  
Quitline telephone counseling vs. minimal intervention | Smokers after 6-month follow-up      | N/A            |
| Stead and Lancaster, 2009      | Meta-analysis  | Group smoking cessation counseling vs. minimal contact or no intervention                      | Smokers after 6-month follow-up      | N/A            |

85 Location is not reported for meta-analyses because they synthesize results from multiple studies conducted in multiple locations.
Table C-1b. Summary of Published Studies on Effectiveness of Smoking Cessation Treatments (Pharmacotherapy)

<table>
<thead>
<tr>
<th>Citation</th>
<th>Type of Trial</th>
<th>Intervention vs. Comparison Group</th>
<th>Population Studied</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stead, Bergson et al., 2008</td>
<td>Meta-analysis</td>
<td>Minimal advice vs. no advice or usual care</td>
<td>Smoker after 6 to 12 months</td>
<td>N/A</td>
</tr>
<tr>
<td>Strassmann et al., 2009</td>
<td>Meta-analysis</td>
<td>Counseling with and without pharmacotherapy vs. usual care</td>
<td>Patients with COPD after 6-month follow-up</td>
<td>N/A</td>
</tr>
<tr>
<td>Tzelepis et al., 2011</td>
<td>Meta-analysis</td>
<td>Proactive telephone counseling vs. no intervention or self-help materials</td>
<td>Smokers after at least 6 month follow-up</td>
<td>N/A</td>
</tr>
<tr>
<td>Cahill et al., 2011</td>
<td>Meta-analysis</td>
<td>Varenicline vs. placebo</td>
<td>Smokers after 6-month follow-up</td>
<td>N/A</td>
</tr>
<tr>
<td>Coleman et al., 2010</td>
<td>Meta-analysis</td>
<td>Any NRT and behavioral treatments vs. behavioral treatment or behavioral treatment and placebo NRT</td>
<td>Pregnant women who smoke</td>
<td>N/A</td>
</tr>
<tr>
<td>Coleman et al., 2012</td>
<td>RCT</td>
<td>NRT patches and behavioral treatment vs. NRT patch or visible identical placebo patch</td>
<td>Pregnant women who smoke</td>
<td>N/A</td>
</tr>
<tr>
<td>Eisenberg et al., 2008</td>
<td>Meta-analysis</td>
<td>Bupropion SR vs. placebo NRT vs. placebo</td>
<td>Smokers after 6-month follow-up</td>
<td>N/A</td>
</tr>
<tr>
<td>Fiore et al., 2008</td>
<td>Meta-analysis</td>
<td>Bupropion vs. placebo</td>
<td>Smokers after 5-month follow-up</td>
<td>N/A</td>
</tr>
<tr>
<td>Gourlay et al., 2008</td>
<td>Meta-analysis</td>
<td>Clonidine vs. placebo</td>
<td>Smokers after 3-month or greater follow-up</td>
<td>N/A</td>
</tr>
<tr>
<td>Hughes et al., 2010</td>
<td>Meta-analysis</td>
<td>Bupropion vs. placebo and varenicline</td>
<td>Smokers after 6-month follow-up</td>
<td>N/A</td>
</tr>
<tr>
<td>Myung et al., 2007</td>
<td>Meta-analysis</td>
<td>Nicotine patch vs. placebo</td>
<td>Smokers after 12-month follow-up</td>
<td>N/A</td>
</tr>
<tr>
<td>Nayan et al., 2011</td>
<td>Meta-analysis</td>
<td>Behavioral and pharmacotherapy vs. usual care</td>
<td>Patients with various types of cancer after 6-month follow-up</td>
<td>N/A</td>
</tr>
<tr>
<td>Shah et al., 2008</td>
<td>Meta-analysis</td>
<td>Nicotine patch plus another first-line medication vs. single medication</td>
<td>Smokers after 6-month follow-up</td>
<td>N/A</td>
</tr>
</tbody>
</table>

86 Nicotine replacement therapy (NRT) is available in five forms: gum, patch, lozenge, inhaler, and spray. Three meta-analyses assessed findings from randomized controlled trials (RCTs) of multiple types of NRT (Eisenberg et al., 2008; Fiore et al., 2008; Stead et al., 2008b).
87 Fiore et al., 2008, does not indicate whether all of the RCTs included in their meta-analysis received bupropion SR. Some of the RCTs may have assessed the efficacy of other formulations of bupropion.
88 Hughes et al., 2010, does not indicate whether all of the RCTs included in their meta-analysis received bupropion SR. Some of the RCTs may have assessed the efficacy of other formulations of bupropion.
### Table C-1b. Summary of Published Studies on Effectiveness of Smoking Cessation Treatments (Pharmacotherapy) (Cont’d)

<table>
<thead>
<tr>
<th>Citation</th>
<th>Type of Trial</th>
<th>Intervention vs. Comparison Group</th>
<th>Population Studied</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stead, Perera, et al., 2008</td>
<td>Meta-analysis</td>
<td>NRT vs. placebo or no treatment</td>
<td>Smokers after 6-month follow-up</td>
<td>N/A</td>
</tr>
</tbody>
</table>

### Table C-1c. Summary of Published Studies on Effects of Copayments, Coinsurance, and Deductibles on Use of Smoking Cessation Treatments and on Abstinence from Smoking

<table>
<thead>
<tr>
<th>Citation</th>
<th>Type of Trial</th>
<th>Intervention vs. Comparison Group</th>
<th>Population Studied</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kaper, Wagena, Severens, et al., 2005</td>
<td>Meta-analysis</td>
<td>Comparison of full vs. partial and no coverage</td>
<td>Smokers after 6-month follow-up</td>
<td>N/A</td>
</tr>
<tr>
<td>Boyle et al., 2002*</td>
<td>Observational study—nonequivalent comparison group</td>
<td>Coverage for NRT and bupropion SR vs. no coverage</td>
<td>2,327 persons who received employer-sponsored health insurance coverage through a group/staff model HMO or a network-based insurer</td>
<td>United States—Minnesota</td>
</tr>
<tr>
<td>Curry et al., 1998*</td>
<td>Observational study—two analyses: (1) 3-group pre/post design; (2) 2-group post design</td>
<td>Analysis 1: Coverage for smoking cessation services in 3 groups: (1) standard plan (50% coverage for behavioral intervention and 100% coverage for NRT) vs. (2) full plan (100% coverage for behavioral intervention and NRT), and (3) flipped plan (100% coverage for behavioral intervention and 50% coverage for NRT) Analysis 2: Comparison based on coverage for smoking cessation: (1) standard plan (50% coverage for behavioral intervention and 100% coverage for NRT), and (2) reduced plan (50% coverage for behavioral intervention and 50% coverage for NRT) Analysis 3: Comparison of standard plan (50% coverage for behavioral intervention and 100% coverage for NRT) to (1) flipped plan (100% coverage for behavioral intervention and 50% coverage for NRT), (2) reduced plan (50% coverage for behavioral intervention and 50% coverage for NRT), and (3) full plan (100% coverage for behavioral intervention and NRT)</td>
<td>Analysis 1: 10,669 adults enrolled in a group/staff model HMO Analysis 2: 12,386 adults enrolled in a group/staff model HMO Analysis 3: 345 adults enrolled in a group/staff model HMO</td>
<td>United States—Washington State</td>
</tr>
</tbody>
</table>

* Included in the meta-analysis (Kaper, Wagena, Severens, et al., 2005)

* For purposes of this report, full coverage is defined as 100% coverage for smoking cessation services (i.e., health plan pays entire cost and does not charge a copayment or coinsurance and does not require an enrollee to meet a deductible before receiving coverage).
Table C-1c. Summary of Published Studies on Effects of Copayments, Coinsurance, and Deductibles on Use of Smoking Cessation Treatments and on Abstinence from Smoking (Cont'd)

<table>
<thead>
<tr>
<th>Citation</th>
<th>Type of Trial</th>
<th>Intervention vs. Comparison Group</th>
<th>Population Studied</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dey et al., 1999*</td>
<td>Randomized controlled trial</td>
<td>Coverage for nicotine patches: prescription for free patches vs. prescription for patches at slight discount from retail price</td>
<td>General practice</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Halpin et al., 2006</td>
<td>Randomized controlled trial</td>
<td>Comparison of three models of coverage for smoking cessation services: (1) pharmacotherapy only, (2) pharmacotherapy and/or counseling, and (3) pharmacotherapy conditional on participation in counseling</td>
<td>388 smokers enrolled in a group/staff model HMO</td>
<td>United States—California</td>
</tr>
<tr>
<td>Hughes et al., 1991*</td>
<td>Randomized controlled trial</td>
<td>Comparisons based on cost sharing for nicotine gum: (1) free, (2) $6 per box, and (3) $20 per box</td>
<td>106 adults recruited from rural family practices</td>
<td>United States—rural Vermont</td>
</tr>
<tr>
<td>Kaper, Wagena, Willemsen, et al., 2005</td>
<td>Randomized controlled trial</td>
<td>Coverage for NRT, bupropion,90 and behavioral counseling vs. no offer of coverage</td>
<td>Smokers insured by De Friesland Zorgverzekeraar company</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Kaper et al., 200691</td>
<td>Randomized controlled trial</td>
<td>Coverage for NRT, bupropion, and behavioral counseling vs. no offer of coverage</td>
<td>Smokers insured by De Friesland Zorgverzekeraar company</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Land et al., 2010</td>
<td>Interrupted time series</td>
<td>Pre-post analysis of a state law mandating Medicaid coverage for smoking cessation counseling and pharmacotherapy</td>
<td>Adult Medicaid recipients</td>
<td>United States—Massachusetts</td>
</tr>
</tbody>
</table>

* Included in the meta-analysis (Kaper, Wagena, Severens, et al., 2005)

90 Kaper, Wagena, Severens, et al. (2005) does not indicate whether smokers in the intervention group received coverage for bupropion SR, the only formulation of bupropion approved by the FDA for smoking cessation or for other forms of bupropion.

Table C-1c. Summary of Published Studies on Effects of Copayments, Coinsurance, and Deductibles on Use of Smoking Cessation Treatments and on Abstinence from Smoking (Cont’d)

<table>
<thead>
<tr>
<th>Citation</th>
<th>Type of Trial</th>
<th>Intervention vs. Comparison Group</th>
<th>Population Studied</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Petersen et al., 2006</td>
<td>Observational study—survey data</td>
<td>15 U.S. states are categorized into three levels of coverage for smoking cessation interventions and compared: (1) extensive (pharmacotherapies and counseling), (2) some (pharmacotherapies or counseling), and (3) none</td>
<td>Analysis 1: 7,513 women enrolled in Medicaid who smoked 3 months before pregnancy</td>
<td>United States—15 States</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Analysis 2: 2,898 women enrolled in Medicaid who smoked 3 months before pregnancy and quit smoking during pregnancy</td>
<td></td>
</tr>
<tr>
<td>Schauffler et al., 2001*</td>
<td>Randomized controlled trial</td>
<td>Coverage for group behavioral counseling, OTC NRT, and self-help kit vs. self-help kit alone</td>
<td>1,204 persons enrolled in two large, independent practice association model HMOs</td>
<td>United States—California</td>
</tr>
</tbody>
</table>

* Included in the meta-analysis (Kaper, Wagena, Severens, et al., 2005.
Appendix D: Cost Impact Analysis: Data Sources, Caveats, and Assumptions

This appendix describes data sources, as well as general and mandate-specific caveats and assumptions used in conducting the cost impact analysis. For additional information on the cost model and underlying methodology, please refer to the CHBRP website at http://www.chbrp.org/analysis_methodology/cost_impact_analysis.php.

The cost analysis in this report was prepared by the members of cost team, which consists of CHBRP task force members and contributors from the University of California, San Diego and the University of California, Los Angeles, as well as the contracted actuarial firm, Milliman, Inc. (Milliman). Milliman provides data and analyses per the provisions of CHBRP’s authorizing legislation.

Data Sources

In preparing cost estimates, the cost team relies on a variety of data sources as described below.

Health insurance

1. The latest (2009) California Health Interview Survey (CHIS), which is used to estimate health insurance for California’s population and distribution by payer (i.e., employment-based, individually purchased, or publicly financed). The biennial CHIS is the largest state health survey conducted in the United States, collecting information from approximately 50,000 households. More information on CHIS is available at www.chis.ucla.edu.

2. The latest (2011) California Employer Health Benefits Survey is used to estimate:
   - size of firm,
   - percentage of firms that are purchased/underwritten (versus self-insured),
   - premiums for health care service plans regulated by the Department of Managed Health Care (DMHC) (primarily health maintenance organizations [HMOs] and Point of Service Plans [POS]),
   - premiums for health insurance policies regulated by the California Department of Insurance (CDI) (primarily preferred provider organizations [PPOs] and fee-for-service plans [FFS]), and
   - premiums for high deductible health plans (HDHPs) for the California population with employment-based health insurance.
   - This annual survey is currently released by the California Health Care Foundation/National Opinion Research Center (CHCF/NORC) and is similar to the national employer survey released annually by the Kaiser Family Foundation and the Health Research and Educational Trust. Information on the CHCF/NORC data is available at: www.chcf.org/publications/2010/12/california-employer-health-benefits-survey.

3. Milliman data sources are relied on to estimate the premium impact of mandates. Milliman’s projections derive from the Milliman Health Cost Guidelines (HCGs). The HCGs are a health care pricing tool used by many of the major health plans in the United States. See
www.milliman.com/expertise/healthcare/products-tools/milliman-care-guidelines/index.php. Most of the data sources underlying the HCGs are claims databases from commercial health insurance plans. The data are supplied by health insurance companies, Blues plans, HMOs, self-funded employers, and private data vendors. The data are mostly from loosely managed health care plans, generally those characterized as preferred provider plans or PPOs. The HCGs currently include claims drawn from plans covering 4.6 million members. In addition to the Milliman HCGs, CHBRP’s utilization and cost estimates draw on other data, including the following:

- The MarketScan Database, which includes demographic information and claim detail data for approximately 13 million members of self-insured and insured group health plans.

- An annual survey of HMO and PPO pricing and claim experience. The most recent survey (2010 Group Health Insurance Survey) contains data from seven major California health plans regarding their 2010 experience.

- Ingenix MDR Charge Payment System, which includes information about professional fees paid for healthcare services, based upon approximately 800 million claims from commercial insurance companies, HMOs, and self-insured health plans.

- These data are reviewed for applicability by an extended group of experts within Milliman but are not audited externally.

4. An annual survey by CHBRP of the seven largest providers of health insurance in California (Aetna, Anthem Blue Cross of California, Blue Shield of California, CIGNA, Health Net, Kaiser Foundation Health Plan, and PacifiCare) to obtain estimates of baseline enrollment by purchaser (i.e., large and small group and individual), type of plan (i.e., DMHC-regulated or CDI-regulated), cost-sharing arrangements with enrollees, and average premiums. Enrollment in plans or policies offered by these seven firms represents an estimated 94.3% of the persons with health insurance subject to state mandates. This figure represents an estimated 93.9% of enrollees in full service (non-specialty) DMHC-regulated health plans and an estimated 95.5% of enrollees in full service (non-specialty) CDI-regulated policies. CHBRP analysis of the share of enrollees included in CHBRP’s Bill-Specific Coverage Survey of the major carriers in the state is based on "CDI Licenses with HMSR Covered Lives Greater than 100,000" as part of the Accident and Health Covered Lives Data Call September 30, 2010 by the California Department of Insurance, Statistical Analysis Division, data retrieved from The Department of Managed Health Care’s interactive Web site “Health Plan Financial Summary Report,” July-September 2011," and CHBRP's Annual Enrollment and Premium Survey.

Publicly funded insurance subject to state benefit mandates

5. Premiums and enrollment in DMHC-regulated health plans and CDI-regulated policies by self-insured status and firm size are obtained annually from CalPERS for active state and local government public employees and their dependents who receive their benefits through CalPERS. Enrollment information is provided for DMHC-regulated health care service plans covering non-Medicare beneficiaries—about 74% of CalPERS total enrollment. CalPERS
self-funded plans—approximately 26% of enrollment—are not subject to state mandates. In addition, CHBRP obtains information on current scope of benefits from evidence of coverage (EOCs) documents publicly available at www.calpers.ca.gov.

6. Enrollment in Medi-Cal Managed Care (beneficiaries enrolled in Two-Plan Model, Geographic Managed Care, and County Operated Health System plans) is estimated based on CHIS and data maintained by the Department of Health Care Services (DHCS). DHCS supplies CHBRP with the statewide average premiums negotiated for the Two-Plan Model, as well as generic contracts that summarize the current scope of benefits. CHBRP assesses enrollment information online at www.dhcs.ca.gov/dataandstats/statistics/Pages/RASS_General_Medi_Cal_Enrollment.aspx.

7. Enrollment data for other public programs—Healthy Families Program (HFP), Access for Infants and Mothers (AIM), and the Major Risk Medical Insurance Program (MRMIP)—are estimated based on CHIS and data maintained by the Managed Risk Medical Insurance Board (MRMIB). The basic minimum scope of benefits offered by participating health plans under these programs must comply with all requirements for DMHC-regulated health plans, and thus these plans are affected by state-level benefit mandates. CHBRP does not include enrollment in the Post-MRMIP Guaranteed-Issue Coverage Products as these persons are already included in the enrollment for individual market health insurance offered by DMHC-regulated plans or CDI-regulated insurers. Enrollment figures for AIM and MRMIP are included with enrollment for Medi-Cal in presentation of premium impacts. Enrollment information is obtained online at www.mrmib.ca.gov/. Average statewide premium information is provided to CHBRP by MRMIB staff.

General Caveats and Assumptions

The projected cost estimates are estimates of the costs that would result if a certain set of assumptions were exactly realized. Actual costs will differ from these estimates for a wide variety of reasons, including:

- Prevalence of mandated benefits before and after the mandate may be different from CHBRP assumptions.
- Utilization of mandated benefits (and, therefore, the services covered by the benefit) before and after the mandate may be different from CHBRP assumptions.
- Random fluctuations in the utilization and cost of health care services may occur.

Additional assumptions that underlie the cost estimates presented in this report are:

- Cost impacts are shown only for plans and policies subject to state benefit mandate laws.
- Cost impacts are only for the first year after enactment of the proposed mandate.
- Employers and employees will share proportionately (on a percentage basis) in premium rate increases resulting from the mandate. In other words, the distribution of premium paid by the subscriber (or employee) and the employer will be unaffected by the mandate.
• For state-sponsored programs for the uninsured, the state share will continue to be equal to the absolute dollar amount of funds dedicated to the program.

• When cost savings are estimated, they reflect savings realized for 1 year. Potential long-term cost savings or impacts are estimated if existing data and literature sources are available and provide adequate detail for estimating long-term impacts. For more information on CHBRP’s criteria for estimating long-term impacts, please see: http://chbrp.org/documents/longterm_impacts08.pdf.

• Several recent studies have examined the effect of private insurance premium increases on the number of uninsured (Chernew et al., 2005; Glied and Jack, 2003; Hadley, 2006). Chernew et al. (2005) estimate that a 10% increase in private premiums results in a 0.74 to 0.92 percentage point decrease in the number of insured, while Hadley (2006) and Glied and Jack (2003) estimate that a 10% increase in private premiums produces a 0.88 and 0.84 percentage point decrease in the number of insured, respectively. The price elasticity of demand for insurance can be calculated from these studies in the following way. First, take the average percentage point decrease in the number of insured reported in these studies in response to a 1% increase in premiums (about -0.088), divided by the average percentage of insured persons (about 80%), multiplied by 100%, i.e., \(\{[-0.088/80] \times 100\} = -0.11\). This elasticity converts the percentage point decrease in the number of insured into a percentage decrease in the number of insured persons for every 1% increase in premiums. Because each of these studies reported results for the large-group, small-group, and individual insurance markets combined, CHBRP employs the simplifying assumption that the elasticity is the same across different types of markets. For more information on CHBRP’s criteria for estimating impacts on the uninsured please see: http://chbrp.org/documents/uninsured_010109.pdf.

There are other variables that may affect costs, but which CHBRP did not consider in the cost projections presented in this report. Such variables include, but are not limited to:

• Population shifts by type of health insurance: If a mandate increases health insurance costs, some employer groups and individuals may elect to drop their health insurance. Employers may also switch to self-funding to avoid having to comply with the mandate.

• Changes in benefit plans: To help offset the premium increase resulting from a mandate, subscribers/policyholders may elect to increase their overall plan deductibles or copayments. Such changes would have a direct impact on the distribution of costs between the health plan and policies and enrollees, and may also result in utilization reductions (i.e., high levels of patient cost sharing result in lower utilization of health care services). CHBRP did not include the effects of such potential benefit changes in its analysis.

• Adverse selection: Theoretically, individuals or employer groups who had previously foregone health insurance may now elect to enroll in a health plan or policy, postmandate, because they perceive that it is to their economic benefit to do so.

• Medical management: Health plans and insurers may react to the mandate by tightening medical management of the mandated benefit. This would tend to dampen the CHBRP
cost estimates. The dampening would be more pronounced on the plan types that previously had the least effective medical management (i.e., PPO plans).

- Geographic and delivery systems variation: Variation in existing utilization and costs, and in the impact of the mandate, by geographic area and delivery system models: Even within the health insurance types CHBRP modeled (HMO—including HMO and point of service [POS] plans—and non-HMO—including PPO and fee for service [FFS] policies), there are likely variations in utilization and costs by type. Utilization also differs within California due to differences in the health status of the local population, provider practice patterns, and the level of managed care available in each community. The average cost per service would also vary due to different underlying cost levels experienced by providers throughout California and the market dynamic in negotiations between providers and health plans or insurers. Both the baseline costs prior to the mandate and the estimated cost impact of the mandate could vary within the state due to geographic and delivery system differences. For purposes of this analysis, however, CHBRP has estimated the impact on a statewide level.

- Compliance with the mandate: For estimating the postmandate coverage levels, CHBRP typically assumes that plans and policies subject to the mandate will be in compliance with the coverage requirements of the bill. Therefore, the typical postmandate coverage rates for populations subject to the mandate are assumed to be 100%.

Potential Effects of the Federal Affordable Care Act

As discussed in the Introduction, there are a number of the ACA provisions that have already gone into or will go into effect over the next 3 years. Some of these provisions affect the baseline or current enrollment, expenditures, and premiums. This subsection discusses adjustments made to the 2012 Cost and Coverage Model to account for the potential impacts of the ACA that have gone into effect by January, 2012. It is important to emphasize that CHBRP’s analysis of specific mandate bills typically address the marginal effects of the mandate bill—specifically, how the proposed mandate would impact benefit coverage, utilization, costs, and public health, holding all other factors constant. CHBRP’s estimates of these marginal effects are presented in the Benefit Coverage, Utilization, and Cost Impacts section of this report.

CHBRP reviewed the ACA provisions and determined whether and how these provisions might affect:

1. The number of covered lives in California, and specifically the makeup of the population with health insurance subject to state mandates
2. Baseline premiums and expenditures for health insurance subject to state mandates, and
3. Benefits required to be covered in various health insurance plans subject to state mandates

There are still a number of provisions that have gone into effect for which data are not yet available. Where data allows, CHBRP has made adjustments to the 2012 Cost and Coverage model to reflect changes in enrollment and/or baseline premiums and these are discussed here.
Coverage for adult children

PPACA Section 2714, modified by HR 4872, Section 2301, requires coverage for adult children up to age 26 as dependents to primary subscribers on all individual and group policies, effective September 23, 2010. California’s recently enacted law, SB 1088 (2010) implements this provision. As a result of the ACA, many of these young adults have gained access to health insurance through a parent. This dynamic has both diminished the number of uninsured and also shifted some young adults from the individually-purchased health insurance market into the group market. Responses to CHBRP’s Annual Enrollment and Premium Survey have captured the effects of this provision.

Minimum medical loss ratio requirement

PPACA Section 2718 requires health plans offering health insurance in group and individual markets to report to the Secretary of Health and Human Services the amount of premium revenue spent on clinical services, activities to improve quality, and other non-claim costs. Beginning in 2011, large group plans that spend less than 85% of premium revenue and small group/individual market plans that spend less than 80% of premium revenue on clinical services and quality must provide rebates to enrollees. According to the Interim Final Rule, (45 CFR Part 158) “Issuers will provide rebates to enrollees when their spending for the benefit of policyholders on reimbursement for clinical services and quality improvement activities, in relation to the premiums charged, is less than the MLR standards established pursuant to the statute.”92 The requirement to report medical loss ratio is effective for the 2010 plan year, while the requirement to provide rebates is effective January 1, 2011. The MLR requirement, along with the rebate payment requirement, will affect premiums for 2012, but the effects are unknown and data are not yet available. There is potential for substantial impact on markets with higher administrative costs, including the small and individual group markets. Responses to CHBRP’s Annual Enrollment and Premiums Survey indicate that carriers intend to be in compliance with these requirements. For those that may not be in compliance, the requirement to pay rebates is intended to align the MLR retrospectively. Therefore for modeling purposes, CHBRP has adjusted administrative and profit loads to reflect MLRs that would be in compliance with this provision.

Pre-Existing Condition Insurance Plan

PPACA Section 1101 establishes a temporary high-risk pool for individuals with pre-existing medical conditions, effective 90 days following enactment until January 1, 2014. In 2010, California enacted AB 1887 and SB 227, providing for the establishment of the California Pre-existing Conditions Insurance Plan (PCIP) to be administered by the Managed Risk Medical Insurance Board (MRMIB) and federally funded per Section 1101. MRMIB has projected average enrollment of 23,100 until the end of 2013, when the program will expire. As of December 2010, there were approximately 1,100 subscribers.93 The California PCIP is not

subject to state benefit mandates, and therefore this change does not directly affect CHBRP’s Cost and Coverage Model. CHBRP has revised its annual update of *Estimates of the Sources of Health Insurance in California* to reflect that a slight increase in the number of those who are insured under other public programs that are not subject to state level mandates.

**Prohibition of pre-existing condition exclusion for children**

PPACA Sections 1201& 10103(e): Prohibits pre-existing condition exclusions for children. This provision was effective upon enactment). California’s recently enacted law, AB 2244 (2010) implements this provision. AB 2244 also prohibits carriers that sell individual plans or policies from refusing to sell or renew policies to children with pre-existing conditions. Carriers that do not offer new plans for children are prohibited from offering for sale new individual plans in California for 5 years. This provision could have had significant premium effects, especially for the DMHC-regulated and CDI-regulated individual markets. The premium information is included in the responses to CHBRP’s Annual Enrollment and Premium Survey. Thus the underlying data used in CHBRP annual model updates captured the effects of this provision.

**Prohibition of lifetime limits and annual benefit limit changes**

PPACA Section 2711 prohibits individual and group health plans from placing lifetime limits on the dollar value of coverage, effective September 23, 2010. Plans may only impose annual limits on coverage and these annual limits may be no less than $750,000 for “essential health benefits.” The minimum annual limit will increase to $1.25 million on September 23, 2011, and to $2 million September 23, 2012. Earlier in 2010, CHBRP conducted an analysis of SB 890 which sought to prohibit lifetime and annual limits for “basic health care services” covered by CDI-regulated policies. CHBRP’s indicated that DMHC-regulated plans were generally prohibited from having annual or lifetime limits. The analysis also indicated that less than 1% of CDI-regulated policies in the state had annual benefit limits and of those, the average annual benefit limit was approximately $70,000 for the group market and $100,000 for the individual market. Almost all CDI-regulated policies had lifetime limits in place and the average lifetime limits was $5 million. After the effective date of the PPACA Section 2711, removal of these limits may have had an effect on premiums. As mentioned, premium information is included in the responses to CHBRP’s Annual Enrollment and Premium Survey. Thus the underlying data used in CHBRP annual model updates captured the effects of this provision to remove lifetime limits and to increase annual limits for those limited number of policies that had annual limits that fell below $750,000.

**Medi-Cal Managed Care enrollment: seniors and persons with disabilities**

While the PPACA allows states the option to expand coverage to those not currently eligible for Medicaid (Medi-Cal in California), large scale expansions are not expected to be seen during 2012. However, as a result of the 2010–2011 California Budget Agreement, there are expected to be shifts in coverage for seniors and persons with disabilities. Specifically, “Seniors and persons with disabilities who reside in certain counties which have managed care plans, and who are not also eligible to enroll in Medicare, will be required to enroll in a managed care plan under a

---

**Notes:**

94 Correspondence with John Symkowick, Legislative Coordinator, MRMIB, October 19, 2010.


phased-in process." The Medi-Cal Managed Care enrollment in CHBRP’s 2012 Cost and Coverage Model has been adjusted to reflect this change. Baseline premium rates have also been adjusted to reflect an increase in the number of seniors and persons with disabilities in Medi-Cal Managed Care. Information from DHCS indicated that by November 2011, an estimated 289,000 seniors and persons with disabilities had enrolled in Medi-Cal Managed Care. CHBRP used data from DHCS to adjust enrollment in Medi-Cal Managed Care, and to adjust premiums to account for the change in acuity in the underlying populations.

Bill Analysis–Specific Caveats and Assumptions

CHBRP assumes that high-deductible health plans (HDHP) would cover smoking cessation treatments as “preventive services,” and thus would not be required to include copayments or deductibles for smoking cessation as part of their charter under Sec. 223 of the federal regulatory code for keeping their HDHP status. In this arrangement, any out-of-pocket expenses for smoking cessation treatment could possibly be reimbursed by the health savings account (HSA), and if so, that would be considered taxable income for the enrollee. CHBRP assumes that this income would have been taxable for an enrollee with an HSA regardless, and therefore it does not change the marginal impact of the costs for insured enrollees under AB 1738.

CHBRP used the 2008 California Tobacco Survey (CTS) data and the RAND Health Insurance Experiment’s (HIE) estimated impact of cost sharing for well care to estimate premandate and postmandate utilization among smokers who make an attempt to quit. An illustration of CHBRP’s calculations to develop premandate and postmandate utilization by coverage status for NRT is as follows:

Premandate (baseline)

Step 1. (% use of counseling treatments among smokers using CTS data) = (% usage among smokers who attempt to quit) x (% attempting to quit among smokers)

8.3% = 13.8% x 60.2%

Step 2. (weighted average % relative utilization under various coverage) = (sum-product of % relative utilization from HIE and % distribution of coverage from CHBRP health plan survey)

89.9% = [(45% relative utilization under no coverage) x (17.2% enrollees with no coverage)] + [(80% relative utilization under partial coverage) x (3.4% with partial coverage)] + [(100% relative utilization under full coverage) x (79.9% with full coverage)].

Step 3a. (% usage among smokers with full coverage) = (% usage among smokers) / (weighted average % relative utilization under various coverage) x (100% NRT use under full coverage)

\[ 9.2\% = \frac{8.3\%}{89.9\%} \times 100\% \]

Step 3b. (% usage among smokers with partial coverage) = (% usage among smokers) / (weighted average % relative utilization under various coverage) x (80% NRT use under partial coverage)

\[ 7.4\% = \frac{8.3\%}{89.9\%} \times 80\% \]

Step 3c. (% usage among smokers with no coverage) = (% usage among smokers) / (weighted average % relative utilization under various coverage) x (45% NRT use under no coverage)

\[ 4.2\% = \frac{8.3\%}{89.9\%} \times 45\% \]

Postmandate

Postmandate, those enrollees currently with partial or no coverage will have full coverage, so 100% of the weight is given to full coverage. In other words, the utilization among those with full coverage is applied to everybody.

Short-term cost impact of reduction in low birth weight deliveries and hospitalizations due to AMI

Low birth weight deliveries. CHBRP estimated the mandate could result in one fewer low birth weight deliveries statewide during 2012, using the application of the lower rate of low birth weight babies to former smokers as compared to smokers for the larger population who would be successful quitters based on the increased number of pregnant women who would use smoking cessation treatment covered by AB 1738.100 The average savings per avoided low birth weight delivery is estimated to be approximately $42,500. This number is derived from the 1999 Lightwood study, which estimated $21 million saved (in 1995 dollars) as a result of 1,300 fewer low birth weight deliveries (Lightwood et al., 1999). This estimated savings was then was updated to 2012 dollars at a rate of 8.4% per year.101 Therefore, as a result of the mandate, quitting produces an average first-year savings in health care expenditures of about $846,000 from avoided low birth weight deliveries.

AMI. CHBRP estimated the mandate could result in six fewer hospitalizations due to AMI during 2012, based on the reduction in AMI risk due to smoking cessation applied to the larger population using smoking cessation services covered by AB 1738 (Critchley and Capewell, 2003).102 The average savings per avoided AMI hospitalization is estimated to be approximately $125,400. This calculation is derived from the 1997 Lightwood study (Lightwood and Glantz, 1997), which estimated an approximate $44 million savings (1995 dollars) in 1 year due to reduced numbers of AMI (based on 924 fewer hospitalizations). Using this estimate in savings, CHBRP calculated the expected total savings per avoided AMI, and then updated this number to

100 This is out of the total of 27,000 insured pregnant women who were smokers prior to the mandate.
101 This trend rate was based on the average annual increase in California HMO premiums from 1995 to 2006 as measured by the Milliman Intercompany HMO Rate Survey.
102 This is out of a total of 1.92 million insured adults who were smokers with drug coverage prior to the mandate.
2012 terms at a rate of 8.4% per year. In total, CHBRP estimated that quitting produces an average first-year savings in health care expenditures of about $754,000 from avoided AMIs.
Appendix E: Information Submitted by Outside Parties

In accordance with CHBRP policy to analyze information submitted by outside parties during the first 2 weeks of the CHBRP review, the following parties chose to submit information.

The following information was submitted by the Office of Assembly Member Jared Huffman in February, 2012.


Centers for Disease Control and Prevention (CDC). *Smoking and Tobacco Use*. Available at: [http://www.cdc.gov/tobacco/](http://www.cdc.gov/tobacco/)


For information on the processes for submitting information to CHBRP for review and consideration please visit: [http://www.chbrp.org/recent_requests/index.php](http://www.chbrp.org/recent_requests/index.php).
Appendix F: Public Health Calculations

Due to the number of assumptions that must be made to estimate the impacts of AB 1738 on smoking cessation utilization for the insured population, CHBRP chooses to round its conclusions to avoid misrepresentation of bill impact. The methods and calculations below explain the logic behind this report’s estimates, but the outcomes will change if assumptions are varied.

Public Health Calculations: Successful Quitters

The premandate number of quitters sums two elements: number of people who successfully quit while using a smoking cessation treatment and the number of people who successfully quit without using a smoking cessation treatment. The medical literature suggests that “attempters” using smoking cessation treatment experience twice the success rate of smokers attempting to quit with no use of treatment. The formula is summarized as: Overall success rate = (% of people who used a treatment × success rate for using a treatment) + (% of people who use no treatment × success rate for no treatment). The 2008 California Tobacco Survey reports that 8% of smokers attempting to quit are successful at 90 days after quitting. This overall 8% success rate represents a mix of persons who used no cessation treatment, who therefore experienced a low success rate, and persons who used a cessation treatment, who therefore experienced a higher success rate. The equation for determining the success rates for these two groups is:

\[(0.26 \times 2r) + (0.74 \times r) = 0.08\]

Where \(r\) is the success rate among the 74% of attempters using no cessation treatment, and \(2r\) is the success rate among the 26% of persons who used a cessation treatment.

Solving the equation algebraically yields 6.3% as the success rate for those who use no treatment and 13.7% as the success rate for those who use a treatment.

Using data submitted to CHBRP by the insurers, CHBRP estimates the number of people who used at least one treatment for their quit attempt pre-mandate: 304,370 (Table 1). Therefore, 304,370 (from Table 1) × 12.70% = 38,655 people who successfully quit while using a treatment. To calculate the number of smokers who attempt to quit with no assistance, CHBRP uses the total number of smokers multiplied by the probability that they try to quit (60.2%) and then subtracts the group of smokers who attempted to quit using a treatment. This subset was multiplied by the probability of quitting with no use of a treatment. The equation is: \([1,917,674 \times 60.2\%) – 304,370] \times 6.35\% = 53,979\ people who successfully quit without using a treatment.

The postmandate calculation uses the same process, except the number of people using at least one treatment increases from 304,370 to 387,638 due to new coverage (Table 1). The premandate successful quitters are subtracted from the postmandate successful quitters to find the incremental increase in successful quitters attributable to AB 1738. Using figures available from the Utilization, Cost, and Coverage model, CHBRP estimates that approximately 5,287 persons will succeed in quitting attributable to passage of AB 1738.
REFERENCES


Halpin HA, McMenamin SB, Rideout J, Boyce-Smith G. The costs and effectiveness of different benefit designs for treating tobacco dependence: Results from a randomized trial. *Inquiry*. 2006;43:54-65.


Le Strat Y, Rehm J, Le Foll B. How generalisable to community samples are clinical trial results for treatment of nicotine dependence: A comparison of common eligibility criteria with respondents of a large representative general population survey. *Tobacco Control*. 2011;(5)338-343


California Health Benefits Review Program Committees and Staff

A group of faculty and staff undertakes most of the analysis that informs reports by the California Health Benefits Review Program (CHBRP). The CHBRP Faculty Task Force comprises rotating representatives from six University of California (UC) campuses and three private universities in California. In addition to these representatives, there are other ongoing contributors to CHBRP from UC. This larger group provides advice to the CHBRP staff on the overall administration of the program and conducts much of the analysis. The CHBRP staff coordinates the efforts of the Faculty Task Force, works with Task Force members in preparing parts of the analysis, and coordinates all external communications, including those with the California Legislature. The level of involvement of members of the CHBRP Faculty Task Force and staff varies on each report, with individual participants more closely involved in the preparation of some reports and less involved in others. As required by CHBRP’s authorizing legislation, UC contracts with a certified actuary, Milliman Inc., to assist in assessing the financial impact of each legislative proposal mandating or repealing a health insurance benefit. Milliman also helped with the initial development of CHBRP methods for assessing that impact.

The National Advisory Council provides expert reviews of draft analyses and offers general guidance on the program to CHBRP staff and the Faculty Task Force. CHBRP is grateful for the valuable assistance and thoughtful critiques provided by the members of the National Advisory Council. However, the Council does not necessarily approve or disapprove of or endorse this report. CHBRP assumes full responsibility for the report and the accuracy of its contents.

Faculty Task Force

Todd Gilmer, PhD, *Vice Chair for Cost*, University of California, San Diego
Joy Melnikow, MD, MPH, *Vice Chair for Public Health*, University of California, Davis
Ed Yelin, PhD, *Vice Chair for Medical Effectiveness*, University of California, San Francisco
Wayne S. Dysinger, MD, MPH, Loma Linda University Medical Center
Susan L. Ettner, PhD, University of California, Los Angeles
Theodore Ganiats, MD, University of California, San Diego
Sheldon Greenfield, MD, Loma Linda University Medical Center
Susan L. Ettner, PhD, University of California, Los Angeles
Theodore Ganiats, MD, University of California, San Diego
Sheldon Greenfield, MD, University of California, Irvine
Sylvia Guendelman, PhD, LCSW, University of California, Berkeley
Kathleen Johnson, PharmD, MPH, PhD, University of Southern California
Thomas MaCurdy, PhD, Stanford University

Task Force Contributors

Catherine Acquah, MHA, University of California, Los Angeles
Wade Aubry, MD, University of California, San Francisco
Diana Cassady, PhD, University of California, Davis
Janet Coffman, MPP, PhD, University of California, San Francisco
Gina Evans-Young, University of California, San Francisco
Margaret Fix, MPH, University of California, San Francisco
Erik Groessl, PhD, University of California, San Diego
Julia Huerta, MPH, University of California, Davis
Shana Lavarreda, PhD, MPP, University of California, Los Angeles
Jennifer Kempster, MS, University of California, San Diego
Stephen McCurdy, MD, MPH, University of California, Davis
Sara McMenamin, PhD, University of California, San Diego
Ninez Ponce, PhD, University of California, Los Angeles
Dominique Ritley, MPH, University of California, Davis
Meghan Soulsby, MPH, University of California, Davis
Chris Tonner, MPH, University of California, San Francisco
Arturo Vargas Bustamante, PhD, MA, MPP, University of California, Los Angeles
National Advisory Council

Lauren LeRoy, PhD, President and CEO, Grantmakers In Health, Washington, DC, Chair

Deborah Chollet, PhD, Senior Fellow, Mathematica Policy Research, Washington, DC
Michael Connelly, JD, President and CEO, Catholic Healthcare Partners, Cincinnati, OH
Joseph P. Ditré Esq, Executive Director, Consumers for Affordable Health Care, Augusta, ME
Allen D. Feezor, Deputy Secretary for Health Services, North Carolina Department of Health and Human Services, Raleigh, NC
Charles “Chip” Kahn, MPH, President and CEO, Federation of American Hospitals, Washington, DC
Jeffrey Lerner, PhD, President and CEO, ECRI Institute Headquarters, Plymouth Meeting, PA
Trudy Lieberman, Director, Health and Medicine Reporting Program, Graduate School of Journalism, City University of New York, New York City, NY
Marilyn Moon, PhD, Vice President and Director, Health Program, American Institutes for Research, Silver Spring, MD
Carolyn Pare, CEO, Buyers Health Care Action Group, Bloomington, MN
Michael Pollard, JD, MPH, Senior Fellow, Institute for Health Policy Solutions, Washington, DC
Christopher Queram, President and CEO, Wisconsin Collaborative for Healthcare Quality, Madison, WI
Richard Roberts, MD, JD, Professor of Family Medicine, University of Wisconsin-Madison, Madison, WI
Frank Samuel, LLB, Former Science and Technology Advisor, Governor's Office, State of Ohio, Columbus, OH
Patricia Smith, President and CEO, Alliance of Community Health Plans, Washington, DC
Prentiss Taylor, MD, Regional Center Medical Director, Advocate Health Centers, Advocate Health Care, Chicago, IL
J. Russell Teagarden, Vice President, Clinical Practices and Therapeutics, Medco Health Solutions, Inc, Brookfield, CT
Alan Weil, JD, MPP, Executive Director, National Academy for State Health Policy, Washington, DC

CHBRP Staff

Garen Corbett, MS, Director
John Lewis, MPA, Associate Director
Laura Grossmann, MPH, Principal Policy Analyst
Tory Levine-Hall, Policy Intern
Stephanie McLeod, Graduate Health Policy Intern
Hanh Kim Quach, Principal Policy Analyst
Karla Wood, Program Specialist

California Health Benefits Review Program
University of California
Office of the President
1111 Franklin Street, 11th Floor
Oakland, CA 94607
Tel: 510-287-3876 Fax: 510-763-4253
chbrpinfo@chbrp.org
www.chbrp.org

The California Health Benefits Review Program is administered by the Division of Health Sciences and Services at the University of California, Office of the President. The Division is led by John D. Stobo, M.D., Senior Vice President.